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 I
Abstract 
 
In the UK, stroke is the third most common cause of death after heart disease 
and cancer. Importantly, most strokes are not fatal meaning stroke is the 
leading cause of adult disability, with one third of survivors still functionally 
dependent after one year.  
Post stroke hyperglycaemia (PSH) predicts poor outcome independent of age, 
stroke type or severity and occurs in over 60% of patients without a diagnosis of 
diabetes and in more than 90% of diabetic patients. Around 56% of 
hyperglycaemic acute stroke patients are subsequently diagnosed with insulin 
resistance, manifesting as impaired glucose tolerance, impaired fasting glucose 
or the “metabolic syndrome.”  Clinical guidelines recommend routine blood 
glucose monitoring, and intervention with insulin for hyperglycaemia. However, 
there is currently no clinical evidence of benefit from insulin use, and recent 
findings raise concerns about the safety of insulin use in predominantly non-
diabetic acute stroke populations. Hyperglycaemia in animal models of cerebral 
ischaemia is associated with increased infarct size. However, a recent 
systematic review highlighted uncertainties about the relevance of many 
previously published preclinical studies to the typical clinical picture of PSH with 
respect to whether clinically relevant elevations in blood glucose exacerbate 
ischaemic brain damage in models other than those of type I diabetes, or 
whether responses are different in animals with and without features of 
metabolic syndrome.  
The aim of this thesis was to investigate the differential effects of clinically 
relevant hyperglycaemia on the acute evolution of damage in animals with and 
without features of the metabolic syndrome and to investigate the potential 
mechanistic role of oxidative stress in glucose mediated ischaemic damage. I 
hypothesised that hyperglycaemia would exacerbate acute lesion evolution and 
final infarct volume in animals with and without features of the metabolic 
syndrome and that oxidative stress mechanisms would be involved. 
 
 II
Developing suitable animal models for investigating post stroke 
hyperglycaemia and metabolic syndrome 
The first aim of this thesis was to develop a series of animal models for the 
investigation of clinically relevant PSH, metabolic syndrome in the presence and 
absence of PSH, and an appropriate focal cerebral ischaemia model. A previously 
described model of metabolic syndrome using the spontaneously hypertensive 
stroke-prone rat (SHRSP) fed on a 60% fructose diet for two weeks was set up in 
the laboratory and glucose tolerance, adiposity, plasma insulin, plasma 
triglycerides, cholesterol were measured and compared to the SHRSP reference 
strain, the Wistar-Kyoto (WKY). Fructose fed-SHRSP rats exhibited glucose 
intolerance, hypertriglyceridaemia, hyperinsulinaemia, increase adiposity and 
reduced HDL cholesterol compared to the WKY controls. This suitably modelled 
the features of the metabolic syndrome. Clinically relevant levels of PSH were 
achieved using a bolus intraperitoneal injection of 15% glucose (10ml/kg) 10 
minutes prior to permanent middle cerebral artery occlusion (MCAO). Two 
methods of MCAO were compared; intraluminal filament (ILF) model and a distal 
diathermy MCAO model. The ILF method produced expansive lesions 
incorporating the majority of the ipsilateral hemisphere whereas the distal 
diathermy occlusion produced smaller cortical infarcts which were shown to 
produce a large volume of penumbra. The diathermy model was selected for all 
future experiments. 
Investigating the effects of hyperglycaemia on acute lesion growth after 
focal cerebral ischaemia in rats with and without components of the 
metabolic syndrome 
 The second aim of this thesis was to determine the effects of hyperglycaemia 
on acute ischaemic lesion evolution and infarct volume in rats with and without 
features of the metabolic syndrome. Hyperglycaemia was induced in WKY or 
fructose-fed SHRSP rats 10 minutes prior to permanent MCAO. Magnetic 
resonance imaging (MRI) was used to quantify the expansion of the lesion using 
ADC maps calculated from diffusion weighted imaging (DWI) carried out over the 
first 4 hours after MCAO. Acute hyperglycaemia, at clinically relevant levels, 
exacerbated early ischaemic damage in both normal and metabolic syndrome 
rats. Hyperglycaemia worsened infarct volume at 24h in normal but not 
 III
metabolic syndrome rats. These data suggest that management of 
hyperglycaemia may be most beneficial in the absence of an underlying 
dysglycaemia. Using a marker of oxidative stress to probe the tissue sections 
suggested that perhaps hyperglycaemic effects were mediated through oxidative 
stress mechanisms.  
Investigation of oxidative stress mechanisms in hyperglycaemia-dependant 
ischaemic damage. 
Based on the potential involvement of oxidative stress mechanisms in 
hyperglycaemia-associated ischaemic damage this was investigated in a proof of 
concept study using pre-treatment with a SOD/catalase mimetic, EUK-134. The 
rationale for this study was based on the involvement of increased superoxide 
production in chronic hyperglycaemia and diabetic complications. Sprague-
Dawley rats received the same dose of glucose previously used 10 minutes prior 
to MCAO by distal diathermy. EUK-134 (2.5mg/kg) or vehicle (saline) was 
administered 20 minutes prior to MCAO. Infarct volume, calculated from RARE 
T2-weighted MR images and neurological scoring was measured 24 hours post 
MCAO. Arterial superoxide levels were measured along with the lipid 
peroxidation marker malondialdehyde in cerebral tissue. Hyperglycaemia 
increased infarct volume although no effect of high blood glucose on tissue lipid 
peroxidation was observed. EUK-134 failed to reduce infarct volume. EUK-134 
reduced lipid peroxidation in ipsilateral cortex of normoglycaemic rats but not in 
hyperglycaemic rats. Thus, hyperglycaemia associated damage was not reduced 
by attenuating oxidative stress. 
Generating a threshold for quantitative T2 maps 
Using the data generated in the previous Chapter a study was carried out to 
determine if improvements could be made in the analysis of MRI data in pre-
clinical rat studies. RARE T2-weighted images, where T2 relaxation time denotes 
contrast, have been used for infarct quantification 24 hours post MCAO. 
Generating a lesion volume from these images requires manual tracing of the 
visually defined infarct from the images. A degree of error is associated with this 
methodology either as inter-investigator reproducibility or in repeats conducted 
by the same investigator. The RARE T2 images are not quantifiable as arbitrary 
 IV
values denote contrast and this prevents direct comparison of T2 relaxation 
times for a particular structure between subjects. Using a MSME T2 sequence, 
quantitative T2 maps can be generated which calculate absolute T2 relaxation 
times for each voxel.  
Using quantitative maps an attempt was made to establish a threshold to 
discriminate between normal and ischaemically damaged tissue in animals that 
had undergone MCAO using the distal diathermy model. This threshold aimed to 
minimise inter- or intra-investigator error. A T2 threshold of abnormality for the 
quantitative T2 maps was established from the RARE T2 weighted images. Tissue 
that had a T2 relaxation time of 76 ms or more was deemed to be infarct 
according to the derived threshold. The suitability of the threshold was then 
assessed in a separate cohort and was found to produce similar infarct volumes 
to the manual delineation of RARE T2-weighted images. The 76ms threshold was 
also applied to animals that had undergone MCAO using the intraluminal filament 
model. However, the calculated threshold was not suitable for the intraluminal 
filament model due to interferences from cerebrospinal fluid signal. A more 
selective method for determining infarct volume in animals subjected to 
intraluminal filament MCAO needs to be established. 
Conclusions 
The studies presented in this thesis highlight that acute hyperglycaemia 
increases the rate of ischaemic lesion growth and final infarct volume in rats 
lacking insulin resistance and associated cardiovascular co-morbidities. The 
mechanism by which hyperglycaemia exacerbates ischaemic damage remains 
elusive. Oxidative stress may be involved, although from the investigations 
conducted in this thesis, it is not a primary mechanism of hyperglycaemia 
associated ischaemic damage following permanent MCAO.  
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 Chapter 1 - Introduction 
 2
1.1 Stroke  
1.1.1 Stroke Incidence 
Stroke is the second commonest cause of death worldwide behind ischaemic 
heart disease, accounting for around 51,000 deaths in the UK each year (Donnan 
et al 2008). The rate of stroke deaths varies geographically, with parts of 
Scotland having the highest rates in the UK, around 50% higher than in London 
(http://www.heartstats.org, Stroke Statistics 2009). Age is a major risk factor 
with 75% of all strokes occurring after the age of 65 (Sudlow and Warlow 1997). 
The aged population continues to grow in the UK and it has been suggested that 
the incidence of stroke death will increase exponentially in the next 20 years 
(Mackay and Mensah 2004).  
Most strokes are not fatal and therefore the condition represents the greatest 
cause of severe adult disability worldwide with nearly half of stroke patients 
requiring constant care and 30% expected to die within the first year of stroke-
onset (Donnan et al 2008; Warlow et al 2003). In the UK around 20% of all acute 
NHS hospital beds and 25% of long-term beds are occupied by stroke patients, 
and this is expected to rise with the growing aged population so further 
increasing the health and economic burden (Department of Health, 2005). In 
2007 the total economic cost of stroke was £4.5 billion, of which, £1.1 billion 
was devoted to inpatient hospital care and £900 million for residential care 
(http://www.heartstats.org Stroke Statistics 2009). 
Despite the scale of the economic and social burden of stroke only thrombolytic 
therapy (recombinant tissue plasminogen activator, rt-PA) is currently licensed 
for treatment of stroke patients in the UK. Since fewer than 10% of patients can 
receive thrombolysis (Cocho et al 2005) experimental research is invaluable for 
understanding the extensive pathological mechanisms of stroke to help identify 
new therapies and provide better management of patients.  
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1.1.2 Classification of Stroke 
Stroke results from a severe reduction in cerebral blood flow (CBF) that leads to 
tissue loss and functional impairments. The brain receives around 15% of total 
cardiac output even though it only equates to 2-3% of body weight. This is 
because the brain has a limited capacity to store energy and requires a constant 
nutritive supply to maintain normal metabolic function. The brain utilises around 
20% of the total oxygen consumption and 25% of total glucose consumption by 
the body and this high metabolic demand exemplifies how damaging a reduction 
in CBF could be to brain tissue. Reductions in CBF associated with stroke can 
occur from either the occlusion or haemorrhage of a cerebral artery (Figure 1.1)   
Haemorrhagic stroke accounts for a small proportion of cases (~20%) and 
commonly occurs due to the presence of an arterial aneurysm, arteriovenous 
malformation or as a result of persistent hypertension (Warlow et al 2003). This 
type of stroke can be sub classified into intracerebral haemorrhage and 
subarachnoid haemorrhage, which account for 25% and 75% of all haemorrhagic 
strokes, respectively.  
The majority of strokes are ischaemic, accounting for approximately 80-87% of 
all cases (Chen et al 2010; Donnan et al 2008; Rothwell et al 2005). Ischaemic 
stroke often arises either from atherosclerotic plaques, or from a displaced 
embolus such as a blood clot that travels from the heart to the brain and 
becomes lodged in a cerebral artery (Figure 1.1). Atherosclerotic plaques result 
from endothelial disruption, extracellular lipid deposits, smooth muscle cell 
migration and proliferation, and thickening of the intima, which causes the 
lumen of the affected blood vessel to become narrowed. Complicated 
atherosclerotic plaques may rupture exposing the extremely thrombogenic fatty 
component of the lesion to flowing blood leading to thrombus formation and 
occlusion of the artery (Zaman et al 2000). Atherosclerosis is associated with 
approximately 50% of all ischaemic strokes whereas emboli originating from the 
heart, commonly as a result of atrial fibrillation, accounts for 20% of cerebral 
artery occlusions. The remainder are as a result of occlusions in small 
intracranial vessels and lacunar strokes, which affect small arterioles, often 
caused by hypertension leading to morphological changes. 
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Figure 1.1: The major types of ischaemic and haemorrhagic stroke. Reproduced from 
Richard Green et al (2003).(Richard Green et al 2003). 
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1.2 The rat as a stroke model  
Ischaemic stroke has been modelled in a variety of animal species enabling an 
extensive understanding of the mechanisms and pathways associated with 
cerebrovascular occlusion. However concerns have been raised over the animal 
models used due to the number of neuroprotective compounds that have failed 
to show benefit in clinical trials after promising results in animal models (Savitz 
and Fisher 2007). There are a number of species that have been used to 
generate models of human stroke   including non-human primates, cats, rabbits 
and rodents (Tamura et al, 1996). The greatest relevance to the human 
condition is undoubtedly from the study of non-human primates due to their 
gyrencephalic brains and their behavioural similarities to humans, in particular 
manual dexterity which is lacking in lower mammals. However there are a 
number of problems associated with the use of primates in animal research, in 
particular economical and ethical considerations due to the lower social 
acceptance of using these animals (Carmichael 2005).  
Rodent models of cerebral ischaemia have become the most widely used in pre-
clinical research primarily using young male rats and mice, due to the 
availability of transgenic lines (Cenci et al 2002; Hunter et al 1995; Mhairi 
Macrae 1992). The relevance of the rat as an animal model of ischaemic stroke is 
still debated due to the lack of success of neuroprotective drugs tested in 
clinical trials however there are a number of similarities between humans and 
rats including the mechanisms of ischaemic damage and the sensorimotor 
deficits observed following middle cerebral artery (MCA) occlusion (Cenci et al 
2002), and the similarities in the structure and organisation of the cerebral 
vasculature, with both species possessing a circle of Willis (Figure 1.2). Studies 
in rats are also economically viable due to low maintenance costs and the 
availability of inbred strains bred for genetic homology mean that infarction size 
and distribution is relatively reproducible. 
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Figure 1.2: Organisation of blood vessels in the brain for A) Human, and B) Rat (taken 
from Lee, 1995) 
 7
1.2.1 Rodent models of focal ischaemia  
Most human strokes involve the middle cerebral artery (MCA) territory (Barnett, 
Mohr, Stein et al, 1992, Figure 1.3). MCA occlusions account for approximately 
80% of cases in Caucasians (Derouesne et al, 1993; Warlow et al, 2003), and 
because of this the majority of animal models of focal ischaemia that have been 
developed involve occlusion of the MCA (McAuley 1995) (Figure 1.4).  
 
Figure 1.3: CT angiography displaying MCA occlusion (red arrow) in a stroke patient. 
Modified from Wong et al (1996) 
 
 
1.2.1.1 Intraluminal filament model (ILF) 
The most commonly used method of inducing permanent or transient focal 
ischaemia is the intraluminal filament (ILF) model (Koizumi et al 1986). This 
involves the insertion of a silicon rubber-coated monofilament into the external 
carotid artery, where it is introduced into the internal carotid artery and 
advanced to block the origin of the MCA. The filament can remain in this 
position permanently, or be retracted and removed to allow tissue reperfusion.  
The ILF model is advantageous because it does not require a craniotomy, 
although adherence of the filament to the blood vessel walls may cause 
mechanical endothelial damage. Additionally, the infarcts tend to be more 
variable than with some other MCA occlusion (MCAO) models, with higher 
mortality often reported (Minematsu et al 1992). A typical pattern of ischaemic 
damage using the ILF method is shown with Magnetic Resonance Imaging (MRI) 
(Figure 1.5). 
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Figure 1.4: Two commonly used rodent MCAO models. A. Sagittal representation of the 
intraluminal filament method of MCAO, where the bulbed monofilament is introduced 
through the external and internal carotid arteries to block the origin of the MCA, thus 
precluding flow and inducing ischaemia, and B. Coronal representation of the 
electrocoagulation method of MCAO, in which the MCA occluded by electrocoagulation is 
coloured black. The pink shading represents the ischaemic territory following MCA 
occlusion. Illustration A courtesy of C Stock, University of Manchester. Illustration B 
courtesy of J Sharkey, University of Glasgow 
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Figure 1.5: T2-weighted coronal rat brain images at 24 hours following the intraluminal 
filament model of permanent MCAO (rostral (A) to caudal (H)). On T2 images, ischaemic 
tissue appears hyperintense due to its high water content. Similarly the cerebrospinal fluid 
(CSF) in the ventricles also appears bright. Considerable brain swelling is evident in the 
ipsilateral hemisphere at this time point due to cerebral oedema, and this accounts for the 
midline shift. Small haemorrhages are also common in this model, for example in the 
caudate nucleus (dark structures)   on Images (E) & (F). Courtesy of C. Robertson, 
University of Glasgow. 
A    B 
C    D 
E    F 
G    H 
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1.2.1.2 Electrocoagulation model 
A second MCAO model involves electrocoagulation of the MCA with diathermy 
forceps, following a craniotomy, which was developed by Robinson and 
colleagues (1975) and further modified by Tamura and colleagues (1981). The 
method described by Tamura involves direct ligation of the MCA proximal to the 
lenticulostriate artery inducing both cortical and striatal damage, whereas the 
technique by Robinson and colleagues involves electrocoagulation of a more 
distal region of the MCA at the rhinal fissure of the rat which induces cortical 
damage only. Thus, the extent of ischaemic damage is dependent upon the 
position and length of the occlusion. A more distal occlusion produces more 
variability in the extent of the ischaemic lesion and occlusion of only a small 
segment (1-2 mm) can lead to low rates of infarction. Increasing the length of 
vessel occluded can greatly improve the reproducibility of the lesion (Bederson 
et al 1986b). The craniotomy diminishes the deleterious consequences of brain 
swelling following ischaemia, making this method popular due to the low post 
surgical mortality rate; however, it cannot be used to study transient focal 
ischaemia. A typical pattern of ischaemic damage using the distal diathermy 
model is shown with MRI (Figure 1.6). 
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Figure 1.6: T2-weighted coronal rat brain images at 24 hours following the distal 
diathermy model of permanent MCAO (rostral (A) to caudal (H)). On T2 images, ischaemic 
tissue appears hyperintense. The lesion is primarily restricted to the cortex and spatial 
profile is much smaller compared to the intraluminal filament model. Mechanic damage to 
the brain can occur due to the diathermy of the MCA which is apparent in (D). 
A    B 
C    D 
E    F 
G    H 
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1.2.2 Pathophysiology of Ischaemic Stroke 
Ischaemic stroke initiates a constellation of pathophysiological processes, 
including energy failure, increased intracellular calcium, excitotoxicity, necrosis 
and secondary pathogenic mechanisms, inflammation and apoptosis that develop 
for hours and even days after the initial occlusion (Figure 1.7).  
 
1.2.2.1 Energy Failure  
A reduction in cerebral blood flow due to an occlusion of a cerebral artery 
prevents the necessary substrates for energy production, namely glucose and 
oxygen from reaching the supplied tissue. The brain relies almost solely on 
oxidative phosphorylation to generate energy and therefore insufficient delivery 
of glucose and oxygen leads to energy failure within the tissue through a loss of 
adenosine triphopshate (ATP)(Martin et al 1994). Consequently neuronal 
membrane potentials are lost as the Na+-K+ pump Na+/K+-ATPase and Ca2+/H-
ATPase pumps, as well as the reversal of the Na+-Ca2+ exchanger cannot maintain 
ionic gradients (Lipton 1999). This results in an elevation of intracellular Na+, 
Ca2+, and Cl− causing cytotoxic oedema and events triggered by excess 
intracellular Ca2+ (Durukan, and Tatlisumak, 2007).  
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Figure 1.7: The time course and impact of the pathophysiological cascade following 
cerebral ischaemia. (Brouns and De Deyn 2009). 
 
1.2.2.2 Elevation of intracellular Calcium 
The excessive accumulation of intracellular Ca2+ is thought to initiate many 
downstream mechanisms that can cause cell damage and even death via 
apoptotic pathways and necrosis. Depolarisation of neurones and glia, caused by 
the diminished energy production, leads to the activation of presynaptic and 
postsynaptic voltage gated Ca2+ channels and the influx of Ca2+. Free calcium is 
also released from the mitochondria and the endoplasmic reticulum further 
increasing the concentration of Ca2+ in the cytosol.  
The rise in intracellular Ca+2 ions can induce the proteolytic degradation of 
cytoskeletal proteins (actin and spectrin) and the extracellular protein laminin 
(Chen and Strickland 1997; Furukawa et al 1997). Ca2+ is also known to stimulate 
phospholipase A and C which break down membrane phospholipids, resulting in 
the release of free arachidonic acid which directly increases membrane 
permeability and also has profound secondary metabolic events. It is presumed 
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that cellular oedema occurs as an almost immediate consequence of cerebral 
ischaemia.  
1.2.2.3 Excitotoxicity 
Excitotoxicity is the pathological process triggered by the excessive release of 
glutamate and other excitatory neurotransmitters, as a result of cellular energy 
failure, which causes nerve cell damage and death. Diminished energy 
production and failure of ion pumps leads to the activation of presynaptic and 
postsynaptic voltage gated Ca2+ channels and the depolarisation of neurones and 
glia and the release of glutamate into the extracellular space (Dirnagl et al 
1999). Normal glutamate re-uptake into the presynaptic cell is impeded by lack 
of available energy which maintains a high level of extracellular glutamate. This 
increase in extracellular glutamate has been demonstrated in an experimental 
model of stroke (Shimizu-Sasamata et al 1998). The excessive extracellular 
glutamate triggers a rise in intracellular [Ca2+] by binding to glutamate 
receptors: N-methyl-D-aspartate (NMDA), -amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) and metabotropic glutamate receptors (mGluRs). Group I 
mGluRs facilitate this by releasing Ca2+ from its intracellular stores via 
phospholipase C and IP3 (inositol 1,4,5-triphosphate) signalling (Abe et al 1992; 
Aramori and Nakanishi 1992). Na+ ions enter cells via AMPA (α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid) receptors which creates an osmotic 
gradient due to slower K+ efflux. Water can then diffuse into cells and the 
ensuing oedema can affect perfusion in surrounding areas as well as causing 
secondary problems such as increasing intracranial pressure and compressing 
cerebral vessels (Dirnagl et al 1999).  
1.2.2.4 Free Radical Generation  
Ischaemia leads to the production of various free radicals and reactive oxygen 
species (ROS) via a number of mechanisms (Figure 1.8). The activation of the 
enzyme phospholipase A2 triggers the generation of arachidonic acid from the 
breakdown of membrane phospholipids. Ischaemic neurones are known to 
express the enzyme COX2 which is capable of producing ROS and neurotoxic 
prostanoids  
 15
 
 
 
 
Figure 1.8: Reactive oxygen species generation during ischaemia. (Muralikrishna 
Adibhatla and Hatcher 2006) 
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from arachidonic acid (Nogawa et al 1997). The phospholipase A2 pathway 
involves a positive feedback cycle, as free radical production further stimulates 
phospholipase A2 activity and consequently augments the further production of 
free radicals. Free radicals may also be generated as a result of hypoxanthine 
oxidation. Hypoxanthine accumulates under hypoxic conditions due to the 
breakdown of adenine nucleotides. Xanthine dehydrogenase is converted to 
xanthine oxidase which is capable of producing superoxide during the 
metabolism of hypoxanthine. This has been shown in Long-Evans rats where the 
fraction of xanthine dehydrogenase present as the superoxide producing 
xanthine oxidase rose from 23% to 30% following ischaemia although this is not 
thought to be a major contributor to ROS generation in cerebral ischaemia 
(Lindsay et al 1991). 
ROS are proposed to play important roles in coordinating and regulating a 
number of cellular signalling pathways (redox signalling) (Taylor and Crack 
2004). These systems depend on a balance between ROS and the endogenous 
defences capable of detoxifying ROS, including superoxide dismutase (SOD), 
catalase and glutathione. Oxidative stress results when the formation of ROS 
exceeds the capacity of the antioxidant defence systems. Neurons may be 
particularly vulnerable to free radical damage since they contain low levels of 
glutathione (Taylor and Crack 2004). Mice and rats overexpressing SOD1 showed 
significantly smaller infarcts compared to their respective wildtypes following 
transient focal cerebral ischaemia supporting the role of ROS in ischaemic 
damage (Chan et al 1998; Wang et al 1998).  
Nitric oxide (NO) production increases during ischaemia due to increased 
activation of nitric oxide synthase (NOS), the enzyme which catalyzes the 
synthesis of NO from its precursor, L-arginine (Zhang et al 1993). Under normal 
physiological conditions, NO functions as a neurotransmitter and has a role in 
synaptic plasticity as well as in the control of cerebral blood flow, where it acts 
as a vasodilator (Pacher et al 2007). Under ischaemic conditions, NO reacts with 
superoxide to form peroxynitrite, which is a highly reactive oxidant. 
Peroxynitrite is extremely cytotoxic and causes extensive tissue damage via 
inhibition of DNA synthesis, nucleic acid damage and lipid peroxidation leading 
to membrane breakdown. The neutralisation of NO by increased levels of 
superoxide can potentially lead to the loss of NO-dependant vasodilation (Didion 
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and Faraci 2002), causing a reduction in cerebral blood flow further extending 
the perfusion deficit following occlusion in addition to the detrimental effects of 
peroxynitrite. 
Under ischaemic conditions the brain is particularly susceptible to oxidative 
stress due to the limited antioxidant capabilities of the tissue (Adibhatla & 
Hatcher, 2010). The extensive production of ROS and other free radicals 
overwhelms the limited endogenous free radical scavengers and cause 
widespread cellular damage mediated via enzyme inactivation, release of 
calcium ions from intracellular stores, protein denaturation, lipid peroxidation 
and damage to DNA and RNA, in addition to cytoskeletal component breakdown 
(Brouns and De Deyn 2009). Free radicals also act as signalling molecules to 
induce an inflammatory response and trigger apoptosis (Brouns and De Deyn 
2009). Free radicals have detrimental effects on mitochondria, where they 
disrupt the inner mitochondrial membrane via lipid peroxidation and oxidise 
electron transport chain proteins, causing impairments in ATP production (Dugan 
and Choi 1994). Overall, free radicals result in severe mitochondrial dysfunction 
and mediate cellular damage via numerous actions within the cell. 
1.2.2.5 Peri-infarct Depolarisations 
Secondary mechanisms can contribute to the expansion of the ischaemic lesion 
into the surrounding tissue. These include spreading depolarisations which are 
waves of neuronal depolarisations caused as a result of the primary cellular 
energy failure in the core area of the ischaemic damage and the high 
extracellular glutamate and K+ ion concentration. These depolarisations 
propagate out with the ischaemic core in to the tissue at risk, i.e. moderately 
hypoperfused tissue deemed the ischaemic penumbra (explained in more detail 
below). The short supply of ATP means that further depolarisations can exhaust 
energy supply and lead to further cell death and therefore expand the infarct. 
These repetitive depolarisations are known as peri-infarct depolarisations and 
have been detected in many animal models of stroke (Dirnagl et al 1999; 
Hossmann 1996). They have been found to occur several times per hour and the 
number of these depolarisations is proportional to infarct size (Mies et al 1993). 
Unfortunately peri-infarct depolarisations have not been observed in human 
ischaemic stroke therefore the significance of these findings is unclear with 
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regards to the human disease. Interestingly however, in traumatic brain injury 
and aneurysmal subarachnoid haemorrhage spreading cortical depolarisations 
have been identified as mechanisms of ischaemic damage suggesting that these 
may still be observed in the future (Dreier et al 2009; Fabricius et al 2006) 
1.2.2.6 Inflammation 
Many pro-inflammatory genes are expressed in response to the increase in free 
radical production and activation of Ca2+-dependant pathways initiated by 
excitotoxicity. Tumour necrosis factor α (TNF-α) and interleukin 1β (Il-1β) and 
platelet activating factor which are known mediators of inflammation are 
produced by damaged cells in the brain (Rothwell and Hopkins 1995). This 
promotes expression of various adhesion molecules allowing neutrophil 
infiltration followed by monocytes and macrophages with further inflammatory 
cells being recruited to the ischaemic area by the release of chemokines 
(Yamasaki et al 1995). Preceding this infiltration, microglial cells become 
activated particularly in the ischaemic penumbra where they are thought to 
contribute to brain injury (Schilling et al 2003).  
This post-ischaemic inflammation is thought to exacerbate ischaemic brain 
injury via a multitude of mechanisms. Studies have shown that preventing 
infiltration of neutrophils can reduce ischaemic damage (Dirnagl et al 1999). 
Also blocking the binding of adhesion molecules to their receptors has proved 
beneficial. One study has shown that in null ICAM-1 mice infarct volume was 
significantly attenuated (Connolly et al 1996). Neutrophils are thought to evoke 
cell damage by producing excessive amounts of NO via inducible NOS (Forster et 
al 1999). This can lead to peroxynitrite formation, from NO reacting with 
superoxide, which is a highly reactive ROS that causes cell damage. Secondly 
neutrophils are also thought to have a physical role in exacerbating ischaemia by 
occluding the microvasculature and this has been shown in baboons (del Zoppo 
et al 1991).  In addition the activated microglia found in the penumbra and to a 
lesser extent the ischaemic core can produce deleterious compounds such as ROS 
adding to cell damage (Giulian et al 1994). TNF-α is also produced by these 
neurones but some studies have suggested that TNF-α has a beneficial role by 
inducing antioxidant enzymes (Barone et al 1997; Bruce et al 1996). 
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1.2.2.7 Necrosis and Apoptosis 
Under ischaemic conditions in the brain, cells die either by necrosis or apoptotic 
pathways. These pathways are highly conserved biochemical pathways that 
signal and execute cell death. The mechanism of cell death for a cell is 
dependant on the severity of ischaemia, the excitotoxic stimulus and the cell 
type (Leist and Nicotera 1998). Necrosis is the most common mechanism of cell 
death in severe ischaemia, especially within the ischaemic core of the insult 
(Dirnagl et al 1999). The process of cellular necrosis involves disruption of 
membrane structural and functional integrity, rapid influx of Ca2+ and water, 
and subsequently, dissolution of the cell. Therefore, cellular necrosis results 
from abrupt environmental changes and a loss of normal physiological 
conditions. When cells die via the necrotic pathway, they release more 
glutamate and toxic mediators into the surrounding environment affecting 
neighbouring cells (Brouns and De Deyn 2009).  
Apoptosis is a programmed mechanism that orchestrates cell death in cells that 
are affected by milder injury such as in the ischaemic penumbra (Dirnagl et al 
1999). These apoptotic pathways can be either caspase dependant or 
independent although caspase dependant pathways are primarily involved in 
neuronal cell death following focal cerebral ischaemia. Caspases are a family of 
protein cleaving enzymes that are constitutively expressed in neurones and 
other brain cells. These enzymes can cleave numerous proteins leading to 
protein activation or inactivation, both of which may promote cell death. 
Caspases 1 and 3 are thought to be primarily involved in ischaemia-mediated 
apoptosis. Caspase 3 has been found to be present in the ischaemic core and the 
penumbra following reperfusion in a mouse model of temporary MCA occlusion 
(Namura et al 1998) and caspase 1 knockout mice elicit a reduced lesion size 
following focal MCA occlusion (Schielke et al 1998). The exact nature of the 
upstream mechanism that leads to the activation of these caspases following 
ischaemia is still not well understood. However, it has been found that 
cytochrome C release from mitochondria, which occurs during excitotoxicity, 
forms part of an apoptosome complex which can activate the various 
executioner caspases and induce apoptosis (Green and Reed 1998).  
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1.3 The Ischaemic Penumbra 
1.3.1 Cerebral Blood Flow 
Following stroke, there is a heterogeneous reduction in cerebral blood flow 
(CBF) across the affected vascular territory. Tissue in end artery territory has 
the greatest severity of ischaemia where complete or profound loss of CBF 
represents tissue that will progress to an infarct and this is deemed the 
ischaemic core.  
The brain has a complex network of anastomosing vessels which means perfusion 
of the adjacent region to the core is partially achieved by collateral supply and 
thus the hypoperfusion is less severe. Following vascular occlusion this tissue will 
have functional impairment but will not immediately undergo irreversible 
morphological changes and is termed the ischaemic penumbra (Figure 1.9).  
The concept of the penumbra was first described in a series of experiments 
conducted in the 1970s into the effects of progressive reductions in cerebral 
blood flow on the baboon cortex which found that different cerebral blood flow 
thresholds existed in the pathogenesis of stroke relating to tissue function and 
survival (Astrup et al 1977; Branston et al 1974; Branston et al 1977; Symon et al 
1974). These studies examined cortical-evoked responses at varying thresholds 
of blood flow and found that there was an area of hypoperfused tissue with 
cellular dysfunction but not death and that full restoration of blood flow had the 
potential to reverse cellular dysfunction in this region. It was established from 
examining cortical-evoked responses that there were three blood flow 
thresholds; one threshold that determines morphological damage (ischaemic 
core), a less severe threshold for functional impairment (ischaemic penumbra) 
and finally normal tissue thought to include some benign oligaemia.  Benign 
oligaemic tissue refers to tissue that has suffered a modest reduction in blood 
flow which is not severe enough to threaten its survival. In primates, following 
blockage of a cerebral vessel the end artery territory (ischaemic core) has CBF 
of <10 mL/100 g per min within which irreversible cell damage takes place 
within minutes. The intermediate tissue around the periphery of this core 
(ischaemic penumbra) experiences a more modest reduction in CBF, where flow 
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is ~15% to 40% of normal levels. Unless blood flow is restored, this penumbral 
tissue will progressively become incorporated into the infarct, and this process 
can take a number of hours (Pulsinelli, 1992). There are often some areas of 
modest hypoperfusion which are not expected to become incorporated into the 
infarct under normal circumstances. This benign oligaemic tissue and its blood 
flow can range from normal CBF values down to ~20 mL/100g/min (Baron et al, 
2001). It is expected that this region enters a less severely hypoperfused state 
(above 30 mL/100g/min), which prevents the tissue undergoing infarction 
(Linskey et al, 1994). However, benign oligaemic regions are not completely safe 
from infarction as factors such as hyperglycaemia, fever and hypotension, 
present in conjunction with small reductions in CBF, may induce progressive 
damage.  
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Figure 1.9:  Depiction of the nature of ischaemic injury, with penumbral tissue 
surrounding an ischaemic core following blockage of a cerebral artery. Adapted from Allan 
and Rothwell (2001) 
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1.3.2 Imaging the ischaemic penumbra 
There are several imaging modalities available to visualise the ischaemic 
penumbra following cerebral artery occlusion both clinically and experimentally. 
In the clinical setting the rapid detection of penumbral tissue will improve 
patient selection for treatment with thrombolysis. It may also provide the 
potential to group similar patients in distinct cohorts in clinical trials. It is 
thought that a lack of efficacy in both thrombolysis and neuroprotection trials 
may have arisen from treating patients who lacked a significant volume of the 
potentially salvageable penumbral tissue even within the conventional time 
windows (Muir 2002). The possible improvement in selection for thrombolysis 
safety based on more advanced penumbral imaging has been suggested 
(Schellinger et al 2003).  
1.3.3 Computed tomography  
Computed tomography (CT) is currently the most accessible clinical technique 
for identification of the ischaemic penumbra due to its widespread availability in 
hospitals, speed of image acquisition and its relative cost-effectiveness. Non 
contrast CT scans cannot identify the penumbra reliably with acute 
hypoperfused regions often appearing as normal (Ebinger et al 2009). However, 
CT perfusion (CTP) techniques using injection of an iodinated contrast agent are 
useful in predicting the fate of ischaemic tissue (Parsons et al 2007). CT 
perfusion imaging defines penumbra based on changes in cerebral blood volume 
(CBV), CBF and the contrast mean transit time (MTT).  Using these methods, the 
ischaemic core has been defined as a region with CBV below 2 mL/100g and a 
relative MTT above or equal to 145% of the contralateral value (Tan et al 2007). 
CTP defines penumbral tissue as a region with increased cerebral blood volume 
(relative to the ischaemic core due to local vasodilatation, where autoregulatory 
processes compensate for reduced relative (rCBF)), as well as reduced CBF and 
increased MTT. Xenon-enhanced CT has also been used to identify ischaemic 
core and penumbra. Xenon crosses the blood-brain barrier after inhalation and 
due to its high atomic number can be measured on the CT scanner. This 
technique has been shown to give a high resolution and sensitivity (Yonas and 
Jungreis 1995).  However, these CT techniques suffer from a lack of validation 
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for visualisation of the penumbra. The software provided with each different 
system varies in the post-processing algorithms and whole brain scanning is still 
very limited. Radiation exposure may prevent serial scanning, and iodinated 
contrast agent administration may cause nephropathy (Ebinger et al, 2009). 
 
1.3.4 Positron Emission Tomography (PET) 
PET is widely regarded as the gold standard for clinical assessment of penumbra 
as it can quantifiably measure CBF, cerebral oxygen metabolism (CMRO2) and 
oxygen extraction fraction (OEF). PET relies on the intravenous administration of 
a positron emitting radioisotope bound to a tracer ligand. The gamma rays 
emitted by the tracer are detected and reconstructed to produce a tomographic 
image. Multi-tracer PET using 15O or H2
15O as tracers has been used to identify 
the penumbra as tissue with reduced CBF, preserved CMRO2 and an increased 
OEF (Baron 1999; Ebinger et al 2009)(Figure 1.10). This signature of penumbral 
tissue was termed ‘misery perfusion’ by Baron and colleagues (1981). In humans, 
oxygen metabolism and CBF thresholds of irreversibly damaged tissue have been 
defined as 65 µmol/100g/min and 12 mL/100g/min, respectively (Heiss 2003). 
 
 
Figure 1.10: Multimodal imaging 5 hours post-stroke in a human patient. Penumbra is 
defined as a region with reduced CBF, preserved CMRO2 and increased OEF circled in 
red. Adapted from Heiss et al (2004) 
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Modern PET tracers like the hypoxic ligand [18F]-fluromisonidazole (FMISO) and 
the neuronal receptor ligand, [11C]-flumazenil (FMZ) can also identify penumbral 
tissue. FMZ is a central benzodiazepine receptor ligand which is a marker of 
neuronal integrity capable of detecting neuronal damage within the first few 
hours of stroke onset. FMISO is a tracer of hypoxic viable tissue and is therefore 
useful in the detection of penumbra where increased areas of tracer are 
detected (Heiss 2003). The use of these ligands was supported by Takasawa and 
colleagues (2007), who reported increased FMISO uptake in the first hours in a 
MCAO rat model in the absence of reperfusion when the tissue was not yet 
irreversibly damaged. However, increased FMISO uptake has been shown 20 
hours post-stroke despite reperfusion in the rat (Saita et al 2004). It was 
suggested that the persistent hypoxia may have occurred due to peri-infarct 
oedema, small vessel occlusion, or the ‘no-reflow’ phenomenon where removal 
of the intraluminal filament fails to recanalise the previously occluded vessel.  
Although PET is an accurate means of physiological monitoring which permits 
quantitative measurements, it is impractical for clinical use (Muir and Santosh 
2005; Schellinger et al 2003). It necessitates arterial catheterisation for blood 
sampling, and it is prohibited when the administration of thrombolytics is 
planned (Heiss et al 1998). Additionally, although serial PET scanning has been 
done pre-clinically to assess the temporal evolution of the penumbra, multiple 
scans cannot be performed in humans due to the radiation dose administered. It 
is also expensive, technically challenging and of limited availability in stroke 
units (Muir and Santosh 2005; Schellinger et al 2003). As such, MRI and CTP are 
preferred for penumbral imaging in the clinical research domain. 
1.3.5 Magnetic Resonance Imaging (MRI)   
MRI is a non-invasive imaging modality that is based upon the electromagnetic 
activity of atomic nuclei, namely hydrogen atoms, since they are the most 
abundant in the body. MRI is capable of producing high resolution anatomical 
images as well as imaging pathological processes, organ function and even neural 
activity which means it is an extremely useful technique with regards to, but not 
limited to, diseases of the central nervous system. The presence of a strong 
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external magnetic field takes advantage of the intrinsic characteristics of the 
hydrogen nuclei in the body.  Each hydrogen nucleus consists of a single 
positively charged proton which rotates around its own axis. Each proton 
generates its own magnetic field on the basis of their spin and the positive 
charge these protons possess. This magnetic field is known as a magnetic 
moment. When a subject is placed in a magnetic field such as created by an MRI 
scanner, the protons are forced to align in one of two possible positions; either 
parallel or anti-parallel with the magnetic field. In order to generate a magnetic 
resonance signal the protons must be excited from a low to high energy state by 
exposure to electromagnetic radiation of radio frequency (RF). When radio 
waves are sent toward these hydrogen atoms, the alignment of the 
magnetisation (magnetisation vector) is altered. This causes the emittance of a 
weak radio signal that can be amplified and detected by the scanner. The 
magnetisation vector is altered by either 90° or 180° by exposure to specific 
radio frequencies know as RF 90° and RF 180°. Following the excitation of 
protons and the changes imposed on the magnetisation vector, the protons 
return to magnetic equilibrium within the scanner. The time taken for the 
magnetic resonance signal to fade and equilibrium to be reached is known as the 
relaxation time which can be measured. This relaxation time is reliant on two 
independent processes that almost happen simultaneously. The first known as 
spin-lattice interaction (T1 relaxation) involves the dissipation of energy into the 
surroundings in order to regain equilibrium. Spin-spin interaction (T2 relaxation) 
is where the MR signal fades as the magnetic fields from adjacent protons 
interfere with each other. Different types of tissues send back different signals, 
allowing differentiation between internal structures, which leads to a 
reconstruction of the image of the subject. MRI images can be ‘weighted’ to 
allow one factor to determine the contrast of the image. T1 relaxation time can 
be used to primarily determine the image contrast and these are known as T1-
weighted images. Similarly T2-weighted images can be generated by using T2 
relaxation to determine the contrast.  
1.3.6 T2-weighted imaging 
T2-weighted imaging has been used in clinical and preclinical studies to assess 
ischaemic brain tissue 12 to 24 hours following stroke but in the critical period 
 27
regarding the ischaemic penumbra (up to 12 hours post stroke) this imaging 
modality is unable to adequately determine the extent of ischaemically damaged 
tissue (Baird and Warach 1998). Ischaemically damaged tissue has a longer T2 
relaxation time than normal parenchymal tissue meaning that it has a higher 
signal intensity on T2-weighted images. Some T2-weigted sequences can be 
converted to quantitative T2 maps which enable the comparison of T2 relaxation 
times of different tissue compartments between subjects. There is also the 
potential to derive a threshold of abnormality to distinguish between 
ischaemically damaged tissue and unaffected tissue. 
Different MRI sequences have been developed to allow the penumbra to be 
visualised based on the use of diffusion and perfusion weighted imaging.  
 
1.3.7 Diffusion weighted imaging 
Diffusion-weighted imaging utilises signal changes, which are dependant on the 
diffusion of water protons within tissues. DWI is based on the sensitivity of MR to 
motion, which shows the signal intensity changes that are due to the movement 
of water by diffusion. Water molecules have isotropic diffusion properties which 
mean they are free to move in all directions. However the rate of water 
diffusion within a voxel is determined by cellular structures such as cell 
membranes which act as diffusion barriers and therefore increase anisotropic 
diffusion, i.e. diffusion in a particular direction. Within brain tissue under 
normal conditions, extracellular water molecules diffuse relatively freely which 
results in a low signal on DWI images. Following energy failure associated with 
ischaemia, the loss of ion pump function leads to the shift of water from the 
extracellular space to the intracellular space resulting in cytotoxic oedema, cell 
swelling and the restriction of water molecule diffusion (Moseley et al 1990a). 
This reduced mobility of protons leads to an increase in the diffusion constant 
and a high signal intensity on DWI images. The diffusion constants can be used to 
generate a quantitative measure of diffusion for a particular voxel, which is 
known as the apparent diffusion coefficient (ADC). These ADC values can be used 
to generate ADC maps where a higher intensity represents areas of free diffusion 
of water and lower intensity represents restrictive diffusion, which is the 
opposite of DWI images. A decrease in the ADC of the ischaemic brain tissue has 
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been shown to coincide with the onset of cytotoxic oedema and so ADC has been 
taken as an indicator of irreversibly damaged tissue (Davis et al, 1994). DWI can 
detect ischaemic injury within minutes of MCA occlusion in animal models of 
stroke (Moseley et al 1990b) which has similarly been observed in humans 
(Yoneda et al 1999). This is far quicker than can be achieved with CT scans and 
T2-weighted MRI scans where ischaemic damage can only be detected between 3 
and 12 hours post-stroke, respectively (Roberts et al, 2002). Although reduced 
ADC is thought to represent irreversibly damaged tissue there is evidence that 
shows following rapid reperfusion some of the ADC-defined lesion can be 
reversed suggesting that the ADC-defined ischaemic damage may overestimate 
the extent of ischaemic injury (Hasegawa et al 1994). However clinically 
relevant reversal of the ADC-defined lesion has been found to be uncommon and 
often transient (Campbell et al 2012) 
1.3.8 Perfusion weighted imaging (PWI) 
Cerebral blood flow can be quantified using perfusion based MR imaging by 
monitoring the signal changes induced by a tracer entering the brain. One 
commonly used MR technique for perfusion imaging is known as contrast agent 
bolus tracking which involves the intravenous administration of a gadolinium-
based contrast agent into the circulation. These agents are paramagnetic which 
results in magnetic inhomogeneity. This results in a decrease in signal intensity 
as the contrast agent passes through the cerebral vasculature. As the contrast 
agent passes away from the detection plane the homogeneity of the magnetic 
field is restored and the signal returns to normal. This change in signal intensity 
enables the contrast agent to be tracked throughout the brain and identify areas 
of low perfusion. However, CBF values generated with this technique tend to 
overestimate the region of perfusion deficit when compared with the gold 
standard PET techniques (Zaro-Weber et al 2009).  
Another MR based technique for CBF quantification, called Arterial Spin 
Labelling (ASL), uses electromagnetically labelled arterial blood as an 
endogenous tracer rather than relying on the introduction of a contrast agent 
(Figure 1.11). The technique involves using a specific RF pulse sequence that 
inverts the spin of protons in an artery supplying an area of interest (labelled 
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slice). A coronal image is acquired at the region of interest and the signal 
intensity is measured (imaging slice). The signal intensity for a pixel is 
dependant on the number of labelled protons that have travelled to that 
particular pixel which is proportional to the amount of inflowing blood. This is 
known as the labelled image. A second image, the non-labelled image, is 
acquired without the labelling of protons so that a simple mathematical 
equation will produce qualitative CBF maps. Quantitative CBF maps can be 
generated subsequently by taking into account the T1 relaxation time. ASL 
sequences have been widely used in rodent models of cerebral ischaemia 
(McCabe et al 2009; Meng et al 2004; Robertson et al 2011) as well as in humans 
(Chalela et al 2000), and provide a non-invasive, multi-slice perfusion measure 
that can be repeated for serial analysis of CBF without the need for exogenous 
contrast agents.  
 
Figure 1.11: Concept of arterial spin labelling, shown on a sagittal scan of a rat brain 
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1.3.9 MRI Perfusion-Diffusion Mismatch 
The combination of DWI and PWI in stroke has enabled an MRI based 
identification of suspected penumbral tissue (Baird and Warach 1998). In this 
method the DWI based ADC maps are used to identify the region of ischaemic 
injury that is thought to be irreversibly damaged, i.e. the ischaemic core. This 
area of ischaemic injury is overlaid onto a CBF map generated from PWI which 
indicates the hypoperfused area resulting from cerebral vascular occlusion 
(Figure 1.12).  
Acutely after occlusion, the area of hypoperfusion usually incorporates a greater 
area than the ADC-derived ischaemic lesion, and this difference, known as the 
diffusion-perfusion mismatch (DWI/PWI mismatch) approximately represents the 
ischaemic penumbra (Schlaug et al 1999).  The DWI/PWI mismatch was used in 
the phase II Desmoteplase in Acute Ischaemic Stroke (DIAS) Trial as part of the 
patient selection criteria for thrombolysis. All patients that were recruited had 
at least a 20% PWI/DWI mismatch and patients who received desmoteplase 
within 9 hours of stroke symptom onset demonstrated a higher rate of 
reperfusion and improved clinical outcome compared with patients treated with 
placebo (Hacke et al 2005). The diffusion and perfusion imaging evaluation for 
understanding stroke evolution (DEFUSE) study also supported the validity of the 
DWI/PWI mismatch hypothesis in patients treated with thrombolysis therapy in 
the 3 to 6 hour time window (Albers et al 2006). This study showed that patients 
who presented with a DWI/PWI mismatch (perfusion deficit 120% of ADC-derived 
ischaemic injury) were associated with a more favourable clinical outcome after 
early reperfusion, with thrombolysis, than patients where no mismatch was 
present (Albers et al 2006). Similar findings were observed in the Echoplanar 
Imaging Thrombolytic Evaluation Trial (EPITHET) where thrombolysis treatment 
was given between 3 and 6 hours following stroke symptom onset. Patients who 
presented with mismatch again showed improved functional outcome, which was 
associated with reduced infarct growth and increased reperfusion (Davis et al 
2008). 
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Figure 1.12: Coronal images of rat brain obtained 1 hour after permanent MCAO. The 
thresholded PWI (57% reduction of mean contralateral CBF values) illustrates the 
perfusion deficit, whilst the thresholded DWI (16.5% reduction in mean contralateral ADC 
values) is an indication of ischaemic damage. The thresholded area on the DWI is 
subtracted from the region of hypoperfusion, the mismatch corresponding to the 
ischaemic penumbra. 
 
The DWI/PWI mismatch has been used in pre-clinical research to assess the 
temporal evolution of the penumbra. It has been shown that following 
permanent MCAO in Sprague Dawley rats the diffusion lesion expands temporally 
to encompass the perfusion deficit, reducing the amount of penumbral tissue 
over time (Meng et al 2004). This mismatch has been demonstrated in 
spontaneously hypertensive stroke-prone rats (SHRSP) and their normotensive 
control strain Wistar-Kyoto (WKY) where a reduction in mismatch was observed 
in the SHRSP compared to the WKY (McCabe et al 2009; Reid et al 2012).  
There are a few disadvantages to the DWI/PWI mismatch which include the 
inability to differentiate between penumbral tissue and benign oligaemia, the 
partial or full reversibility of the DWI-defined ischaemic injury (Kidwell et al 
2000) and the lack of standardised viability thresholds for both DWI and PWI 
(Butcher et al 2005; Guadagno et al 2004). 
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injury 
DWI PWI 
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1.3.10 Salvaging the ischaemic penumbra 
The nature of the ischaemic penumbra has made it the primary focus for 
treatment of acute ischaemic stroke. As it is known that the penumbra is 
hypoperfused yet still metabolically active, it represents tissue that is at risk of 
infarction if restoration of blood flow or attenuation of the ischaemic cascade is 
not achieved. This means that the penumbra is tissue that can be potentially 
salvaged and its rescue has been associated with improvements in both 
neurological function and recovery (Molina and Saver 2005).  
Using animal models of stroke, a vast quantity of potential neuroprotective 
agents have been investigated that pharmacologically target aspects of the 
ischaemic cascade and the pathophysiology of cerebral ischaemia. Many of these 
agents showed preclinical efficacy by reducing infarct size and functional 
deficits.  However the translation of these neuroprotectants to the human 
condition has proved extremely difficult (Howells et al 2010) Preclinical data 
from 1026 potential stroke treatments in acute cerebral ischaemia were 
evaluated and showed that out of these potential neuroprotectants 603 were 
tested in models of focal cerebral ischaemia, of which 374 were found to show 
efficacy. Of these, 97 were assessed in clinical trials but only a single treatment 
was found to be effective in human stroke (O'Collins et al 2006). This treatment 
was thrombolysis using recombinant tissue plasminogen activator (rt-PA). rt-PA is 
an enzyme that catalyses the conversion of plasminogen to plasmin, which can 
break down the blood clot responsible for the blood  vessel occlusion, 
reperfusing the territory of the artery and potentially rescuing the penumbra 
(Figure 1.13). 
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Figure 1.13: 3D CT image of the Circle of Willis of an acute stroke patient with an 
occluded middle cerebral artery identified by the missing vessel (red arrow) (A) and 
following thrombolysis (B), where flow is restored to previously ischaemic regions (Images 
provided by Professor K Muir, Southern General Hospital) 
 
The National Institute of Neurological Disorders and Stroke (NINDS) trial of rt-PA 
found that intravenous administration up to 3 hours after stroke symptom onset 
improved clinical outcome and patients that received rt-PA were 30% more likely 
to have little or no disability after 3 months compared to placebo treated 
patients(1995). This trial led to the recommendation for use within this short 
time window (Adams et al 1996). The European Cooperative Acute Stroke Study 
(ECASS) investigated extending the time window for treatment with rt-PA up to 6 
hours from stroke symptom onset. ECASS found that although functional 
outcome was improved in patients with a moderate to severe neurological 
deficit following thrombolysis, the mortality rate was higher at 30 days post 
stroke than the placebo treated group (Hacke et al 1995). This increase in 
mortality was partially attributed to an increased frequency of parenchymal 
haemorrhage and these factors led to the conclusion that rt-PA should not be 
administered up to 6 hours post stroke onset in an unselected population. This 
trial was followed by a second (ECASS II) which failed to show any neurological 
improvement with treatment up to 6 hours following stroke onset, similarly 
reporting increased risk of haemorrhage after thrombolysis (Hacke et al 1998). 
The third ECASS trial (ECASS III) reported that improvements in clinical outcome 
were observed in patients treated with rt-PA between 3 and 4.5 hours following 
       A                B 
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symptom onset (Hacke et al 2008), and subsequently the guidelines for rt-PA 
were adjusted to allow treatment within 4.5 hours of stroke onset (Saver et al 
2009). 
However, even with the extended time window for treatment many patients are 
ineligible for thrombolytic therapy, with less than 10% of stroke patients 
receiving rt-PA (Cocho et al, 2005; Molina and Saver, 2005). The low treatment 
rates are due to a number of factors including, presenting outside the time 
window, and lack of rapid medical assessment (Katzan et al, 2004, Kahn et al, 
2005). In addition, patients are excluded if they are experiencing mild or rapidly 
improving symptoms, if the time of onset is unclear (due to waking with 
symptoms) and the concern over potential haemorrhage (Barber, 2001).The 
Stroke Association ran a campaign recently to raise awareness of the symptoms 
of stroke and the importance of getting to hospital quickly for timely treatment 
(Figure 1.14). The Department of Health reported that in the 2 months following 
the Act F.A.S.T campaign 16% of patients were arriving at hospital quicker which 
is imperative to increase the thrombolysis therapy rate. 
(http://www.dh.gov.uk/health/2012/02/act-fast/). 
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Figure 1.14: Example of a poster produced by the NHS to promote the Act F.A.S.T 
campaign which aimed to raise awareness of the common symptoms of stroke and the 
need to be treated quickly in hospital.  
 
It is widely appreciated in preclinical research that physiological parameters can 
affect the amount of ischaemic damage resulting from MCAO. Blood gases, 
including PaO2 and PaCO2, and blood pressure outside the normal limits for CBF 
autoregulation can cause a significant decrease in global CBF which in turn can 
affect consequential ischaemia. Core body temperature changes have also been 
associated with alterations in neuronal injury (as reviewed by Macrae, 1992). 
Plasma glucose concentrations have also been implicated in altering ischaemic 
injury and this is potentially a target for managing stroke patients.   
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1.4 Hyperglycaemia and Stroke 
Hyperglycaemia is a condition of abnormally high levels of circulating glucose 
dissolved in the plasma as a result of an imbalance in normal glucose 
homeostasis. A rise in blood sugar stimulates the release of insulin from the β-
cells of the pancreas into the circulation. Insulin acts on insulin receptors in the 
liver to stimulate glycogen synthesis. Insulin also stimulates glucose uptake 
through glucose transporters into insulin sensitive tissues, such as skeletal 
muscle and adipose tissue maintaining the level of glucose at a physiological 
level. Hyperglycaemia occurs when either the secretion of insulin is perturbed or 
the sensitivity to insulin of various tissues is lost.  
Hyperglycaemia following ischaemic stroke is common, occurring in 60% of 
patients who are not diagnosed with diabetes and in 90% of diabetic patients 
following acute stroke (Muir et al 2011). Post-stroke hyperglycaemia (PSH) is a 
predictor of mortality and disability which is independent of age, stroke type or 
severity from clinical studies (Capes et al 2001; Weir et al 1997).There has been 
much debate about the origin of hyperglycaemia in stroke. Many initial studies 
proposed that the mechanism of hyperglycaemia was the result of a stress 
response following more severe stroke (Murros et al 1992; O'Neill et al 1991; 
Tracey and Stout 1994) but later larger studies failed to correlate 
hyperglycaemia with stress response mechanisms, anatomical location or stroke 
severity suggesting that this was not the case (Christensen 2005; Moreton et al 
2007). It has been found that around 56% of patients who present with 
hyperglycaemia following acute stroke have an unrecognised dysglycaemic state 
such as impaired glucose tolerance, metabolic syndrome or diabetes (Gray et al 
2004b).  
The availability of neuroimaging techniques has provided information on the fate 
of the penumbra under hyperglycaemic conditions. Using the MRI based DWI/PWI 
mismatch for defining penumbra, blood glucose was shown to correlate with 
reduced penumbral salvage, greater infarct size and worse functional outcome 
(Parsons et al 2002).  
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Hyperglycaemia at hospital admission has also been found to be deleterious in 
patients treated with rt-PA. A small study (47 patients) showed that patients 
who experienced hyperglycaemia (blood glucose >7.7 mmol/l) prior to 
recanalisation, led to the DWI-defined ischaemic lesion growing  2.7 times faster 
than in normoglycaemic patients (Ribo et al 2007). Baird et al. (2003) used a 
similar continuous measurement of blood glucose to Ribo et al (2007) and 
identified persistent hyperglycaemia as an independent determinant of infarct 
expansion and also correlated it with reduced functional outcome (Baird et al 
2003). Data from the NINDS rt-PA stoke trial found that admission plasma  
glucose levels were  not associated with altered effectiveness of thrombolysis 
but increasing glucose levels in the blood  did predict worse outcome and 
increased risk of intracerebral haemorrhage (Bruno et al 2002). The risk of 
haemorrhage following rt-PA, regardless of glycaemic state, is significant and 
has been a major factor for not extending the treatment time window of 
thrombolysis. Patients suffering from symptomatic or asymptomatic 
intracerebral haemorrhage following rt-PA treatment  were  found to have a 
higher serum glucose concentration, further suggesting that hyperglycaemia 
increases the rt-PA associated risk of intracerebral haemorrhage (Tanne et al 
2002). This potentially means that in the presence of hyperglycaemia the time 
window for effective rt-PA could actually be much shorter than the 4.5 hours 
recommended currently.      
1.4.1 Preclinical research into post stroke hyperglycaemia 
The research investigating hyperglycaemia in animal models of stroke is 
extensive and generally supports the findings of clinical observations. 
Hyperglycaemia has been associated with increases in infarct size, brain oedema 
and worsening neurological scores (de Courten-Myers et al 1988; Kamada et al 
2007; Lin et al 1998; Warner et al 1995). Preclinical data (de Courten-Myers et 
al 1994; Zhu and Auer 2004), indicated that hypoglycaemia is potentially as 
detrimental as hyperglycaemia with an optimal blood glucose level of 6-7 
mmol/l in rats being suggested for minimal damage(Zhu and Auer 2004). There 
are a number of models of hyperglycaemia which commonly feature in the 
literature and these will be discussed in the subsequent sections.  
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1.4.1.1 Streptozotocin-induced hyperglycaemia 
Streptozotocin was first identified as an agent to create a model of type 1 
diabetes mellitus in the early sixties (Karunanayake et al 1974; Like and Rossini 
1976; Rakieten et al 1963).  Streptozotocin causes pancreatic islet cell 
destruction resulting in an insulin deficiency which mimics human type 1 
diabetes mellitus and the severity of the ensuing diabetes is dose dependent 
(Junod et al 1969). This model of hyperglycaemia has been used in combination 
with focal, both transient and permanent, and global cerebral ischaemia models.  
In rats, using a permanent MCAO model, streptozotocin-induced hyperglycaemia 
(blood glucose ~30.8 mmol/l) led to a significant increase in infarct volume 
compared to controls (blood glucose <11.1 mmol/l) measured 48 hours post 
MCAO (Bomont and MacKenzie 1995). This study supported previous findings in 
rats using a 48 hour permanent focal ischaemia model, where severe 
hyperglycaemia (blood glucose ~25.3 mmol/l) induced by streptozotocin resulted 
in a more substantial lesion volume than control rats (Duverger and MacKenzie 
1988). Nedergaard & Diemer (1987) found acute administration of streptozotocin 
(2 days) was not sufficient to increase infarct volume compared to 
normoglycaemic controls, but chronic (4 months) administration exacerbated 
cerebral infarction compared to control rats showing that the length of the 
dosing period is important. The effect of streptozotocin-induced hyperglycaemia 
on ischaemic injury has been seen far earlier than 48 hours after MCAO. Using 
serial DWI and T2-weighted MRI from 20 minutes to 6 hours post MCAO, the rate 
of incorporation of tissue into the ADC-defined ischaemic lesion has been shown 
to be increased in hyperglycaemic animals compared to controls (Huang et al 
1996). Quast et al (1997) also utilised MRI using single slice DWI for ischaemic 
damage determination and also relative CBF and CBV measurements using 
different MR sequences. They failed to show any difference in ischaemic injury 
following a 4 hour MCAO, although it seemed that the perfusion deficit changes 
correlated to ischaemic damage (Quast et al 1997). It was suggested that the 
effect of hyperglycaemia on cerebral ischaemia perhaps relied on the presence 
of collateral vessels. A study using the spontaneously hypertensive (SHR) rats, 
which are known to suffer from poor collateral flow, showed that chronic 
hyperglycaemia induced by streptozotocin had no effect on infarct volume using 
a two vessel (MCA and ipsilateral CCA) focal ischaemia model (Slivka 1991).   
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The use of transient MCAO has also been studied in streptozotocin-induced 
hyperglycaemic rats and has complemented the research conducted in 
permanent MCAO models. Nedergaard (1987) found that following temporary 
occlusion of the MCA proximal to the lenticulostriate branches, for 10 or 15 
minutes,  hyperglycaemic animals (plasma glucose >20 mmol/l) exhibited 
significantly larger infarcts than control animals, when assessed histologically 4 
days post MCAO. Streptozotocin administration only began two days before 
MCAO which in a permanent model failed to exacerbate infarct volume, even 
though blood glucose was elevated considerably (Nedergaard and Diemer 1987). 
Utilising MRI to assess the potential acceleration of damage in the acute phase 
of cerebral ischaemia it has been shown that streptozotocin-mediated 
hyperglycaemia augments DWI-defined ischaemic injury compared to controls 
following 1 hour of MCAO and subsequent reperfusion (Huang et al 1996). 
Interestingly the damage in hyperglycaemic animals following transient MCAO 
was more pronounced than after permanent MCAO up to 3 hours post occlusion 
suggesting that hyperglycaemia may stimulate or enhance reperfusion injury 
mechanisms. Similarly, following 1 hour of MCAO and reperfusion, 
streptozotocin-mediated hyperglycaemia increased final infarct volume by 41% 
compared to control rats. This was associated with a diminished restoration of 
CBF in hyperglycaemic rats compared to controls potentially caused by a 
downregulation in cerebral vessel t-PA expression (Kittaka et al 1996). Quast et 
al (1997) utilised single-slice DWI to investigate hyperglycaemia mediated 
damage following transient MCAO. They observed that after a 2 hour MCAO 
followed by 2 hours of reperfusion DWI-defined ischaemic injury was increased 
by 118% in hyperglycaemic animals compared to controls, yet in a permanent 
MCAO model hyperglycaemia failed to have any effect (Quast et al 1997). 
Another study utilising MRI showed that 5 hours after MCAO (2 hour occlusion 
followed by 3 hours reperfusion) DWI-defined ischaemic injury was significantly 
augmented compared to controls and this was associated with a larger area of 
no-reflow similar to what Kittaka et al (1996) had reported (Wei and Quast 
1998). A high frequency of seizures following streptozotocin-induced 
hyperglycaemia has been observed following transient MCAO, occurring in up to 
40 % of the hyperglycaemic animals (Li et al 1998). The effect of streptozotocin-
induced hyperglycaemia in transient MCAO consistently produces a greater 
effect on the expansion of ischaemic injury and infarction than following 
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permanent MCAO. A recent meta-analysis highlighted that the effect estimate 
for infarct volume was 55.2 in permanent MCAO compared to 319.1 for transient 
MCAO for streptozotocin induced hyperglycaemia (MacDougall and Muir 2010). 
1.4.1.2 D-glucose administration mediated hyperglycaemia 
D-glucose administration has been used widely to model the effects of 
hyperglycaemia on cerebral ischaemia. Many different protocols have been used 
with differences in route of administration (intraperitoneal or intravenous), the 
dose used and the frequency of dosing. The majority of studies have 
administered glucose prior to induction of MCAO which has resulted in 
hyperglycaemia levels of between 13 mmol/l and 31 mmol/l with an average of 
~23 mmol/l. A number of early studies were conducted in cats using both 
permanent and transient MCAO models. Infusion with glucose 1 hour prior to 
MCAO followed by either 8 hours of saline infusion or 6 further hours of glucose 
and 2 hours of saline infusion cause a marked increase in infarct size, assessed 2 
weeks post MCAO, compared to controls infused with saline only (de Courten-
Myers et al 1988). A quarter of hyperglycaemic animals receiving pre and post 
occlusion glucose died within 24 hours highlighting that prolonged 
hyperglycaemia is more detrimental and that hyperglycaemia-dependant damage 
is dose dependant. Further studies by de Courten-Myers et al highlighted that 
using insulin to reduce hyperglycaemia had a detrimental, not beneficial, effect 
on infarct size in animals that became hypoglycaemic following the treatment 
(de Courten-Myers et al 1994). Transient (8 hours) MCAO in the presence of 
hyperglycaemia was also responsible for a 10 fold increase in infarct volume 
compared to normoglycaemic controls with permanent MCAO. Transient (4 hour) 
MCAO in cats mirrored what had been seen in streptozotocin treated rats with a 
greater effect observed on outcome than in permanent MCAO. Although infarct 
volume following transient MCAO was considerably smaller in both 
normoglycaemic and hyperglycaemic cats than after permanent MCAO, 
approximately 50% of cats died prior to the experimental end point as a result of 
infarct expansion, haemorrhagic transformation and MCA territory oedema (de 
Courten-Myers et al 1989). However, hyperglycaemia in cats has been shown to 
lessen the extent of neuronal injury 6 hours after permanent MCAO compared to 
normoglycaemic controls (Zasslow et al 1989). Combs et al (1990) failed to 
reproduce any differences between hyperglycaemic cats, in the presence or 
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absence of raised plasma insulin, and normoglycaemic cats following an 8 hour 
permanent MCAO although a greater variability was present in the 
hyperglycaemic groups. This lack of consistency in the literature could be due 
to: the nature of the animal model; genetic heterogeneity and the use of both 
sexes in these studies.  
The D-glucose model has also been applied to rats in conjunction with 
permanent or transient MCAO to investigate the effects of acute hyperglycaemic 
on ischaemic injury. Permanent MCAO in rats treated with D-glucose prior to 
ischaemia caused more extensive tissue infarction, two days post MCAO, 
compared to controls administered with saline (Bomont and MacKenzie 1995). 
However the effect of glucose loading in other studies using permanent models 
of MCAO have not produced the same level of  evidence gathered from 
streptozotocin-induced hyperglycaemia in rats, with a number of studies failing 
to show any changes in infarct volume. Diemer (1987) found that following a 
permanent MCAO occlusion acute hyperglycaemia, induced by intravenous 
administration of 50% glucose solution 5 minutes after MCAO and the repeated 
intraperitoneally 2 hours post MCAO, failed to have any effect on infarct volume 
measured four days after MCAO. Similarly in SHR rats, no difference in ischaemic 
damage was seen between hyperglycaemic and control rats after permanent 
MCAO, although this mirrored what was seen with streptozotocin in this rat 
model (Slivka 1991).  
Transient MCAO models have provided more consistent evidence of the 
detrimental effect of D-glucose-mediated hyperglycaemia in focal ischaemia. 
Serial DWI scanning protocols have demonstrated that after 1 hour of ischaemia 
followed by reperfusion the rate of DWI-defined ischaemic injury growth in 
hyperglycaemic rats was  increased compared to normoglycaemic rats leading to 
a significantly greater volume of ischaemically damaged tissue (Wei et al 2003). 
This effect was attenuated by the introduction of 2-deoxyglucose which 
competitively inhibits glucose metabolism and reduces the level of brain lactate, 
the latter thought to be a primary mediator of damage under hyperglycaemic 
conditions (see later). Intraperitoneal injection of D-glucose 30 minutes prior to 
1 hour MCAO caused an almost 3 fold increase in infarct volume compared to 
vehicle-treated controls which was associated with a worsening of neurological 
scores (Martin et al 2006). Liu et al (2007) investigated the acute damage 
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following induction of hyperglycaemia with an intraperitoneal injection of 10% D-
glucose. They found that following permanent MCAO, the resulting ischaemic 
damage, as measured by TTC 4 hours post MCAO, was significantly more 
widespread that in normoglycaemic controls. However the extent of ischaemic 
injury following transient MCAO was again more substantial than the permanent 
occlusion (Liu et al 2007). 
1.4.1.3 Limitations to the preclinical literature 
Streptozotocin-induced hyperglycaemia is a model of type 1 diabetes which does 
not accurately reflect the pathophysiology of PSH and studies that induce 
hyperglycaemia using pre-ischaemic D-glucose injections or infusions may have 
greater clinical relevance. Generally the levels of hyperglycaemia achieved in D-
glucose injection studies, which are similar to those following streptozotocin 
treatment, are very severe and are grossly misrepresentative of the blood 
glucose levels experienced by the majority of patients following stroke.  
Around 56% of hyperglycaemic acute stroke patients are subsequently diagnosed 
with insulin resistance, manifesting as impaired glucose tolerance, impaired 
fasting glucose or the “metabolic syndrome,” a phenotype comprising 
combinations of insulin resistance, hypertension, hypertriglyceridaemia and 
obesity that is a significant risk factor for cardiovascular disease. The current 
literature assessing both PSH and insulin treatments have seldom incorporated 
this phenotype into the design of experiments, even though the incidence of 
some form of insulin resistance pathology is extremely frequent in the human 
disease. Models of metabolic syndrome could potentially replicate the 
pathophysiology more closely than has been achieved until now as the majority 
of human patients with PSH do not have type-1 diabetes mellitus yet 60% have 
insulin resistance manifesting commonly as type-2 diabetes or metabolic 
syndrome. 
1.4.1.4 Models of the metabolic syndrome 
The fatty Zucker rat was first described in 1961(Zucker and Zucker 1961). The 
Zucker rat strain has a spontaneous mutation (fa or fatty) that affects the action 
of the adipocyte peptide hormone leptin.  Leptin is a key element in the 
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regulation of food intake through the inhibition of the release of hypothalamic 
neuropeptide Y.  The Zucker rat also has a degree of glucose intolerance, 
variable hyperglycaemia, hyperinsulinaemia, insulin resistance and a potent 
tendency to obesity (Berthiaume and Zinker 2002; Ionescu et al 1985). These 
features are only seen in the homozygous fa/fa animals and are not seen the 
lean heterozygous Fa/fa or the homozygous Fa/Fa Zucker rats(Russell and 
Proctor 2006). The Zucker rat may be more representative of the average human 
stroke patient and may be a better model for post-stroke hyperglycaemia than 
animals treated with streptozotocin or dextrose infusions. 
The spontaneously hypertensive stroke-prone (SHRSP) rat is a well characterised 
model of hypertension compared to its reference Wistar-Kyoto (WKY) strain. 
Feeding SHRSP rats on a fructose rich diet for 2 weeks has been shown to induce 
insulin resistance, hypertriglyceridaemia, reduced HDL and increased adiposity 
in addition to the known hypertension compared to the reference WKY strain 
(Strahorn et al 2005).  
1.4.2 Mechanisms of hyperglycaemia-induced harm 
The mechanisms by which hyperglycaemia can possibly exacerbate ischaemic 
brain injury have been investigated using various animal models of stroke and 
through clinical observations.  
1.4.2.1 Reduction in CBF 
In rats, induction of hyperglycaemia (plasma glucose, 39mmol/L)  by 
intraperitoneal D-glucose injection caused a 24% reduction in regional blood flow 
compared to controls receiving saline (Duckrow et al 1985). This reduction in 
blood flow could not be explained purely by the increase in plasma osmolality 
caused by increased blood glucose since administration of mannitol,  leading to a 
similar blood osmolality, only reduced blood flow by 10% (Duckrow et al 1985). 
Similarly in cats, but using an intravenous infusion of glucose, at 3 hours post 
MCAO, hyperglycaemic animals (plasma glucose, 20mmol/L) showed at 70% 
reduction in blood flow compared to a 34% reduction in normoglycaemic controls 
(Wagner et al 1992). The ability of glucose to reduce cerebral perfusion could 
therefore increase the volume of hypoperfused tissue and lead to substantially 
larger infarcts and greater penumbral loss. The ability of glucose to reduce 
 44
regional cerebral blood flow in this manner is comparable to the effect of 
diabetes on cerebral blood flow regulation. A 5% CO2 challenge following 
normocapnia is known to increase cerebral blood flow in non-diabetic patients, 
but this effect is markedly attenuated in diabetics suggesting a loss 
cerebrovascular reactivity (Dandona et al 1978).  Nitric oxide mediates cerebral 
vasodilation induced by CO2 and in diabetics it has been shown that NO 
production is reduced (Brownlee 2001). Glucose-induced reactive oxygen species 
can neutralise NO, further reducing its availability for NO dependant vasodilation 
(Frank et al 2005). This suggests that post-stroke hyperglycaemia may reduce 
cerebral perfusion by impairing NO production or diminishing its availability.  
 
1.4.2.2 Lactic Acidosis 
In the penumbra where tissue is hypoperfused yet still viable, changes in the 
cerebral metabolism occur, which can lead to deleterious effects and it is 
postulated that hyperglycaemia can augment this, further exacerbating damage. 
Oxygen delivery is not adequately maintained, due to the reduction in cerebral 
blood flow to the penumbra, which causes a shift from aerobic to anaerobic 
metabolism. This leads to the production of lactic acid. Increasing the 
availability of glucose for metabolism causes excessive production of lactic acid 
and intracellular acidosis within the ischaemic tissue (Kagansky et al 2001). In a 
study on cats, normoglycaemia prevented rises in lactate due to depletion of 
tissue glucose (Wagner et al 1992). Acidosis was not markedly increased in this 
study until 4 hours suggesting that the effect of H+ ions is successfully buffered 
in the early stages of ischaemia (Wagner et al 1992). Tissue acidosis may lead to 
more extensive ischaemic damage by enhancing production of free-radicals, 
activation of endonucleases leading to DNA fragmentation and altering gene 
expression or protein synthesis (Siesjo et al 1996). A clinical study using MR 
spectroscopy to measure lactate and choline peaks has supported this hypothesis 
concluding that increases in acute-subacute lactate-to-choline ratios were 
predicted by higher acute blood glucose concentration and a doubling of plasma 
glucose concentration from 5 mmol/L to 10 mmol/L almost tripled the acute-
subacute lactate-to-choline ratio (Parsons et al 2002). This study also reported 
that doubling plasma glucose concentration from 5 mmol/L to 10 mmol/L 
increased infarct size on average by 56 cm3and led to a 60% reduction in 
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penumbra salvage (Parsons et al 2002). Similar results have been found in cats 
following MCAO. Hyperglycaemic cats (plasma glucose, 11-17 mmol/L) had 
elevated lactic acid as well as reduced cerebral high energy phosphates, such as 
ATP, and larger infarcts compared to controls in the occluded MCA territory 
(Chew et al 1991). Mitochondria within the ischaemic penumbra may also be 
directly affected by hyperglycaemia leading to intracellular acidosis in the brain. 
In hyperglycaemic rabbits (plasma glucose, >28 mmol/L), intracellular pH was 
substantially reduced and NADH regeneration, a measure of the redox state, was 
diminished compared to controls  in the ischaemic penumbra (Anderson et al 
1999). This acidosis led to the incorporation of penumbra into the ischaemic 
core.   
  
1.4.2.3 Enhancing excitotoxicity 
Excitotoxicity is a major pathological mechanism in the expansion of ischaemic 
damage. The initiation of excitotoxicity is dependant on an excessive increase in 
extracellular glutamate concentration so that postsynaptic NMDA receptors and 
other glutamate receptors can be activated (Dirnagl et al 1999). This facilitates 
the rise in intracellular [Ca2+] that precedes organelle failure and eventually cell 
death. In a model of forebrain ischaemia the rise in extracellular glutamate 
observed in the cerebral cortex following an insult was significantly larger in 
hyperglycaemic rats (plasma glucose, 21 mmol/L) compared with controls 
suggesting raised blood glucose may increase ischaemic damage by facilitating 
the excitotoxic mechanism (Li et al 2000). 
 
1.4.2.4 Oxidative stress and Inflammation 
Hyperglycaemia is known to be involved in oxidative stress and inflammation and 
can contribute to these pathological processes through a number of mechanisms. 
Firstly, hyperglycaemia can increase the production of reactive oxygen species 
(ROS), such as superoxide. Using a global transient ischaemic model with a 
glucose infusion prior to ischaemia, hyperglycaemia (plasma glucose, 20 
mmol/L) caused around a 2-fold increase in neuronal superoxide production 
compared to normoglycaemic animals and this rise in superoxide preceded an 
exacerbation of cell death in CA1 hippocampal neurons (Muranyi and Li 2006). 
Moreover a simple glucose challenge has shown in humans to increase the 
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production of ROS from leukocytes as well as increase the expression of p47phox, 
the key protein component in the formation of NADPH oxidase (Mohanty et al 
2000). NADPH oxidase is the enzyme responsible for the conversion of O2 to the 
superoxide anion. This rise in p47phox potentially could be due to glucose 
modulating the p47phox gene. Superoxide has been shown to significantly disrupt 
the blood-brain barrier (BBB) and increase brain oedema (Kamada et al 2007). 
During reperfusion, elevated blood glucose levels are thought to enhance ROS 
production, which are known to be detrimental to the BBB (Muranyi and Li 2006; 
Weir et al 1997). Kamada et al. (2007) recently demonstrated that 
hyperglycaemia increased production of superoxide ions as well as increasing 
expression of COX2 and NADPH oxidase, which are both enzymes responsible for 
superoxide production in the later stages of ischaemic reperfusion. Matrix 
metalloproteinase-9 (MMP-9) is also implicated in the proteolytic degradation of 
the BBB following focal cerebral ischaemia and superoxide is known to be 
involved in MMP-9 activation (Asahi et al 2001; Jian Liu and Rosenberg 2005). 
Hyperglycaemia therefore can exacerbate BBB dysfunction and brain oedema by 
augmenting oxidative stress and activity of MMP-9 (Kamada et al 2007).   
 
1.4.3 Management of Hyperglycaemia 
Hyperglycaemia has been associated with poorer outcome after stroke in a 
number of human studies and this has led to the production of international 
guidelines that recommend hyperglycaemia following acute stroke should be 
treated with insulin therapy to reduce blood glucose (Adams et al 2007; 2009). 
These guidelines have not been supported by evidence from clinical trials and 
there is huge variation in the protocols that stroke units and hospitals are using. 
Preclinical animal data are partially responsible for introduction of the guidelines 
suggesting tight glycaemic control is beneficial in acute stroke patients, however 
these data are very heterogeneous. In streptozotocin treated rats, pre-ischaemic 
dosing (from 2 days prior to MCAO) with glucose and insulin produced similar 
infarct sizes, measured 1 week after MCAO, supporting the use of insulin 
(Hamilton et al 1995). In streptozotocin treated rats, pre-ischaemic dosing (from 2 
days prior to MCAO) with insulin resulted in a marked decrease in infarct volume, 
measured 2 days after MCAO (Bomont and MacKenzie 1995). However, more 
recently, no benefit was reported from insulin use in hyperglycaemic animals. This 
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was attributed to insulin-induced hypoglycaemia which seems to be as 
potentially detrimental as hyperglycaemia with the preferred blood glucose level 
for minimal damage lying between 6 and 7 mmol/l (Zhu and Auer 2004). In rats 
with transient MCAO reducing blood glucose from 8-9 mmol/l to around 3-4 
mmol/l with insulin dramatically reduced subsequent cerebral infarction which 
contradicts the finding of Zhu et al (2004)(Hamilton et al 1995). However the 
study by Hamilton et al (1995) was conducted in rats previously absent of 
hyperglycaemia, which  is similar to the study conducted by Izumi et al (1992) 
where insulin significantly attenuated lesion expansion compared to controls and 
this reduction was also achieved in the absence of prior hyperglycaemia. The 
relevance of this to PSH is unknown as subsequent clinical trials have failed to 
reproduce the beneficial effects of insulin. 
The UK Glucose-Insulin Stroke Trial (GIST-UK) is the largest clinical trial in acute 
stroke addressing the management of blood glucose (Gray et al 2007). GIST-UK 
failed to produce conclusive evidence of beneficial effects of tight glycaemic 
control in the acute period following stroke onset. The trial used a glucose-
potassium-insulin (GKI) infusion in patients presenting within 24 hours of stroke 
onset with blood glucose level between 6.0 – 17 mmol/l. Although a significant 
reduction in blood glucose was observed (mean glucose 0.57mmol/L less than 
controls) there was no change in mortality or secondary outcomes after 3 
months. In fact patients in the GKI treatment group with the greatest reduction 
in plasma glucose concentration had a higher mortality rate and the infusion of 
saline alone was able to reduce plasma glucose (Gray et al 2007). The results 
from the GIST-UK trial are difficult to interpret due to the much smaller sample 
size recruited (only ~30% of intended sample size) and only minor reductions in 
blood glucose achieved compared to controls.  The SELESTIAL (Spectroscopic 
Evaluation of Lesion Evolution in Stroke: Trial of Insulin for Acute Lacticacidosis) 
(McCormick et al 2010), aimed to assess the effects of GKI infusion on brain 
lactate levels using MRI and MR spectroscopy. The rationale for SELESTIAL was 
based on a previous clinical study which reported that lactic acidosis, in 
anaerobically metabolising tissue, is a potential mechanism for hyperglycaemia-
mediated ischaemic injury acceleration following stroke (Parsons et al 2002). 
The SELESTIAL trial found that although GKI infusion significantly reduced blood 
glucose for around 12 hours after the start of the treatment compared to 
controls and attenuated the increase in brain lactate, there was no difference in 
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infarct volume between GKI and control groups at any time point. In addition to 
this there was a significant incidence of hypoglycaemia in the GKI groups even 
with frequent monitoring. A relationship was also discovered between the GKI 
treatment and intracranial artery patency which highlights a safety issue with 
using insulin (McCormick et al 2010).  
Hyperglycaemia is a common finding in myocardial infarction and similar trials to 
those conducted in acute stroke have been conducted targeting plasma glucose. 
One trial found that in diabetic patients with acute myocardial infarction, an 
insulin-glucose infusion and subsequent insulin-based therapy reduced mortality 
by 52% (Malmberg et al 1995). Studies in patients in medical and surgical 
intensive care units have also shown positive effects of insulin based glycaemic 
control (van den Berghe et al 2001; Van den Berghe et al 2006). Van den Berghe 
et al. (2006) showed that intensive insulin treatment reduced mortality by 32% 
in patients staying more than 5 days in a surgical intensive care unit. More 
recent trials have failed to reproduce these results with some even reporting 
negative effects of intense insulin treatment (Griesdale et al 2009; Malmberg et 
al 2005). These findings with regards to myocardial infarction and stroke suggest 
that the use of insulin therapy needs further investigation before it can be 
recommended clinically (Gray et al 2007; Griesdale et al 2009). 
1.4.4 Summary 
In light of the potential risk of hypoglycaemia with insulin regimes in stroke, it is 
important to question whether the harmful effects of acute hyperglycaemia 
pertain to all stroke patients, or whether they differ in those with and without 
pre-existing insulin resistance. Addressing this question could potentially 
improve the effectiveness of glycaemic control by selecting those patients who 
are likely to benefit most from glucose lowering therapies. 
The hyperglycaemia preclinical literature on experimental stroke reports 
increased infarct size which is consistent with the clinical observations from 
stroke patients. However, the recent systematic review by MacDougall et al 
(2011) highlighted the uncertain relevance of preclinical studies to the typical 
clinical picture of PSH with respect to whether clinically relevant elevations in 
blood glucose exacerbate ischaemic brain damage in models other than those of 
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type I diabetes, or whether responses are different in animals with and without 
features of metabolic syndrome.  
1.5 Study Aims 
1. To characterise and optimise rodent models for investigations of  post 
stroke hyperglycaemia. Firstly, establish a previously described model of 
insulin resistance and metabolic syndrome in the lab (Strahorn et al 
2005). Secondly, optimise a method of inducing acute hyperglycaemia in 
rats that led to a level of blood glucose that reflects what has been found 
in hyperglycaemic stroke patients by the GIST-UK clinical trial (Gray et al 
2004b). Finally, compare two different methods of middle cerebral artery 
occlusion (MCAO) to decide which one should be carried forward to future 
experiments.   
2. To determine the effects of clinically relevant levels of hyperglycaemia 
and insulin resistance with associated cardiovascular co-morbidities on 
acute ischaemic damage following MCAO using DWI and PWI MR imaging. 
Assess whether hyperglycaemia, in the presence and absence of insulin 
resistance and associated co-morbidities leads to any changes in infarct 
volume. Finally, to address the potential role of oxidative stress 
mechanisms in hyperglycaemia-mediated damage following permanent 
MCAO. 
3. To investigate the potential mechanistic role of oxidative stress in 
hyperglycaemia mediated damage following experimental stroke using the 
SOD/catalase mimetic EUK-134. 
4. Calculate thresholds for a new quantitative T2-weighted MRI sequence for 
future infarct analysis. 
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2.1 Animals 
All experiments and procedures were carried out under license from the UK 
Home Office (Personal Licence number 60/11925, working under Project Licence 
numbers 60/3759 and 60/3618) and in accordance with the Animals (Scientific 
Procedures) Act, 1986. Male SHRSP and WKY rats were obtained from inbred 
colonies in the Division of Cardiovascular and Medical Sciences at the University 
of Glasgow. Sprague Dawley rats were obtained from Harlan Laboratories UK. All 
rats were allowed a 1 week acclimatisation period before any experimentation. 
Rats were doubly housed in standard laboratory cages with sizzle nest and 
cardboard tubing. All animals were maintained on a 12:12 h light/dark cycle. 
Water and food were available ad libitum. All surgical procedures were carried 
out by David Tarr. 
2.2 Animal preparation  
On the day of surgery rats were transferred from the animal housing unit to the 
operating theatre. Animals were then weighed prior to induction of anaesthesia. 
Reproducible cerebral lesions were achieved by occluding the left middle 
cerebral artery (MCA). Two models of permanent focal ischaemia were used to 
achieve suitable lesion sizes; the intraluminal thread model (Koizumi et al 1986) 
and a distal MCA diathermy model modified from Tamura et al (1981). 
Rats were initially anaesthetised in an anaesthetic chamber using 5% isoflurane 
(Baxter Healthcare Ltd, UK) in an oxygen-nitrous oxide mixture (30:70). The 
depth of anaesthesia was assessed by means of the withdrawal reflex, where the 
footpad of a hindlimb is tightly squeezed to evoke withdrawal of the foot. Once 
the rat showed no foot reflex upon pinching it was considered to be deeply 
anaesthetised and therefore safe to proceed with the surgery. Tracheotomy 
A surgical tracheotomy was performed on all non-recovery animals for 
mechanical ventilation. The rat was transferred from the anaesthetic chamber 
and positioned on its back where a face mask was used to continue the delivery 
of anaesthetic at 2.5% – 3% isoflurane in the same gas mixture used for the initial 
anaesthesia.  The neck area was shaved using electric clippers (Wahl, UK) and 
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70% alcohol was used to clean the exposed area. A small incision using blunt 
ended scissors was made through the skin and fascia of the neck and the trachea 
was exposed and isolated from connective tissue using blunt dissection 
techniques. Two ligatures of 2-0 thread (Sofsilk, Tyco Healthcare, USA) were 
loosely tied around the proximal and distal ends of the trachea approximately 
1.5 cm apart. The area was dried using triangular absorbent sponge to prevent 
fluid entering the trachea. An incision was made between rings of cartilage using 
micro scissors and a catheter (Linton Instruments, UK) was quickly inserted 20 
mm into the trachea. Care was taken not to advance any further than this to 
prevent the tube blocking off one of the bronchi. The catheter was then 
connected to a ventilator (Ugo Basile, Linton Instruments, UK) where the stroke 
volume was set to ~3 ml at a frequency of 45 strokes per minute. The lower tie 
and the upper tie were then both tied firmly around the trachea and catheter 
before the neck was stitched using 4-0 silk suture (Sofsilk, Tyco Healthcare, 
USA). 
In experiments where the animal was allowed to recover following surgery, 
artificial ventilation was maintained by intubation where the tube can be 
removed without trauma to the trachea. The animal was removed from 
anaesthetic chamber and transferred to a cork board. A loop of thread, which 
was pinned to the board, was attached around the incisors of the rat and the 
board was lifted into a vertical position. A fibre optic light (Meiji Techno) was 
applied to the neck of the rat and the tongue was pulled to one side to allow 
visualization of the vocal cords and the trachea. A 16 gauge catheter (MillPledge 
Veterinary, UK) attached to a guide wire was then advanced into the trachea 
before the guide wire was removed. The catheter was attached to a ventilator 
at a stroke volume of ~3 ml and a frequency of 60 strokes per minute. Chest 
expansion was examined to confirm the intubation tube was correctly positioned 
in the trachea. The tube was secured by stitching it to the side of the mouth 
using 4-0 silk suture to prevent it being pulled out whilst manipulating the 
position of the rat. 
Femoral artery cannulation was performed to monitor mean arterial blood 
pressure and blood gases. The upper part of the right hind limb was shaved using 
electric clippers and wiped clean using 70% alcohol. A small incision using blunt 
ended scissors was made through the skin and fascia and a ~15 mm section 
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femoral artery was isolated from the femoral vein. Two ligatures (4-0 silk 
suture) were loosely tied around the distal and proximal ends of the isolated 
artery. The ligatures were pulled tight and secured to the cork board using 
sticky tape and a small incision was made in the artery using micro scissors. With 
the aid of right-angled sharp forceps a polythene catheter (Portex, UK) was 
inserted into the vessel and advanced approximately 2-3 cm along the vessel. 
Both ligatures were secured tightly around the vessel and the inserted catheter. 
Excess thread was removed before closing the wound with 4-0 thread to prevent 
the tissue drying out. The catheter was connected to transducer linked to a 
computer where physiological parameters including heart rate and blood 
pressure were recorded.  
The femoral cannulation procedure was also performed on the femoral vein for 
drug administration in Chapter 5.  
2.3 Focal cerebral ischaemia 
2.3.1 Intraluminal filament model of MCAO 
Occlusion of the middle cerebral artery (MCA) using the intraluminal filament 
was performed according to the method first described by Koizumi et al (1986) 
with subsequent modifications (Longa et al 1989)(Figure 2.1). All of the surgery 
was performed under a light microscope. The common carotid artery (CCA) was 
isolated through the same site used for the tracheotomy. If the animals were 
intubated the neck area was similarly prepared and an incision was made 
through the skin and fascia. A 4-0 thread ligature was fastened around the CCA 
at the bifurcation of the external carotid artery (ECA) and the internal carotid 
artery (ICA). The ECA was then tied off using a 4-0 silk suture at an intermediate 
point between the ascending pharyngeal artery and the lingual and maxillary 
branches. The three branches from the ECA were cauterised and then cut with 
microscissors. The ECA was then sealed off using diathermy forceps distal from 
ligature and then cut with micro scissors to allow manipulation of the vessel. 
Connective tissue was dissected bluntly from around the area of CCA bifurcation 
and the ICA. The occipital artery branching from the ICA was cauterised using 
diathermy forceps and then cut using micro scissors. A loose tie (4-0 silk thread)  
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Figure 2.1: Diagram of the intraluminal thread model of MCAO. The external carotid 
artery is ligated and all branches are transected to allow the artery to be manipulated for 
ease of passage of the nylon monofilament. The pterygopalatine artery is ligated and the 
monofilament is introduced into the internal carotid artery. The filament is advanced along 
the internal carotid until it lodges in the narrow proximal anterior cerebral artery, where it 
blocks the origin of the middle cerebral artery. This method of MCAO can be transient or 
permanent. Image reproduced from Hunter et al (1995). 
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was then placed around the ICA and secured with enough tension to prevent 
flow. The pterygopalatine artery was identified and a suture (4-0 silk thread) 
secured around the origin of the artery where it meets the ICA. Tension was 
applied to both the ECA tie and the CCA tie to create a triangle with the ICA. A 
small incision was made near the base of the ECA using micro scissors and a 
filament was introduced through the incision. The filament was then advanced 
into the ICA and before continuing to advance the filament 22 mm up the ICA. 
Once inserted 22mm the incision site was electrocoagulated closed and the loose 
ICA tie was tied firmly. Excess thread was removed before closing the wound 
with 4-0 silk thread to prevent drying out. 
2.3.2 Distal MCA Diathermy Model of MCA occlusion 
The animal was positioned laterally with the side of head in clear view. The left 
eye was sutured closed (4-0 thread, Sofsilk, Tyco Healthcare, USA) to prevent it 
from drying out during surgery. The skin between the left eye and auditory canal 
was shaved using electric clippers and wiped clean using alcohol wipes. A small 
incision was made at the midpoint between the auditory canal and the left orbit 
above the longest whisker at the side of the face. Using sharp-ended scissors the 
underlying connective tissue and muscle were dissected until the skull was 
clearly visible. Retractors were used to pull the muscle back to create a large 
enough working area for the exposure of the MCA. The surrounding connective 
tissue and muscle was further removed from area and protected from drilling 
using pieces of absorbent sponge (Surgiswabs, John Weiss International). A 
dental drill (Volvere Vmax, Nakanishi Inc) was used to perform a craniectomy of 
the exposed area. Drilling was conducted in an up and down manner over the 
surface of the skull with little pressure to prevent premature puncturing of the 
skull and damage to the brain. The drilling process continued until the MCA and 
inferior cerebral vein (ICV) were visible through the skull. The remaining thin 
layer of skull and the dura were then removed carefully using a dural hook. If 
bleeding occurred from small vessels of the dura or those surrounding the MCA 
sterile saline (0.9%, Baxter Healthcare Ltd) was applied to the area to help cease 
the bleeding. If this failed then absorbent sponge was used to apply gentle 
pressure or the vessels were electrocoagulated using diathermy forceps. The 
point at which the MCA crossed the ICV was identified and the MCA was 
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electrocoagulated with diathermy forceps 2 mm distally from this point. 
Following this the MCA was cut with microscissors to confirm a complete 
occlusion. The absorbent sponges and retractors were then removed from 
working area and haemostatic sponge (Spongostan™, Ferrosan UK) was used to 
cover the craniectomy site. The muscle was then allowed to close over and the 
skin was sutured together (4-0 thread, Sofsilk, Tyco Healthcare, USA). 
2.3.3 Physiological monitoring 
Whilst under anaesthesia a number of physiological variables were monitored. 
Temperature was monitored using a rectal thermocouple and was maintained at 
37±0.5°C using a heat lamp. Blood gases were measured immediately after the 
femoral artery was cannulated and each hour after this point until the end of 
anaesthesia. Blood gases and pH were maintained within a defined range [PaCO2 
35-45 mmHg, pH 7.35-7.45]. PaO2 remained outside the normal physiological 
range of 80-100 mmHg due to the high percentage of oxygen ventilating the 
animals. For this reason PaO2 was recorded to confirm no group differences 
being observed. The blood gases and pH were maintained by altering the output 
parameters of the ventilator. Blood pressure was monitored using a pressure 
transducer in combination with an MP150 Biopac system and AcqKnowledge 
software (Linton). Mean arterial blood pressure was maintained within the range 
of 85-95 mmHg in Sprague Dawley and WKY rats and within the range of 105-115 
mmHg for SHRSP rats. 
2.3.4 Recovery of animals from anaesthesia  
In animals that were recovered from surgery once the experimental protocol was 
completed, including the removal of the femoral artery cannula, the isoflurane 
concentration was reduced before being discontinued completely. The animals 
would then be ventilated with 50-50 oxygen-nitrous oxide mixture until 
responsiveness to foot pinching was observed and that the animal had started to 
breathe without the ventilator. At this point the animal was disconnected from 
the ventilator and subsequently the intubation tube was removed. A face mask 
was then applied to the animal (50-50 oxygen-nitrous oxide) until some motor 
function had been restored. The animal was then transferred to a clean cage 
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with soft bedding, softened rat chow and water available ad libitum. The cage 
was transferred to a recovery room maintained at ~ 25 ºC where it remained 
until the animal was killed. The animal was checked every hour post-operatively 
for the next 3 hours and details of its recovery were recorded on animal 
recovery sheets. 
2.4  Brain Processing 
2.4.1 Perfusion fixation 
Rats were transcardially perfused with fixative to allow histological examination 
of the brain following focal cerebral ischaemia. Animals were deeply 
anaesthetised in an anaesthetic chamber with 5% isoflurane in an oxygen-nitrous 
oxide (30:70) mixture before being transferred to an absorbent tray and placed 
on a face mask for continuation of anaesthesia. An incision was made at sternum 
using blunt ended scissors. The rib cage and diaphragm was subsequently cut and 
the rib cage retracted to expose the chest cavity. Once cleared of connective 
tissue the heart was grasped with forceps and a blunt-ended 16 gauge needle, 
attached to a perfusion fixation set-up, was inserted into the base of the heart 
through the left ventricle and advanced into the aorta. The needle was secured 
in place with a clamp and the right atrium was cut to allow drainage of blood. 
Perfusion was started with heparinised (5 ml/litre) saline (0.9 %, 300 ml) at a 
pressure of approximately 100-150 mmHg. When the blood was cleared from the 
body, paraformaldehyde (PAM) (4 % in 50mM phosphate buffer, 300 ml) was 
perfused at the same pressure. Spontaneous movement and a lightened colour of 
the liver were indicative of a successful perfusion fixation. After fixation rats 
were decapitated and the heads immersed in 4 % PAM for 24h – 48h before 
removing the brains. The brains were kept in 4 % PAM for a minimum of 24h prior 
to further processing. 
2.4.2 Tissue Processing 
Following perfusion fixation brains were transferred to an automatic processor 
(Tissue-Tek VIP, Miles Scientific) which cycled through alcohols to allow 
dehydration and then into xylene which acts as a clearing reagent. Brains were 
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then submerged in liquid paraffin wax at 60°C. The entire process takes 59 hours 
to complete (Table 2.1). Brains were then submerged in liquid paraffin wax at 
60oC.  
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Station Solution Temperature Time 
1 70% Alcohol 35oC 2 hours 
2 80% Alcohol 35oC 3 hours 
3 96% Alcohol 35oC 4 hours 
4 Absolute Alcohol 35oC 4 hours 
5 Absolute Alcohol 35oC 5 hours 
6 Absolute Alcohol 35oC 5 hours 
7 Absolute Alcohol 35oC 6 hours 
8 Xylene/ Abs Al 35oC 4 hours 
9 Xylene 1 35oC 5 hours 
10 Xylene 2 35oC 5 hours 
11 Paraffin wax 1 60oC 5 hours 
12 Paraffin wax 2 60oC 5 hours 
13 Paraffin wax 3 60oC 6 hours 
 
Table 2.1: The tissue processing procedure 
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2.4.3 Tissue embedding and sectioning 
The brains are then removed from the processor and individually housed in small 
containers where they were embedded in liquid paraffin wax and left to cool. 
Once the paraffin had set the embedded brains were removed from their 
containers and mounted onto wooden blocks. Each brain was cut coronally into 6 
µm sections using a microtome (leica) and mounted onto poly-l-lysine coated 
glass slides.  
2.4.4 Haematoxylin and eosin histological staining  
Brain sections from each of the eight pre-determined coronal levels were stained 
with haematoxylin and eosin (Surgipath, UK) and assessed for lesion size (Table 
2.2). Sides were placed in a rack and submerged in 100% Histoclear (National 
Diagnostics) for 30 minutes with regular agitation. The sections were then 
rehydrated by being immersed in 100 % alcohol for 2 minutes followed by 90 % 
alcohol and 70 % alcohol for 2 minutes each. Thereafter the slides were 
immersed in running water for 5 minutes before being stained in haematoxylin 
for 4 minutes. The slides were returned to running water for 2-3 minutes or until 
the water ran clear. Slides were differentiated in acid alcohol for 2-3 seconds 
before being immersed in running water again. Slides were then transferred to 
Scots Tap Water Substitute (STWS) for 2 minutes then back into running water 
for a further 5 minutes. The sections were the dehydrated by placing in 70 % 
alcohol and 90 % alcohol for 2 minutes each before being stained in eosin for 4 
minutes. Slides were then washed in 3 different 100 % alcohol baths for 4 
minutes each and then transferred to Histoclear for 5 minutes. Coverslips were 
then mounted on slides using DPX mounting medium.  
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Solution Time 
Histoclear 1 4-5 mins 
Histoclear 2 4-5 mins 
Histoclear 3 4-5 mins 
Absolute Alcohol 1 3 mins 
Absolute Alcohol 2 3 mins 
90% Alcohol 3 mins 
70% Alcohol 3 mins 
Wash in running water 4 mins 
Haematoxylin 4 mins 
Wash in running water 1-2 mins 
Differentiate in acid alcohol A few dips 
Wash well in running water 3 mins 
Scott's Tap Water Substitute 2 mins 
Wash in running water 2 mins 
Dehydrate in 70% Alcohol 2 mins 
Dehydrate in 90% Alcohol 2 mins 
Stain in Alcoholic Eosin (95%) 4 mins 
Dehydrate in Absolute Alcohol 1 4 mins 
Dehydrate in Absolute Alcohol 2 4 mins 
Dehydrate in Absolute Alcohol 3 4 mins 
Clear in Histoclear 1 4 mins 
Clear in Histoclear 2 4 mins 
Clear in Histoclear 3 4 mins 
 
Table 2.2: Chronological list of agents used for the staining procedure 
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2.4.5 Determination of ischaemic damage and quantification of 
infarct size 
The haematoxylin and eosin stained sections were viewed under a light 
microscope at a range of magnifications (x5, x10, x20 and x40) to accurately 
determine the boundary of the infarct.  Morphological characteristics of 
ischaemic neurons compared to non-ischaemic neurons, and pallor/vacuolisation 
of the neuropil were identified on stained sections to delineate areas of 
infarction. Ischaemic neurons were identified as pyknotic (shrunken and 
triangular in shape) with cellular incrustations most evident at x20 
magnification. Pyknotic neurons also showed an eosinphilic cytoplasm and the 
surrounding neuropil was disrupted and displayed pallor. Identification of the 
boundaries between infarcted tissue and unaffected tissue was achieved by 
studying the neuronal morphology combined with changes in the neuropil in the 
form of pallor of staining and microvacuolation. Regions of interest (ROIs) 
representing the ischaemic core (where the majority of cells and neuropil 
showed the irreversible features of ischaemic cell change, Figure 2.2B), border 
zone (mixed population of cells with abnormal and normal morphology, Figure 
2.2C) and adjacent normal zone (normal cell morphology and neuropil, Figure 
2.2A) are shown in Figure 2.2.  
Areas of infarct were transcribed onto line diagrams of 8 pre-determined coronal 
levels with known stereotaxic coordinates (Figure 2.3, Paxinos & Watson, 1998) 
throughout the MCA territory and quantified using image (Image J) based on the 
original method by Osborne and co-workers (1987). The stereotaxic coordinates 
of the coronal levels were between 2.64-12.24mm anterior to the interaural 
line. The total lesion volume was calculated in graphical software (GraphPad 
Prism 4) by integration of the areas with the known distance between each 
coronal level, using stereotaxic endpoints of 13.20mm and 0.50mm. 
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Figure 2.2: Haematoxylin and Eosin stained sections used for infarct quantification. A) 
shows the morphology of  normal tissue, B) exhibits neurons with  and C) border zone. 
Histological photomicrographs of ROI in dorso-lateral cortex ipsilateral to permanent 
MCAO from a representative animal.  Pictures from haematoxylin & eosin stained sections 
have been captured at x 40 magnification: 
a) Normal Cortex. Neurons display normal morphology; 
b) Ischaemic Core. Note darkly stained triangular neurons that have the features of the 
ischaemic cell process within microvacuolated, pale stained neuropil; 
c) Border Zone. Scattered throughout the ischaemic cortex are normal neurons (circled) 
which display a normal morphology 
 
 
 
 
A. Normal tissue 
     (x400) 
 
 
 
 
 
 
 
 
 
 
 
B. Ischaemic tissue 
     (x400) 
 
 
 
 
 
 
 
 
 
 
C. Border zone  
    (x400) 
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    Level 1. Interaural = 12.24 mm     Level 2. Interaural = 10.68 mm 
   
Level 3. Interaural = 8.88 mm   Level 4. Interaural = 7.68 mm   
   
Level 5. Interaural = 6.60 mm   Level 6. Interaural = 5.40 mm            
   
Level 7. Interaural = 3.80 mm     Level 8. Interaural = 2.64 mm 
Figure 2.3:  Line diagram comprising 8 pre-determined coronal levels with the distance 
from interaural of each level adjacent to it. Brain sections were collected at these levels 
and areas of infarct (in green) were transcribed onto the diagram (Paxinos and Watson 
1998) 
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2.4.6 Triphenyltetrazolium chloride (TTC) staining and quantifying 
damage 
2,3,5-triphenyltetrazolium chloride (TTC) is a colourless, water-soluble salt 
which is oxidised by mitochondrial dehygrogenases, to a lipid soluble bright red 
formazan.  In undamaged tissue, TTC is reduced to formazan which stains a deep 
red. The intensity of the stain reflects the functional activity of the 
mitochondria. In infarcted tissue, where the mitochondrial systems are non-
functional, TTC is remains colourless and so no staining is observed (Figure 2.4). 
TTC is effective in assessing infarct volume at 24 hours after cerebral ischaemia.  
The animal was anaesthetised with 5% isoflurane and decapitated for brain 
removal. The brain was then transferred to a freezer for around twenty minutes 
to make it easier to slice. Previously a rat brain matrix (World Precision 
Instruments, Hertfordshire, UK) had been used to slice the brain coronally with 
razor blades positioned 2mm apart, although this proved troublesome as the 
fragile slices were difficult to remove intact. The brain instead was removed 
from the freezer and using the matrix as a guide the brain was sliced, one slice 
at a time, using a single razor blade. The slices were then incubated in 2% TTC 
at 37oC for 15 minutes. TTC staining after 24 hours of focal ischaemia displays 
deep red staining of normal brain tissue and white non-staining of ischaemically-
injured tissue with a distinct border. The slices were stored in 4 % PAM for 24 h 
before quantifying the volume of ischaemic damage. Digital photographs of both 
sides of the slices were taken with a Canon Camcoder Mv750i. The photographs 
were analysed using ImageJ v1.39  
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Figure 2.4:  TTC stained coronal slice of tissue from an animal 4 hours after permanent 
MCAO. The white area represents ischaemic damage 
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(http://rsb.info.nih.gov/ij/). The white areas corresponding to the ischaemic 
damage were measured from both sides of each slice and added together to give 
the total volume of ischaemic damage. This only works due to the slice thickness 
being 2 mm. TTC has been validated for use 24 hours after injury (Bederson et al 
1986a), but it cannot accurately delineate areas of infarcted tissue as early as 4 
hours after permanent MCAO. However, after 36 hours of ischaemia, infiltration 
of macrophages and microglia, neovasculisation and astrocytic reactions occur, 
which can obscure the margin of ischaemic damage (Hudgins and Garcia 1970). 
Also, although the extent of ischaemic damage can be assessed using this 
technique, there is no differentiation of grey and white matter structures, or the 
ability to study the consequences of ischaemia on individual cells. 
2.5 Magnetic resonance imaging  
2.5.1 Magnet specifications        
 
All animals were scanned in a Bruker Biospin Avance 7T (300MHz) Magnetic 
Resonance Imaging (MRI) system, equipped with an inserted gradient coil (121 
mm ID, 400mT/m) and a 72 mm birdcage resonator.  
2.5.2 Physiological monitoring during MRI scans 
Following surgery to induce MCAO, animals were placed prone in a Perspex 
cradle, with the head restrained using ear and tooth bars to limit movement. A 
linear surface receiver coil (2 cm diameter) was placed above the head of the 
animal. The base of the cradle, and a cover placed over the rat’s body, 
contained water channels with circulating warm water connected to a 
temperature controlled combined heater and water pump. This could be pre-set 
for a given temperature to maintain body temperature at 37ºC. Physiological 
variables including core body temperature, electrocardiogram (ECG) and 
respiration rate were monitored with a BioTrig system (Bruker, BioSpin) which 
had both a command and acquisition module. Physiological input was acquired 
by attaching electrocardiogram leads (3M innovation) to the rat with conductive 
electrode gel (Sigma) and electrode adhesive pads; two were attached to the 
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animal’s chest and a third to the inner right thigh.  A rectal thermocouple was 
reinserted for continual temperature monitoring. The system was connected to a 
laptop and AcqKnowledge software used to display the cardiac and respiratory 
waveforms. Stability of physiological variables was determined from the 
waveform patterns and temperature readout, and manual control of anaesthetic 
levels and water heater temperature ensured maintenance of variables within 
the physiological range. MABP was monitored via the femoral artery cannula 
attached to a blood pressure transducer, which was in turn connected to Biopac 
(Bruker, Biospin) software. 
2.5.3 Diffusion-weighted scans  
2.5.3.1 Technical Specifications 
Spin Echo planar (EPI) diffusion-weighted scans consisted of eight contiguous 
coronal slices of 1.5 mm thickness which were generated with an in-plane 
resolution of 260 µm. The field of view was 25 x 25 mm2 and the matrix size was 
96 x 96 mm.  The gradient strengths (B values) were 0 and 1000 s/mm2 and 
gradient directions were x, y and z. The repetition time (TR) was 4000.3 ms and 
the echo time (TE) was 43 ms. A DWI scan over the whole brain takes 
approximately 3 minutes.  
2.5.3.2 Post processing 
ADC maps were generated for each of the 8 coronal slices acquired throughout 
the brain (Figure 2.5).  Raw datasets were initially processed using Paravision v5 
(Bruker Biospin). Subsequent analysis of ADC maps was carried out using ImageJ 
(http://rsb.info.nih.gov.ij) software.  
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Figure 2.5: Diffusion-weighted images and corresponding ADC maps 
A. DWI images of eight coronal slices from a rat brain 2.5 h following intraluminal filament 
model of permanent MCAO (pMCAO) and B. Equivalent ADC maps. The ischaemic 
damage appears bright on the DWI images and dark on acute ADC maps. ADC values 
expressed as x10-3 mm2/sec 
A              B 
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2.5.4 Arterial spin labelling 
2.5.4.1 Technical Specifications 
Non-invasive quantitative CBF was carried out on coronal slices within the MCA 
territory during ischaemia, and immediately following reperfusion for Chapter 5, 
using a form of pseudo-continuous ASL based on a train of adiabatic inversion 
pulses (Moffat et al 2005). The sequence employs a spin-echo echo-planar-
imaging (EPI) imaging module (TE 20 ms, TR 7000 ms, matrix 96 x 96, FOV 25 x 
25 mm2, slice thickness 1.5 mm, 16 averages, 4 shots) preceded by 50 hyperbolic 
secant inversion pulses in a 3 second train. The time taken to generate data for 
a single slice is approximately 5 minutes. In addition to this, a T1-weighted 
image (scan time 10 minutes for the whole brain) was performed to allow 
quantification of CBF in mL per 100 g per minute. 
2.5.4.2 Post-processing 
CBF maps were generated for each of the 6 contiguous slices throughout the 
brain. Raw datasets were processed ImageJ software.  Quantification of the CBF 
images was performed with use of methods described. The labelled CASL images 
were first subtracted from the averaged control images (subtracted CASL) and 
then divided by the signal intensity to generate a relative CBF map. Fully 
quantitative CBF maps were generated by dividing the relative CBF map by the 
T1 values generated from the T1 map (Figure 2.6). A perfusion deficit map can 
then be generated from the quantitative CBF map by applying a relevant 
threshold (e.g. 57% reduction of the mean contralateral hemisphere excluding 
the ventricles 
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Figure 2.6: ASL Images and the corresponding T1 map generated from a rat 1 h following 
intraluminal filament-induced MCAO 
Subtracted CASL Normalised CASL T1 map 
Thresholded CBF      
(57% reduction) 
Quantitative CBF 
(mL/100g/min) 
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2.5.5 T2-weighted scanning        
In Chapter 5 and 6 infarct volume was determined using MRI RARE (rapid 
acquisition with refocused echoes) T2 weighted imaging. T2 weighted imaging 
can be reliably used to identify ischaemic brain tissue 12 to 24 hours following 
stroke but during the critical period of 6-12 hours, this method does not 
adequately assess the severity and extent of ischaemia (Baird and Warach 
1998).In acute stroke, the changes in blood flow and tissue swelling which occur 
are associated with very subtle signal changes in T2 images. Areas of injured 
tissue produce higher signal intensity than normal brain tissue allowing the 
infarct to be clearly distinguished. 
A coronal RARE T2 sequence (effective TE: 46.8 ms, TR: 5000 s; in plane 
resolution of 97 um; 16 slices of 0.75 mm thickness) was used for T2-derived final 
infarct measurements. ImageJ was used to separate the images (8 slices are 
displayed in Figure 2.7) and the hyperintense region that represented the infarct 
was manually delineated using the freehand function. Measurement of individual 
images gave the infarct areas in millimetres squared, and infarct volume was 
calculated by adding up the 16 areas and multiplying by the slice thickness (0.75 
mm). The area of the contralateral and ipsilateral hemisphere on each slice was 
also measured. The volumes of the contralateral and ipsilateral hemispheres 
were calculated by multiplying the total area across the 16 slices by the slice 
thickness (0.75mm). Total infarct volume was corrected for oedema using 
published equations which take compression of the contralateral hemisphere 
into account (Gerriets et al 2004), in addition to swelling of the ipsilateral 
hemisphere (Swanson et al 1990). 
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For the calculation of infarct volume corrected for swelling of the ipsilateral 
hemisphere the following equation was used: 
Corrected lesion = volume of contralateral  –  (volume of ipsilateral – lesion volume) 
volume                hemisphere                     hemisphere 
 
 
A correction factor which accounts for compression of the contralateral 
hemisphere is calculated by the following equation: 
 
Compression Factor=(ipsilateral volume + contralateral volume)/(2 x contralateral volume) 
 
To calculate infarct volume which is corrected for both ipsilateral swelling and 
contralateral compression, the following equation was used: 
Infarct volume = corrected lesion volume x compression factor 
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Figure 2.7: T2-weighted images of eight coronal slices (caudal to rostral) from a rat brain 
following intraluminal filament induced permanent MCAO at 24 hours post-ischaemia. 
Ischaemic damage appears bright on RARE T2 images 
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2.6 Measuring lipid peroxidation 
Lipid peroxidation is a well established mechanism of cellular injury and is used 
as an indicator of oxidative stress in cells and tissues. Lipid peroxides are 
unstable and decompose to form a complex series of compounds including 
reactive carbonyl compounds. Polyunsaturated fatty acid peroxides generate 4-
hydroxyalkenals (HAE) and malondialdehyde (MDA) which have been used as 
markers of lipid peroxidation and oxidative stress 
2.6.1 4-HNE Immunohistochemistry  
Immunohistochemistry for the detection of 4-Hydroxynonenal (4-HNE), which is a 
4-hydroxyalkenal that has been used as an indicator of lipid peroxidation, was 
used in Chapter 4   
Sections adjacent to those used in H&E staining were selected for 
immunohistochemical staining for a marker of lipid peroxidation produced by 
oxidative stress, 4-HNE. Sections were first dewaxed in Histoclear for a minimum 
of 30 minutes. Sections were then placed in citric acid (10mM, pH 6-6.2) and 
heated at full power in a microwave (800W) for 10 minutes. The sections were 
allowed to cool for 10 minutes followed before washing in running water for 5 
minutes. To quench endogenous peroxidases, the sections were then immersed 
in 3% H2O2 in methanol solution for 20 minutes followed by two washes (2 x 5 
minutes) in 50mM phosphate buffered saline (PBS, pH 7.4). Each brain section 
was then circled using a hydrophobic marker to help keep staining reagents 
localized on the tissue sections, reduce the volume needed per section and 
prevent mixing of reagents on the same slide. A blocking solution containing 5% 
bovine serum albumin and 10% normalised goat serum (Vector Laboratories) in 
50mM PBS (pH 7.4) was applied to sections and incubated for 1 hour at room 
temperature to block non-specific surfaces. The monoclonal antibody for 
immunohistochemistry was specific for the 4-HNE adducted protein (4-
Hydroxynonenal monoclonal antibody, Clone 198960, R&D systems). A dilution of 
1:2000 of the 4-HNE primary antibody stock solution (100µg/ml) in the same 
blocking solution was chosen after several trial dilutions were tested. The 
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primary antibody was then applied to sections which were incubated overnight 
at 4°C. Sections were then washed in PBS (2 x 5 minutes). 
Secondary antibody (biotinylated anti-mouse, BA-9200, Vector Laboratories) was 
made to a dilution of 1:100 in 50mM PBS (pH 7.4) and applied to each section for 
1 hour before being washed in PBS (2 x 5 minutes). Sections were incubated in a 
streptavidin-biotinylated horseradish peroxidise complex (ABC Elite kit, Vector) 
for 1 hour. The sections were then washed in PBS and incubated in 3,3’-
diaminobenzidine peroxidase substrate solution (DAB, Vector) for 3 minutes 
before being washed in running water. Finally, the sections were dehydrated in 
stages using graded alcohols (70%, 90%, and 100%), cleared in Histoclear, and 
mounted for light microscopic analysis. Two negative controls, with omission of 
either primary or secondary antibodies, were included in each 
immunohistochemistry protocol. 
Sections were viewed under a light microscope. Cells that exhibited deep, 
intense staining compared to contralateral tissue were classed as 
Immunopositive for 4-HNE (Figure 2.8). Regions of immunopositivity were 
transcribed onto the same scale line diagrams as used in H&E infarct 
determination. Similarly the area of immunopositivity on each coronal section 
was calculated using Image J and the total volume using integration of the 
known distances between the coronal levels using stereotaxic endpoints of 
13.20mm and 0.50mm. 
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Figure 2.8: 4-HNE-immunopositivity analysis 24 h post MCAO. A) 4-HNE immunopositive 
cells had a staining distribution in core and peri-infarct areas. Staining was present within 
cell bodies and axons in grey and white matter B) Normal tissue exhibited faint staining in 
both cell bodies and axons and a low background contrast. Scale Bar = 20µm  
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2.6.2 Quantification of MDA and HAE 
In Chapter 5 quantification of MDA and HAE in cerebral tissue was done using a 
colourimetric assay (LPO-586 Assay, OxisResearch), which is based on the 
reaction of the chromogenic reagent N-methyl-2-phenylindole (R1) with MDA and 
HAE. The reaction of MDA or HAE with N-methyl-2-phenylindole produces a 
stable chromophore which has a maximum absorbance at 586nm, which was 
measured in a spectrophotometer.  
The brain was removed immediately and, using the sagittal slice from the Tri-
Pilot T2 weighted scan as a guide, the section of the brain that was used for 
RARE T2 imaging defined-infarct volume analysis was dissected. The section was 
then divided into 4 ROIs. First the ipsilateral and contralateral hemispheres were 
separated and then subsequently divided into their respective cortex and total 
subcortical structures. Each ROI was transferred to a microfuge tube and snap 
frozen in liquid nitrogen and stored at -80°C to prevent loss of MDA and HAE and 
to prevent further oxidation in the sample. For each ROI, 100 mg tissue was 
weighed out and transferred to a fresh 2 ml microfuge tube. A titanium carbide 
ball was added to each tube along with 1ml of ice-cold 20mM PBS (pH 7.4) and 
10 µl 0.5M butylated hydroxytoluene (BHT).  The samples were then 
homogenised in a tissue lyser (3 x 20 seconds, 28 Hz) before being spun at in a 
microcentrifuge at 4°C (3000 x g, 10 minutes). The supernatant was then 
removed, being careful not to disturb the pellet in the bottom, and 200 µl 
samples were prepared in duplicate for each ROI and kept on ice. Standards of 
known MDA concentrations were then prepared. MDA itself is not stable as an 
aldehyde so the acetal, 1,1,3,3-Tetramethoxypropane (TMOP) was used to 
prepare the standards, which generates MDA during the acid incubation step. 
The TMOP stock was diluted to in deionised water prior to use to generate 200 µl 
of each of the standard concentrations listed in Table 2.3. To each of the ROI 
samples and standards 650 µl of diluted R1 (1:3, R1: diluent, ferric Iron in 
methanol) was added before gently vortexing. Next 150 µl of methanesulphonic 
acid was added and after vortexing, each tube was closed and incubated in a 
water bath at 45°C for 60 minutes. The samples were then removed from the 
water bath and centrifuged for 10 minutes at 15000 x g to produce a clear 
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supernatant. The supernatant was then transferred to a cuvette and the 
absorbance measured at 586 nm in a spectrophotometer. 
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Target concentration of 
standard in reaction 
mixture, µM 
0 0.1 0.25 0.5 1 2 3 4 
Volume of 20 µM standard 
to add (mL) 
0 5 12.5 25 50 100 150 200 
Volume of diH2O or buffer 
used for diluting or mixing 
sample to add (mL) 
200  195 187.5 175 150 100 50 0 
 
Table 2.3: Standard Curve Dilution Volumes for TMOP stock 
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2.7 Neurological Score 
An 18 point composite neurological score was used to assess functional outcome 
in rats following MCAO in Chapter 5 (Garcia et al 1995). The test was conducted 
4 days prior to induction of cerebral ischaemia for baseline assessment and then 
23-24 hours post-MCAO to assess the neurological deficit present. This score 
comprises 6 neurological tests which assess spontaneous activity, symmetry in 
limb movement, forepaw outstretching, climbing ability, body proprioception 
and response to vibrissae touch, with each test scored with a maximum of 3 
points. The scores from each test are added to give an overall neurological 
score, where the maximum score of 18 is achieved where there is no observable 
deficit and the minimum score of 3 indicates the most severely impaired animals 
(Table 2.4).  
2.7.1 Spontaneous Activity 
The rat was observed for a period of 5 minutes in its home cage with the cage 
top removed.  The spontaneous activity of the rat was assessed by its ability to 
approach all four walls of the cage and was scored from 0 to 3. A score of 3 
indicates that the rat moved around the cage, explored the environment and 
approached at least three walls of the cage. A score of 2 was given if the rat 
moved around in the cage but didn’t approach all four walls, although it 
eventually reached at least one upper rim of the cage. A score of 1 indicates 
that the rat barely moved in the cage and didn’t rise up on its hindlimbs to 
approach any of the cage walls and a score of 0 was given if the rat did not move 
at all during the observation period. 
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Test Neurological Score 
 
0 1 2 3 
Spontaneous activity (in 
cage for 5 min) 
No movement Barely moves Moves but does not 
approach at least three 
sides of cage 
Moves and approaches 
at least three sides of 
cage 
Symmetry of movements 
(four limbs) 
Contralateral side: no 
movement 
Contralateral side: 
slight movement 
Contralateral side: moves 
slowly 
Both sides: move 
symmetrically 
Symmetry of forelimbs 
(outstretching while held 
by tail) 
Contralateral side: no 
movement, no 
outreaching 
Contralateral side: 
slight movement to 
outreach 
Contralateral side: moves 
and outreaches less than 
right side 
Symmetrical outreach 
Climbing wall of wire cage ... Fails to climb Contralateral side is weak Normal climbing 
Reaction to touch on 
either side of trunk 
... No response on 
contralateral side 
Weak response on 
contralateral side 
Symmetrical response 
Response to vibrissae 
touch 
... No response on  
contralateral side 
Weak response on 
contralateral side 
Symmetrical response 
 
 
 
Table 2.4. The 18 point composite neurological score to test functional outcome in rats following middle cerebral artery occlusion. This neurological 
evaluation comprises 6 tests which are each given a score up to 3. The scores for each test are added to given an overall score of functional outcome, 
where the maximum score of 18 indicates no observable deficit and the minimum score of 3 indicates severe neurological impairment. Adapted from 
Garcia et al (1995). 
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2.7.2 Symmetry in the Movement of Four Limbs 
Symmetry in the movement of the four limbs was assessed by suspending the rat 
in the air by holding the base of the tail. Scores were assigned as follows: a 
score of 3 was given if all four limbs extended symmetrically and scored 2 if the 
limbs on the contralateral side extended less or more slowly than those on the 
unaffected side. A score of 1 was assigned if limbs on the contralateral side 
showed minimal movement and 0, if the contralateral forelimb did not move at 
all.  
2.7.3 Forepaw Outstretching 
The rat was held by the base of the tail so that it had to walk along the surface 
of the table using its forelimbs only. The hindlimbs were kept in the air and 
symmetry in the outreaching of both forelimbs was observed. Scores indicate the 
following: 3, both forelimbs were outstretched, and the rat walked 
symmetrically on forepaws; 2, the contralateral forepaw outstretched less than 
the ipsilateral forepaw, and forepaw walking was impaired; 1, the contralateral 
forelimb exhibited minimal movement; and 0, the contralateral forelimb did not 
move at all.  
2.7.4 Climbing 
The rat was placed on wire grid and was then pulled off the wire by gripping the 
base of the tail and the strength of attachment was noted. A score of 3 was 
given if the rat climbed easily and gripped tightly to the wire. The rat scored 2 if 
the contralateral side was impaired while climbing or did not grip as hard as the 
ipsilateral side and a score of 1 indicates that the rat failed to climb or tended 
to circle instead of climbing.  
2.7.5 Body Proprioception 
The rat was sharply prodded with a blunt wooden pencil on each side of the 
body, and the reaction to the stimulus was observed. A score of 3 indicates that 
the rat reacted by turning head and was equally startled by the stimulus on both 
sides. A score of 2 was given if the rat reacted slowly to stimulus on the 
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contralateral side and a score of 1 if the rat did not respond to the stimulus at 
all on the contralateral side.  
2.7.6 Response to Vibrissae Touch 
A wooden pencil was brushed against the vibrissae on each side; the stick was 
moved toward the whiskers from the rear of the animal to avoid entering the 
visual fields. A score of 3 was assigned if the rat reacted by turning head or was 
equally startled by the stimulus on both sides. A score of 2 indicates that the rat 
reacted slowly to stimulus on the contralateral side and a score of 1 was given if 
there was no response to the stimulus on the contralateral side.  
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2.8 Glucose Tolerance Test 
Glucose tolerance was assessed for a two hour period following an i.p. injection 
of 15 % glucose solution (10 ml/kg). Rats were fasted overnight (water available 
ad libitum) before commencing experiment. Rats were transferred from their 
cages into a heated box (26 ºC) to aid in vasodilation. Each animal was removed 
from the box and the medial aspect of each hind limb was shaved to expose the 
femoral vein and its distal branches. The area was then cleaned using alcohol 
wipes before a syringe needle was used to puncture the femoral vein. The drop 
of blood formed was analysed using the blood glucose system (Accu-Chek Aviva, 
Roche, Germany) to establish a baseline value for blood glucose (mmol/L). Each 
rat was then administered with 15 % glucose solution (i.p. 1 ml/100 g) and a 
timer started. Subsequent blood samples were collected by venupuncture at 10, 
20, 30, 60 and 120 minutes post glucose load and immediately analysed using the 
blood glucose system. Between each measurement the rats were returned to the 
heated box to help maintain vasodilation. Only 3 samples were taken from each 
leg, one from each femoral vein and two from the distal branches of the vein to 
minimise damage and bruising to the vessels. The blood glucose system accuracy 
was checked using the appropriate control solutions at the start of each new 
pack of test strips. 
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2.9 Non-invasive blood pressure measurements 
It is necessary to monitor systolic blood pressure in both the SHRSP and the WKY 
to ensure that the stroke-prone strain is indeed hypertensive compared to the 
normotensive control strain. The American Heart Association recommends 
indirect measurement of blood pressure to detect substantial group differences 
in systolic blood pressure (Kurtz et al, 2005). The tail cuff method of systolic 
blood pressure (BP) measurement is a non-invasive technique which was 
developed by the West of Scotland’s Department of Clinical Physics and 
Bioengineering, based at the Southern General Hospital in Glasgow (Evans et al, 
1994). This technique involves the placement of a cuff around the proximal end 
of the rat’s tail which is then inflated with air until the point at which the 
pressure in the cuff matches that of the tail artery, resulting in a transient 
occlusion of the vessel. This leads to an absence of a pulse which is detected by 
a signal transducer, which is also located on the tail of the rat, at a more distal 
position than the tail cuff. The signal is relayed to a central monitoring system 
which is connected to a laptop (Dell, UK) which then displays the systolic blood 
pressure reading in mmHg and the cuff is then deflated. This technique is 
advantageous as it does not require catheterisation of an artery as required for 
direct methods of blood pressure measurement and has been validated against 
direct measures of blood pressure measurement (Feng et al, 2008). Furthermore, 
it allows BP measurements to be obtained in conscious animals without the 
influence of anaesthesia on BP, as is the case with invasive methods. However, 
there may be an element of stress associated with the mild restraint involved 
which will be reflected in the measurements obtained but this can be minimised 
by incorporating a thorough acclimatisation and training period into the regime. 
2.9.1 Tail Cuff Apparatus 
Prior to BP measurement, the animals must be pre-warmed to induce maximal 
vasodilatation of the tail artery. This is achieved by placing the animals in an 
insulated heat box (dimensions 37cm x 35cm x 40cm) (Figure 2.9). The upper 
surface of the box has a circular opening (diameter 7cm) to allow the box to be 
warmed to a temperature of 34oC using a hairdryer (Boots, UK). Once the 
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Figure 2.9: The tail cuff apparatus. The top image shows the central blood pressure 
monitoring system which is connected to a laptop, where the systolic blood pressure 
measurements are displayed and recorded. A heat mat and a towel are used to keep the 
rat warm and lightly restrain movement. The bottom image shows the heat box, which is 
pre-warmed to 34oC. The rat is placed in the box for 10-15 minutes to induce maximal 
vasodilation of the tail artery prior to blood pressure measurement. 
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desired temperature was reached it was maintained by positioning an angle 
poise lamp over the opening of the box and this was monitored using a 
thermometer situated on the inner wall of the chamber. The door on the front 
panel of the heat box allowed easy access to the rat in the chamber and the 
removable insulating tile on the door could be removed to observe the animal. 
Removal of the insulating tile and the angle poise lamp from the upper opening 
could be used to promote heat loss if the temperature rose above 35oC. 
The tail cuff was constructed by cutting the medial portion of a 5ml syringe 
(Plastipak, UK) to a length of 2cm. A length of latex tubing (length 6cm, width 
1.5cm) was then inserted into the syringe. A 10 gauge catheter, cut to 4cm in 
length was inserted into the latex tubing and secured in place by tying 5-0 
thread around the tubing. This had to be done meticulously as it was common 
for air to leak if the seal was not complete. The opposite end of the latex tubing 
was turned over to the outer face of the syringe and was secured using a plastic 
o-ring (1.7cm diameter) (Figure 2.10). The catheter was then connected to the 
central BP measurement system. The central monitoring system was also 
connected to a cylinder of medical air (BOC Gases, UK) via a hose, a laptop 
(Dell, UK) and a piezoceramic transducer (Figure 2.9). 
2.9.2 Animal Training Procedure 
All rats were subjected to a 2 day training period to acclimatise them to 
handling and the tail cuff apparatus. On day one of training each rat, were taken 
to the room where the tail cuff apparatus was set up, in their home cage. The 
rat was placed in the heat box with no heat applied and allowed to explore for 
15 minutes. The animals were then handled for a period of 20 minutes and were 
allowed to explore the table where the tail cuff apparatus was set up. They 
were also wrapped in a towel to accustom them to mild restraint.  
On day 2, the training procedure was as described for day 1 but the heat box had 
been heated to 34°C. Then the tail cuff and transducer (Figure 2.10) were 
positioned on the tail whilst the rat was being mildly restrained within a towel. 
After each day training the rats were rewarded with pumpkin seeds. 
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Figure 2.10: The tail cuff and transducer. The top image shows the tail cuff which is 
placed on the base of the tail and inflates and deflates in cycles. The bottom image shows 
the piezoceramic transducer which relays the blood pressure signal to the central blood 
pressure monitoring system.  
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2.9.3 Measurement Protocol 
 The tail cuff method was used to measure systolic blood pressure in WKY and 
SHRSP rats, between 1 and 3 days prior to induction of cerebral ischaemia. BP 
measurement was not performed on a Monday, as it had been found by a 
colleague that because the cages of the rats were cleaned out on this day that 
the animals tended to be more stressed (Emma Reid, personal communication). 
Rats were placed in the pre-warmed heat box for 10-15 minutes and no longer 
than 20 minutes. Care was taken to regularly assess the temperature in the box 
by looking at the thermometer attached to the inner wall of the box. If the 
temperature was above 36oC, then the front panel of the box was removed to 
aid heat loss. The front panel of the heat box also allowed the animals to be 
observed. The rats were deemed to be warm enough when there was very little 
spontaneous movement and the ears looked very pink.  
At this stage the rat was removed from the box and swiftly wrapped in a towel 
with only the tail exposed. The rat was placed onto the heat mat to keep it 
warm and the tail cuff and the signal transducer were positioned on the tail 
(Figure 2.11). Once the rat was settled and was sitting on the heat mat, 
wrapped in the towel, with no need for restraint, then BP measurements were 
taken. The laptop was used to inflate and deflate the cuff in cycles to obtain 
measurements of systolic blood pressure. This was repeated until 8-10 consistent 
measurements of systolic blood pressure were acquired and the mean and 
standard deviation were then calculated. Only the most consistent 
measurements were used to calculate the mean systolic blood pressure for each 
animal. Measurements which were acquired when an animal was visibly stressed 
were excluded. After the tail cuff procedure, the rats were returned to their 
home cage and were rewarded with pumpkin seeds. 
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Figure 2.11: The tail cuff method of non-invasive blood pressure measurement. The top 
image illustrates the positioning of the tail cuff and the signal transducer on the tail of the 
rat, where the cuff is positioned at the base and the transducer is placed distal to the cuff. 
The bottom image shows the computer screen as displayed when blood pressure 
measurements are being recorded. The strength of the signal is shown in the green box in 
the top right hand corner of the display and the measurements are recorded in the box on 
the bottom right corner.  
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 Chapter 3 - Optimisation of the animal models
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3.1 Introduction 
In this chapter data are presented for the purpose of characterising and 
optimising a number of rodent models for use in pre-clinical post stroke 
hyperglycaemia (PSH) experiments. The first aim was to set up a previously 
described model of insulin resistance and metabolic syndrome in the lab 
(Strahorn et al 2005). Secondly, to optimise a method of inducing acute 
hyperglycaemia in rats that led to a level of blood glucose that reflects what has 
been found in hyperglycaemic stroke patients in the GIST-UK clinical trial (Gray 
et al 2004b). Finally, compare two different models of middle cerebral artery 
occlusion (MCAO) to decide which one would be most appropriate for the 
planned studies. 
3.1.1 Models of Hyperglycaemia 
Hyperglycaemia has been widely studied in experimental stroke using a variety 
of rodent models. Intravenous streptozotocin administration has featured often 
in preclinical research to assess the effects of hyperglycaemia on cerebral 
ischaemia yet this is a model of type I diabetes which shares little in common 
with the mechanisms thought to be involved in PSH. Streptozotocin targets the 
insulin producing β cells of the pancreas leading to necrosis which in turn 
diminishes the capacity for insulin release (Szkudelski 2001). As a result of this 
loss of insulin production and release, the levels of glucose in the blood cannot 
be sufficiently controlled and this leads to sustained hyperglycaemia. Data 
included in a recent meta-analysis of studies using the streptozotocin injection 
model to investigate hyperglycaemia in experimental stroke showed blood 
glucose values were on average 25.2mmol/l (MacDougall and Muir 2010). Another 
method commonly used to investigate the impact of hyperglycaemia on 
experimental stroke relies on a bolus injection or an infusion of glucose either 
prior to, at the time of, or after MCAO. A variety of concentrations of glucose 
have been used in experimental stroke studies as well as different 
administration protocols. The plasma glucose values in hyperglycaemic animals 
using the glucose injection model were 23.4 mmol/l from the studies included in 
the recent meta-analysis (MacDougall and Muir 2010).  
94 
Clinically PSH rarely leads to blood glucose values above 16mmol/l (Gray et al 
2007), which raises the question of how pertinent studies that use much higher 
levels of blood glucose are to the typical clinical scenario. Similarly as type II 
diabetes accounts for approximately 90% of all diagnosed cases of diabetes, the 
streptozotocin-induced hyperglycaemia model has little pathophysiological 
relevance to that seen most commonly in stroke patients. Developing a model 
that consistently produces clinically relevant blood glucose values for 
assessment of PSH is imperative for future experimental studies. 
3.1.2 Rodent models of insulin resistance and metabolic 
syndrome 
Approximately  56% of acute stroke patients who develop hyperglycaemia are 
subsequently diagnosed with insulin resistance which is known to manifest as 
impaired glucose tolerance, impaired fasting glucose or the “metabolic 
syndrome”(Gray et al 2004b; McCormick and Muir 2006). Previously 
spontaneously hypertensive stroke prone rats (SHRSP) fed on a 60% fructose diet, 
compared to their reference Wistar-Kyoto (WKY) strain, have been shown to 
develop insulin resistance, hypertension, elevated plasma triglyceride levels and 
reduced high density lipoprotein (HDL) cholesterol, all of which are features of 
the metabolic syndrome (Strahorn et al 2005). This model encompasses the 
majority of features of the metabolic syndrome which makes it an excellent 
model for investigating the role of insulin resistance and other co-morbidities in 
pre-clinical stroke research. The combination of a model of insulin resistance 
with and without acute clinically relevant hyperglycaemia following cerebral 
ischaemia offers an opportunity to investigate the effects of hyperglycaemia 
with and without insulin resistance and commonly occurring associated stroke 
co-morbidities.  
3.1.3 Different models of MCA Occlusion 
It is important to use a model of focal cerebral ischaemia that is suited to the 
research questions being posed. Subsequent studies in this thesis aim to use a 
model of middle cerebral artery occlusion (MCAO) to assess the expansion of the 
lesion and loss of penumbral tissue in the acute phase of ischaemic damage. The 
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intraluminal filament method of MCAO is known to produce substantial infarcts 
especially in the SHRSP and WKY strains. This arises from blocking the origin of 
the MCA leading to extensive damage in the caudate nucleus and other 
subcortical regions as well as a large proportion of the cortex. In-house studies 
of this MCAO model using diffusion weighted imaging and perfusion weighted 
imaging have shown that commonly almost the entire ipsilateral hemisphere can 
be considered ischaemically damaged with very little penumbra as defined by 
diffusion-perfusion mismatch even as early as 1 hour post occlusion in SHRSP 
rats. Such a large initial lesion could therefore restrict the ability to detect a 
detrimental influence of hyperglycaemia or other co-morbidities on infarct 
expansion due to a “ceiling effect” since maximal damage could already be 
achieved in the absence of raised blood glucose. Using a different model of focal 
cerebral ischaemia may allow for smaller initial lesions that have more potential 
to extend into the area of hypoperfusion, in turn perhaps unmasking any 
acceleratory effect of hyperglycaemia on penumbral loss and lesion expansion. 
Diathermy of the MCA distal to the origin has the potential to cause smaller 
cortical lesions which may lead to proportionally more penumbra than seen in 
the intraluminal filament model. It was important therefore to evaluate the 
amount of diffusion –perfusion mismatch defined penumbra in the acute time 
period following diathermy of the MCA and similarly to compare the size of the 
lesions and reproducibility of each model. This information could then be used 
to inform on the model that should be taken forward for future 
experimentation.   
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3.1.4 Study Aims 
Study 1: Glucose tolerance test and lipid profile analysis 
To establish the fructose fed SHRSP model in the lab by confirming the presence 
of insulin resistance compared to the reference WKY strain. Secondly to confirm 
the differences in the blood lipid profile between the fructose fed SHRSP and 
the WKY rat strains. 
Study 2: Investigate normo- and hyperglycaemia after MCAO under 
isoflurane-induced anaesthesia 
To ascertain a glucose dose that would induce clinically relevant levels of 
hyperglycaemia following MCAO using a single glucose load.  
Study 3: Comparison of the intraluminal filament model and the distal 
diathermy model of MCAO occlusion 
To investigate the most suitable model of permanent focal cerebral ischaemia 
for the proposed study; the intraluminal filament model or the distal diathermy 
model. 
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3.2 Materials and Methods 
All experiments were carried out under licence from the Home Office and were 
subject to The Animals (Scientific Procedures) Act, 1986. For studies 1 and 2, 
male rats (9 weeks old) were obtained from breeding colonies of SHRSP and WKY 
within the Institute of Cardiovascular and Medical Sciences, University of 
Glasgow and allowed a one week acclimatisation period upon arrival. SHRSP 
were then fed on a 60% fructose diet for 2 weeks prior to any experimentation. 
WKY were fed on standard rat chow and both food and water were available ad 
libitum to both groups of animals. All experiments were conducted when rats 
were 12 weeks of age. Male Sprague-Dawley rats (250-300g, Harlan, Bicester, 
UK) were used in study 3 for comparison of the two MCAO occlusion models. This 
was due to limited supply of male WKY and SHRSP rats from the breeding colony. 
3.2.1 Glucose tolerance test and lipid profile analysis (Study 1) 
Fructose fed SHRSP (ffSHRSP, n=6) and WKY (n=7) rats were fasted overnight 
then weighed on the morning of the test. The rats were placed in a Perspex 
incubator set at 37°C for 20 minutes to allow for peripheral vasodilation. The 
hind limbs were then shaved and swabbed with alcohol so the femoral vein could 
be visualised. The glucose tolerance test was then performed as previously 
described in Chapter 2.8. Upon completion of the test rats were anaesthetised in 
a Perspex chamber using 5% isoflurane before being transferred to a facemask 
where anaesthesia was maintained at this concentration. An incision into the 
chest was made and the diaphragm cut away from the ribcage. The ribcage was 
then cut back towards the neck to expose the heart. Terminal blood samples 
were taken via cardiac puncture and these samples were spun in a centrifuge (3 
min, 10000 rpm). The plasma was removed and immediately frozen and stored 
at -80°C. Once all the samples were collected insulin and lipid profile analysis 
was conducted on the plasma as described in Chapter 2.  
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3.2.2 Investigating normo- and hyperglycaemia after MCAO under 
isoflurane-induced anaesthesia (Study 2) 
WKY rats were randomly assigned to either glucose (WKY + G, n = 6) or vehicle 
(WKY, n = 6) treatment groups. Fructose fed SHRSP rats were also randomly 
assigned to glucose (ffSHRSP + G, n = 6) or vehicle (ffSHRSP, n = 3) groups. 
Animals were fasted overnight prior to experimentation to improve 
reproducibility in baseline blood glucose values. Animals were anaesthetised 
with 5% isoflurane in a Perspex chamber and then orally intubated. They were 
then mechanically ventilated with 2.5% isoflurane in a nitrous oxide-oxygen 
mixture (70:30). Blood gases were maintained within the normal physiological 
range apart from increased PaO2 due to the oxygen enriched mixture used to 
maintain physiological stability throughout the experiment. A rectal 
thermocouple provided continual monitoring of core body temperature that was 
maintained at 37°C±0.5°C. A polyethylene catheter (Portex: external diameter 
0.96mm; internal diameter 0.58mm; 20cm long) was placed in the right femoral 
artery, to continuously monitor blood pressure and conduct blood gas analysis.  
A single dose of a 15% glucose solution (in distilled water, 10ml/kg) was 
administered i.p. 10 minutes prior to occlusion of the MCA to WKY + G and 
ffSHRSP + G groups. Their respective control groups, (WKY and ffSHRSP) received 
vehicle (distilled water, 10ml/kg). This dose was selected based on results from 
the glucose tolerance test, as in conscious rats it lead to a peak blood glucose 
concentration of between 12 and 16 mmol/l, which was within the clinically 
relevant  range in stroke patients.  
After occlusion of the MCA, anaesthesia was maintained for 4 hours whilst 
arterial blood samples were taken for blood glucose analysis. Animals were then 
recovered before being perfuse fixed with 4% paraformaldyhyde 24 h post MCAO. 
The brains were removed and subjected to further tissue processing (Chapter 
2.4.3) before being embedded in paraffin wax. Each brain was cut using a 
microtome into coronal sections (7 µm) at 8 predefined anatomical levels 
spanning the MCA territory. These sections were stained using haematoxylin and 
eosin as described in Chapter 2.4.4. The areas of ischaemic damage from these 
sections, identified using light microscopy (x 400), were transcribed onto 
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representative line diagrams before being scanned into Image J for infarct 
quantification as described in Chapter 2.4.5.  
3.2.3 Comparison of the intraluminal filament and the distal 
diathermy models of middle cerebral artery occlusion 
(Study 3) 
Male Sprague-Dawley rats (n=6) were initially anaesthetised with 5% inhaled 
isoflurane delivered in a nitrous oxide-oxygen mixture (70:30) in an induction 
chamber at room temperature. A surgical tracheotomy was performed and the 
animals were mechanically ventilated with 2.5% isoflurane in a nitrous oxide- 
oxygen mixture (70:30). A polyethylene catheter (Portex: external diameter 
0.96mm; internal diameter 0.58mm; 20cm long) was placed in the right femoral 
artery, to continuously monitor blood pressure and conduct blood gas analysis. 
Blood gases were maintained within the normal physiological range apart from 
increased PaO2 due to the oxygen enriched mixture used to maintain 
physiological stability throughout the experiment. A rectal thermocouple 
provided continual monitoring of core body temperature that was maintained at 
37°C±0.5°C. Occlusion of the MCA was either induced using the intraluminal 
filament method (n=6) or the distal MCA diathermy model (n=6) both described 
previously in Chapter 2.3. Following MCA occlusion animals were maintained 
under anaesthesia for 4 hours. Animals were then immediately killed by 
overdose of anaesthesia. The brains were removed and transferred to a freezer 
(-18°C) for 20 minutes before being sectioned into 2mm thick coronal slices. 
These sections were then immersed in TTC at 37°C for 10-15 minutes as 
described in Chapter 2.4.6 and the areas and total volume of ischaemic injury 
were calculated in Image J. 
One male Sprague-Dawley rat underwent MRI scanning to assess the amount of 
penumbral tissue created by the distal diathermy model of MCAO. Following MCA 
occlusion the rat was placed prone in a rat cradle and the head was restrained 
using tooth and ear bars to limit head movement. Body temperature was 
maintained for the duration of the scanning protocol using a closed circuit 
thermal jacket and was monitored by a rectal thermocouple. A linear surface 
receiver coil (2cm diameter) was placed above the head of the animal before 
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being transferred to the scanner, as described in Chapter 2.5.1. Diffusion-
weighted imaging was performed to identify ischaemically damaged tissue in 8 
coronal slices within the MCA territory using the sequence described in Chapter 
2.5.3.1. Non-invasive quantitative cerebral blood flow measurements were 
carried out on 6 coronal slices, which were spatially identical to slices 2-7 
acquired from DWI scans, using a form of pseudo-continuous arterial spin 
labelling based on a train of adiabatic inversion pulses (Moffat et al 2005). These 
scans take considerably longer to acquire than DWI images which prevents 8 
coronal images being acquired within the time window available. The sequence 
is described in Chapter 2.5.4.1 
3.2.4 Statistical analysis 
Glucose tolerance data were plotted over time and the area under the curve was 
calculated. Data were analysed using a 2 way ANOVA and an unpaired Student’s 
t-test, respectively. Blood glucose level data in Study 2 were analysed using a 2 
way ANOVA with Bonferroni multiple comparisons post test. Infarct volume data 
were expressed as group means and analysed using a 1 way ANOVA with 
Bonferroni multiple comparisons post test. Data are expressed as mean ± 
standard deviation or as scatterplots with the mean indicated. 
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3.3 Results 
3.3.1 Glucose tolerance test and lipid profile analysis (Study 1) 
3.3.1.1 Body weights 
As expected there was a significant difference between ffSHRSP and WKY rats in 
this study (ffSHRSP, 227.3±13.69 g; WKY, 258.7±13.27 g, p<0.001). This is a 
known characteristic of the SHRSP compared to age-matched WKY control rats 
(Ibrahim et al 2006; Strahorn et al 2005). 
3.3.1.2 Glucose Tolerance test 
The glucose tolerance test was performed on WKY and ffSHRSP rats. Initial blood 
glucose measurements taken prior to the glucose challenge were similar in both 
the WKY and ffSHRSP (WKY, 4.9±0.6 mmol/L; ffSHRSP, 6.0±1.5 mmol/L, p=0.06, 
Figure 3.1a). Following a single i.p. injection of 15% glucose (10ml/kg) the blood 
glucose level rose rapidly in both groups over the first 10 minutes, although the 
rate of increase was significantly higher in the ffSHRSP compared to WKY (WKY, 
33.9±5.0 mmol/L/h; ffSHRSP, 44.0±6.7 mmol/L/h, p=0.009). The mean rate of 
increase diminished in both groups to a similar rate at 20 minutes post glucose 
administration (WKY, 12.3±4.5mmol/L/h; ffSHRSP, 18.1±12.7 mmol/L/h, 
p=0.28). Mean peak glucose was observed in both groups 20 minutes following 
the glucose challenge. The mean peak glucose reached in the ffSHRSP was 
significantly higher than that observed in the WKY group (ffSHRSP, 16.6±3.2 
mmol/L; WKY, 12.6±1.0 mmol/L, p=0.01). This suggests that the ffSHRSP group 
are not responding as well to the challenge of glucose as the WKY group. At the 
2 hour time point, blood glucose in both groups had returned to baseline values 
(WKY, 5.3±0.4; ffSHRSP, 5.9±0.5). The area under the curve data demonstrates 
that the ffSHRSP have a significantly greater blood glucose level over the 2 hour 
tolerance test compared to the WKY strain (ffSHRSP, 1051±79; WKY, 1308±238, 
p=0.02) indicating insulin resistance. There was a considerable amount of 
variability in the ffSHRSP group compared to the WKY group demonstrated in the 
difference in the size of the standard deviations.  
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Figure 3.1: The blood glucose response to a glucose challenge in WKY and ffSHRSP 
rats, presented as the temporal profile (A) and area under the curve (B). The data in A) 
are expressed as mean ± standard deviation. The data in B) are expressed as AUC for 
each animal with the mean indicated and analysed using a unpaired t-test. * P<0.05. 
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3.3.1.3 Plasma insulin, lipid profile and adiposity 
The ffSHRSP group demonstrated a number of differences in the plasma lipid 
profile compared with the WKY group (Table 3.1). The ffSHRSP had a 
significantly greater level of plasma triglycerides than the WKY strain 
(p>0.0001). The total and HDL cholesterol were both significantly lower in the 
ffSHRSP than in the WKY group (p>0.001). Interestingly the mean plasma insulin 
level was significantly increased in the ffSHRSP compared to the WKY group 
(p=0.03). Although the ffSHRSP rats were significantly lighter than the WKY rats 
they exhibited a higher adiposity index (% body fat).  
 
 
 
 
 
 
Table 3.1 Features of the metabolic syndrome in WKY and ffSHRSP. Data are expressed 
as mean ± standard deviation. Analysed using a Student t-test; *, P<0.05; **, P<0.001; ***, 
P<0.0001 compared to WKY.  
  
WKY (n=5) 
 
ffSHRSP (n=5) 
 
Adiposity (% body fat) 
1.40± 0.29 2.40± 0.09** 
 
Plasma triglycerides (mmol/l) 
 
0.28± 0.04 
 
0.65± 0.11*** 
 
Total cholesterol (mmol/l) 
 
2.53±0.09 
 
1.74± 0.11*** 
 
HDL cholesterol (mmol/l) 
 
2.212±0.07 
 
1.58±0.12*** 
 
Insulin(µg/l) 
 
0.30± 0.07 
 
0.46± 0.14* 
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3.3.2 Investigating normo- and hyperglycaemia after MCAO under 
isoflurane-induced anaesthesia (Study 2) 
3.3.2.1 Physiological variables 
During surgical preparation animals in all groups were maintained within normal 
physiological limits (pCO2, 35-45 mmHg; pH, 7.35-7.45; body temperature, 37.0 
±0.5°C) with the exception of pO2 which was higher than normal due to the 
concentration of oxygen used to deliver the anaesthetic.  
3.3.2.2 Blood glucose  
Baseline blood glucose level was similar in all 4 groups. After administration of 
glucose to WKY + G and ffSHRSP + G groups, blood glucose level increased 
substantially compared to respective controls that received vehicle, reaching 
peak glucose between 20 and 30 minutes post glucose loading (Figure 3.2A). 
Peak glucose was similar in WKY + G (10.7±2.6 mmol/L) and ffSHRSP + G (11.6± 
3.1 mmol/L, p=0.58). Blood glucose remained significantly higher in WKY + G 
compared with control up until 2 hours post glucose administration. However, 
although not statistically significant blood glucose remained above the level of 
the control WKY group at each subsequent time point. The ffSHRSP + G group 
again remained high throughout the experiment although only a number of time 
points reached statistical significance (20, 60, 240 minutes). From the area 
under the curve data (Figure 3.2B) generated from the temporal blood glucose 
plot, administration of glucose leads to an overall significant increase in blood 
glucose (WKY vs. WKY + G, 1488±48 vs. 2167±390, p<0.05; ffSHRSP vs. ffSHRSP + 
G, 1625±214 vs. 2542±581, p<0.01). There was no increase in blood glucose 
observed in either control group as a result of vehicle administration or 
induction of MCAO suggesting a lack of influence from these factors on glycaemic 
control in this particular time frame. 
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Figure 3.2: Acute hyperglycaemia in WKY and ffSHRSP. A) The temporal profile of blood 
glucose following glucose or vehicle administration. Red arrow indicates time of MCAO. 
Both ffSHRSP and WKY reached similar peak glucose values at 20 minutes post glucose 
loading. B) Plotting area under the curve shows that loading with glucose leads to a 
significant increase in blood glucose compared to vehicle treated animals. Data analysed 
using 1 way ANOVA with Bonferoni post test. 
B 
A 
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3.3.2.3 Infarct quantification 
Quantitative histology indicated that infarct volume at 24 hours post MCAO using 
the intraluminal filament model was not significantly different between the 
glucose loaded WKYs and the vehicle treated WKY controls (Figure 3.3). Similarly 
there was no difference between the glucose treated ffSHRSP and the vehicle 
treated ffSHRSP controls. Most interestingly no difference was observed between 
the ffSHRSP and WKY vehicle treated animals.  Upon examination of the line 
diagrams, from which the infarct volumes were calculated, it was obvious that 
the lesion sizes were extremely large encompassing the majority of the 
hemisphere (Figure 3.4).   
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Level 1. Bregma = 3.24 mm            Level 2. Bregma = 1.68 mm 
   
Level 3. Bregma = -0.12 mm            Level 4. Bregma = -1.32 mm   
   
Level 5. Bregma = -2.40 mm                      Level 6. Bregma = -3.60 mm            
   
Level 7. Bregma = -5.20 mm                    Level 8. Bregma = -6.36 mm 
Figure 3.3: The infarct areas at 24h after intraluminal filament-induced MCAO in the 
median ffSHRSP rat. Line diagram (Paxinos and Watson, 2007) comprising 8 pre-
determined coronal levels with the blue area representing ischaemic damage. ffSHRSP 
exhibit almost complete hemispheric lesion in all 8 levels. 
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Figure 3.4: Infarct volumes at 24 hours post MCAO. There was no difference associated 
with glucose loading in WKY groups. Glucose had no effect on infarct size in ffSHRSP 
groups.  Interestingly no statistically significant difference in infarct size between WKY and 
ffSHRSP was observed. Glucose loading in ffSHRSP caused a significant increase in 
infarct compared to both WKY treated with glucose and WKY treated with vehicle.  
*, P<0.05 vs. ffSHRSP + G group.
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3.3.3 Comparison of the intraluminal filament and the distal 
diathermy method of MCAO (Study 3) 
3.3.3.1 Physiological variables 
During surgical preparation Sprague Dawley rats in all groups were maintained 
within normal physiological limits (pCO2, 35-45 mmHg; pH, 7.35-7.45; body 
temperature, 36.8-37.2°C) with the exception of pO2 which was higher than 
normal due to the concentration of oxygen used to deliver the anaesthetic. 
There was however no difference in pO2 between any of the groups. 
3.3.3.2 Infarct quantification  
There were notable differences in the extent of ischaemic damage in the 
intraluminal filament model compared to the distal diathermy occlusion model 
(Figure 3.5). Separating the lesion into cortical and subcortical regions (Figure 
3.6), there was no statistically significant difference in cortical damage between 
the 2 models (diathermy, 46.1±18.5 mm3; intraluminal filament, 61.3± 14.3 
mm3). In the intraluminal filament model the majority of the lesion was 
subcortical accounting for over 60% of the lesion (Figure 3.6). The distal 
diathermy occlusion of the MCA produced no subcortical damage in any of the 6 
animals.  
110 
 
 
 
 
 
 
 
 
 
Figure 3.5: Representative coronal TTC stained brain tissue following 4 hour permanent 
MCAO in Sprague Dawley by a) distal diathermy and b) intraluminal filament model. 
MCAO via distal diathermy occlusion results in ischaemic damage being confined to the 
cortex. A large volume of subcortical tissue damage is present using the intraluminal 
filament model.
Rostral 
Caudal 
Caudal 
 
Rostral 
 
a) 
b) 
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Figure 3.6: Infarct volume calculated from TTC stained coronal sections from Sprague 
Dawley rats that underwent MCAO by either the distal diathermy (n=6) or intraluminal 
filament model (n=6). Lesion size is significantly greater following intraluminal filament 
MCAO than distal diathermy occlusion. There is significant subcortical damage caused by 
intraluminal filament MCAO compared to none seen in the distal diathermy model. Data 
are displayed as mean ± standard deviation. 
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3.3.3.3 Identifying the penumbra 
From the MRI images it is clear that at 1 hour post MCAO, there is a large volume 
of diffusion-perfusion mismatch defined penumbra tissue in the distal diathermy 
model (Figure 3.7). The perfusion deficit remained constant throughout the 
scanning period (Figure 3.8A). At subsequent time points the volume of DWI-PWI 
mismatch defined penumbra diminished from 40.5mm3 to 20.7mm
3 as the ADC 
lesion expanded (Figure 3.8B). Even at 4 hours post MCAO there is substantial 
perfusion diffusion mismatch at the rostral caudal poles of the MCA territory 
suggesting the lesion would further expand to match the volume of the perfusion 
deficit.  
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Figure 3.7: MRI DWI and PWI mismatch identifying suspected penumbra in a Sprague Dawley rat with a distal diathermy MCAO.  Scans from 6 coronal 
slices are displayed at hourly intervals following stroke onset. Red areas depict the perfusion deficit and the white areas indicate ADC-defined lesion. 
Penumbra can be identified at all 4 hours post MCAO (remaining red regions). The DWI defined ischaemic damage or injury increases over time. The 
perfusion deficit remains relatively stable.
Caudal 
1 HOUR 
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Time after 
MCAO 
Red area, perfusion deficit; White area, ADC lesion  
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Figure 3.8: Lesion evolution and penumbral loss following MCAO by distal diathermy 
occlusion of the MCA. A) Illustrates the progression of DWI defined ischaemic damage 
over time (red line) and the PWI defined blood perfusion deficit (blue line). B) Shows the 
loss of DWI-PWI mismatch defined penumbral tissue as the ischaemic lesion develops. 
B 
A 
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3.4 Discussion 
The preliminary experiments in this chapter were designed to optimise rodent 
models to be used in subsequent studies of post stroke hyperglycaemia. They 
confirm that the fructose fed SHRSP does exhibit insulin resistance as well as 
other features of the metabolic syndrome. They demonstrated that a single i.p. 
administration of 15% glucose solution induces clinically relevant levels of 
hyperglycaemia in both WKY and fructose fed SHRSP rats under anaesthesia 
which was suitably maintained during the acute period following MCAO. They 
highlight the neuroanatomically extensive lesions produced by the intraluminal 
filament model of MCAO as opposed to those produced by a distal MCAO using 
diathermy, and they indicate that the latter model of MCAO produces smaller, 
purely cortical lesions with a relatively large amount of assumed penumbral 
tissue.  
3.4.1 Fructose fed SHRSP exhibit insulin resistance and other 
features of metabolic syndrome 
The National Cholesterol Education Program (NCEP) set out criteria that stated 
at least 3 risk factors from hypertension, obesity, insulin resistance, 
hypertriglyceridaemia and low HDL cholesterol must be present for diagnosis of 
metabolic syndrome in humans. SHRSP rats fed on a 60% fructose diet for two 
weeks display hypertension, impaired glucose tolerance, dyslipidaemia (reduced 
HDL cholesterol and increase plasma triglycerides), hyperinsulinaemia as well as 
an increased adiposity index compared to the WKY strain thus making it an 
appropriate model for investigating the metabolic syndrome. Previously this 
model was only shown to elicit impaired glucose tolerance without 
hyperinsulinaemia (Strahorn et al 2005). This suggested impaired glucose 
tolerance was primarily due to impairments in glucose-stimulated insulin 
secretion rather than a decreased sensitivity to insulin. It is well established that 
the accumulation of triglycerides and other lipid derived intermediates in the β-
cells of the pancreas is directly linked to impairment in insulin secretion 
(Schaffer 2003; Zhou and Grill 1995). Interestingly since hyperinsulinaemia has 
been observed in the fructose fed SHRSP model of metabolic syndrome it 
addresses both decreased sensitivity to insulin and impaired glucose-stimulated 
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insulin release that together are responsible for impaired glucose tolerance in 
humans.  
When the fructose feeding model was developed, feeding both WKY and SHRSP 
rats on the 60% fructose diet was investigated (Strahorn et al 2005). It was 
observed that feeding WKY rats on the fructose rich diet failed to alter tolerance 
to glucose, producing a similar temporal profile and area under the curve to that 
observed in both WKY and SHRSP rats on standard chow diet. This was also 
observed in our lab on a small subset of animals, confirming that only the SHRSP 
after 2 weeks feeding is sensitive to fructose-induced impaired glucose 
tolerance.  
The data collected from both the glucose tolerance test and from the terminal 
blood samples replicated what was reported  by Strahorn et al (2005) with 
similar results for glucose tolerance, plasma triglycerides and both total and HDL 
cholesterol. However previously it had not been shown in this model that the 
fructose fed SHRSP exhibits elevated plasma insulin levels compared to WKY 
rats.   
3.4.2 Other models of insulin resistance and metabolic syndrome 
The fructose fed SHRSP model of insulin resistance is a variation on the 
commonly used spontaneously hypertensive rat (SHR) which has been shown to 
exhibit insulin resistance in both skeletal muscle (Hulman et al 1993) and 
isolated adipocytes (Reaven et al 1989) without additional feeding with fructose. 
In SHRSP rats I was unable to demonstrate these differences in vivo without the 
addition of a fructose feeding protocol. This is perhaps a sensitivity issue of the 
glucose tolerance test compared to the euglycaemia hyperinsulinaemia clamp 
technique used by Hulman et al (1993) on the SHR. Similarly the results from 
isolated adipocytes may not reflect what is seen in vivo, or the contribution of 
reduced insulin sensitivity in fat tissue may not lead to a measurable effect in 
vivo. More recently a sucrose feeding protocol has been used in SHR rats, which 
reflects the need for fructose feeding that we observed (Pagliassotti et al 1994). 
However the sucrose fed SHR was recently reviewed and showed that although 
an impairment in glucose tolerance was observed this model failed to 
significantly increase plasma insulin or triglycerides or show a difference in total 
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cholesterol compared to control animals (Oron-Herman et al 2008). This study 
also addressed the primarily diet-induced model of metabolic syndrome using 
Sprague Dawley rats which has been frequently used with a variety of feeding 
protocol durations. One study using male Sprague Dawley rats found that a 66% 
fructose feeding regime for 8 weeks led to increased fasting blood glucose, 
plasma insulin and triglycerides compared to controls (D'Angelo et al 2005). This 
reflects aspects of my findings although no differences in fasting blood glucose 
were observed in the WKY or fructose fed SHRSP in the current study. Similarly 
D’Angelo et al (2005) were unable to produce an increase in blood pressure 
which had been seen previously in Sprague Dawley rats having been fed a high 
fructose diet for 2 weeks (Hwang et al 1987) and also after feeding for 7 weeks 
(Oron-Herman et al 2008).  
The main driving force currently for studies of metabolic syndrome and insulin 
resistance is the obesity epidemic that faces the western world. Prior to the 
experiments reported in this chapter consideration was given to the obese 
Zucker rat. In this rat a missense mutation in the leptin receptor causes 
hyperphagia, hyperlipidaemia, hyperinsulinaemia and obesity compared to the 
lean Zucker rat (Phillips et al 1996; Takaya et al 1996; Zucker and Zucker 1961). 
The insulin resistance exhibited by the obese Zucker rat is well characterised 
(Boulange et al 1981; Ionescu et al 1985; Penicaud et al 1987) and has been used 
widely as a model of metabolic syndrome. Hypertension has also been observed 
in a number of studies (Kim et al 1994; Zemel et al 1990; Zemel et al 
1992)which, similar to the model employed in this study, meets the criteria set 
out for the human metabolic syndrome. Although the Zucker represents an 
excellent model for studying insulin resistance in cerebral ischaemia using the 
proposed PSH protocol, there are a few pragmatic issues that prevent the use of 
this model for our planned studies. The main issue relates to the size of the 
obese Zucker rat. The obese Zucker rats, at 10 weeks of age, weigh around 650g 
which is 3 times the size of the SHRSP rats that are currently used in our lab. As 
future experimentation will be investigating the acute evolution of damage using 
MR imaging this size becomes a significant limitation. The rat cradle we have for 
the MRI scanner is not big enough to accommodate a rat of that size. This would 
also pose problems for maintenance of body temperature as the water jacket 
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would not fit correctly. For this reason there was no possibility, using the 
equipment available, that acute imaging studies could be done on Zucker rats.  
3.4.3 Hyperglycaemia was maintained in both WKY and fructose 
fed SHRSP after bolus injection of glucose 
The dose of glucose used in conscious fructose fed SHRSP and WKY rats by 
Strahorn et al (2005) produced a level of hyperglycaemia in the current study 
between 12 and 16 mmol/L. Often studies have used levels of extremely high 
blood glucose levels from around 16 mmol/l to in excess of 27 mmol/l to study 
hyperglycaemia in cerebral ischaemia (Bomont and MacKenzie 1995; de Courten-
Myers et al 1988; Ginsberg et al 1987; Gisselsson et al 1999; Huang et al 1998; 
Kawai et al 1998; Li et al 1998; Wei et al 2003; Yura et al 1986). The GIST-UK 
trial of stroke patients reported admission blood glucose concentrations of 
between 6.0 and 16.6 mmol/l (Gray et al 2004a). This suggests that, in conscious 
WKY and fructose fed SHRSP rats, the blood glucose values obtained from a 
single i.p. 15% glucose (10ml/kg) injection produce more clinically relevant 
levels of hyperglycaemia for studying PSH than the many studies that have 
resorted to much higher blood glucose levels. The 15% glucose (10ml/kg) dose 
was therefore selected as the basis for producing clinically relevant 
hyperglycaemia whilst under anaesthesia.  
The data from Study 2 show that a single bolus injection of glucose in both WKY 
and fructose fed SHRSP rats lead to significant increases in blood glucose levels 
compared to vehicle treated animals.  A similar peak glucose level occurred in 
both WKY and fructose fed SHRSP rats under anaesthesia reaching between 10 
and 12 mmol/L at 20 minutes after administration. This is lower than was 
observed in the conscious animals, which is perhaps due to an additive stress 
response from the procedure; handling the animals, blood sampling, and i.p. 
injections. Interestingly the major difference is that blood glucose concentration 
remains increased for longer, especially in the fructose fed SHRSP group. In a 
study using isolated rat islets of Langerhans it has been found that isoflurane can 
inhibit the release of insulin from the pancreas in response to a glucose 
challenge (Desborough et al 1993). This is also supported by a number of in vivo 
studies that show in both humans and rodents that blood glucose increases under 
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anaesthesia (Kofke et al 1987; Lattermann et al 2001). This could possibly 
explain why hyperglycaemia is prolonged. The control groups, receiving only 
vehicle, show no increase in blood glucose concentration over the 4 hours of 
anaesthesia. There is also no increase following the induction of cerebral 
ischaemia. This suggests firstly that isoflurane has no effect on basal glucose 
levels at these time points and secondly that the insult of precluding flow from 
the MCA causes no measureable hyperglycaemia at the acute time points that 
may be associated with a stress response. This is contradictory to what is 
proposed to be causing a prolonged increase in blood glucose. It is known that 
isoflurane alters energy metabolism in the brain, dampening glucose utilisation 
in a number of areas which perhaps explains why the hyperglycaemia is 
maintained for longer in animals receiving a glucose challenge. 
3.4.4 Distal diathermy MCAO produces small lesions and large 
penumbra. 
Inducing cerebral ischaemia in WKY or SHRSP rats using the intraluminal filament 
model of MCAO has been found previously in our lab to result in large lesions 
encompassing the majority of the ipsilateral hemisphere (Reid et al 2012). There 
are a number of concerns associated with the intraluminal filament method of 
MCAO for recovery studies in WKY and SHRSP rat strains. There is an increased 
possibility of mortality due to the severe ischaemic damage and associated 
cerebral oedema that causes intracranial pressure to rise in closed skull models 
such as the intraluminal filament model. 
There was no significant difference in infarct volume at 24h between the WKY 
and fructose fed SHRSP rats in Study 2. This is surprising as it is well established 
that the SHRSP rat strain is more sensitive to experimental stroke compared to 
the reference WKY strain (Carswell et al 1999; Coyle and Jokelainen 1983; Marks 
et al 2001). Interestingly the studies that have demonstrated the increased 
sensitivity to experimental stroke used a distal MCA occlusion similar to the 
diathermy method of MCAO rather than the intraluminal filament method of 
permanent MCAO which was used in Study 2.  A significant difference was seen 
between the ffSHRSP+G group and the WKY and WKY+G groups suggesting that 
the small n number in the SHRSP group may not have been enough to distinguish 
120 
between the infarct volumes. No difference was seen following the 
administration of glucose to either ffSHRSP or WKY rats compared to their 
respective vehicle treated controls which doesn’t support the majority of the 
available literature (MacDougall and Muir 2010). However it is postulated that 
perhaps, especially in ffSHRSP groups, a ceiling effect applies in permanent 
intraluminal filament induced MCAO such that a maximal amount of damage is 
produced. As future studies aim to elucidate the detrimental effects of 
hyperglycaemia on lesion growth this model of cerebral ischaemia may be 
unsuitable. Moreover MRI studies in our lab using SHRSP and WKY having 
undergone permanent  MCAO by intraluminal filament introduction have shown 
that very little penumbral tissue is present even at early time points as the 
lesion is already very large (McCabe et al 2009; Reid et al 2012) . The rate of 
penumbral loss is an important outcome measure for investigating post stroke 
hyperglycaemia in the acute period of ischaemic injury and therefore a model 
that exhibits a reasonable amount of penumbral tissue is more suited to the 
experimental design proposed for subsequent studies in this thesis. A recent 
study conducted in our lab showed that the intraluminal filament model of 
permanent MCAO only produced a small amount of DWI-PWI mismatch defined 
penumbra in the SHRSP and WKY strain (McCabe et al 2009; Reid et al 2012). 
Even in the outbred Sprague Dawley strain the intraluminal filament model 
exhibits large lesions with only a small proportion of DWI-PWI mismatch defined 
penumbra (Robertson et al 2011) The intraluminal filament method of MCAO can 
also disrupt the extracranial blood flow to the facial muscles responsible for 
mastication, due to the surgical occlusion of the external carotid artery, which 
can cause issues during animal recovery from surgery. This has proved 
problematic with regards to maintaining animal weight and poses more mortality 
problems with recovery for more than 24 hours. 
As shown in this chapter the distal diathermy model of MCAO produces much 
smaller infarcts with all ischaemic tissue confined to the cortex. The need for a 
small craniectomy also helps prevent brain oedema from increasing intracranial 
pressure and hence helping reduce mortality. The MRI data collected suggests 
that there is substantial penumbra associated with this model and even though 
these data were collected from a Sprague Dawley rat, comparisons with the 
intraluminal filament show almost double the volume of penumbra using the 
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distal diathermy model of MCAO in this strain (Robertson et al). The draw back 
with diathermy models is the level of surgical skill required to occlude the MCA. 
This is far more technically demanding than the intraluminal filament model of 
MCAO and led to 2 surgical deaths out of a total of 7 animals subjected to distal 
diathermy occlusion compared to no surgical deaths in the intraluminal filament 
model.   
3.4.5 Summary 
Using the SHRSP fed on a fructose enriched diet for 2 weeks impaired glucose 
tolerance and induced hyperinsulinaemia, hypertriglyceridaemia, reduced HDL 
cholesterol and increase adiposity compared to the WKY control strain. In 
addition to the innate hypertension associated with the SHRSP strain this forms 
an appropriate model of metabolic syndrome for future studies. 
A single bolus i.p. injection of 15% glucose (10ml/kg) produced clinically 
relevant levels of hyperglycaemia that was maintained following MCAO for the 
length of the acute time period of interest. This will be carried forward for 
future experimentation. 
The distal diathermy model of MCAO produced smaller infarcts than permanent 
MCAO induced by intraluminal filament and produced a considerable amount of 
penumbral tissue at acute time points. This model will therefore be used for 
future studies investigating the effects of hyperglycaemia and insulin resistance 
on focal cerebral ischaemia. 
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 Chapter 4 - Effect of hyperglycaemia on ADC-
defined ischaemic lesion growth in rats with and 
without features of metabolic syndrome 
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4.1 Introduction 
The experiments in this chapter were designed to determine the effects of 
clinically relevant levels of acute hyperglycaemia along with insulin resistance 
and cardiovascular co-morbidities on ischaemic damage following MCAO. The 
first aim of these experiments was to investigate the effect of hyperglycaemia, 
in the presence and absence of insulin resistance, on the early expansion of the 
ischaemic lesion and loss of penumbral tissue following permanent MCAO. The 
second aim was to establish whether hyperglycaemia, again with and without 
insulin resistance, caused any differences in infarct volume determined at 24 
hours post MCAO. The mechanisms associated with hyperglycaemia induced 
damage following MCAO are still not well understood and many theories have 
been postulated (Lindsberg and Roine 2004). One potential mechanism for 
hyperglycaemia and insulin resistance mediated damage is thought to be via 
oxidative stress pathways; therefore the level of lipid peroxidation was assessed 
by immunohistochemistry using the lipid peroxidation marker 4-hydroxynonenal.  
4.1.1 Post-Stroke Hyperglycaemia  
The only definitive treatment for ischaemic stroke is the use of the clot busting 
drug rt-PA. The percentage of patients who are receiving this treatment is less 
than 10% (Cocho et al 2005; Molina and Saver 2005) and although this is starting 
to increase there is still scope for other possible interventions either as adjuncts 
or alternatives to rt-PA in acute stroke management. A primary focus of acute 
stroke care is the monitoring of physiological variables and dealing with 
potentially pathological changes in such variables has the potential to affect 
clinical outcome. 
 Post stroke hyperglycaemia (PSH) occurs in over 60% patients without a 
diagnosis of diabetes and in more than 90% of diabetic patients (Muir et al 2011). 
PSH is a predictor of poor outcome independent of age, stroke type or severity 
(Weir et al 1997). The consistent observation of poor outcome associated with 
PSH has led to guidelines recommending routine blood glucose monitoring, and 
intervention with insulin for hyperglycaemia (Adams et al 2007; 2008). However, 
there is currently no clinical evidence of benefit from insulin use, and recent 
124 
findings raise concerns about the safety of insulin use in predominantly non-
diabetic acute populations with stroke (Gray et al 2007; McCormick et al 2010). 
GKI infusions were associated with an increase in infarct size in persistent 
occlusions and a high incidence of hypoglycaemia which is also detrimental to 
stroke outcome.  
Around 56% of hyperglycaemic stroke patients are subsequently diagnosed with 
insulin resistance, manifesting as impaired glucose tolerance, impaired fasting 
glucose or the “metabolic syndrome,” a phenotype comprising combinations of 
insulin resistance, hypertension, hypertriglyceridaemia and obesity that is a 
significant risk factor for cardiovascular disease (Gray et al 2004b; McCormick 
and Muir 2006). In light of the potential risk of hypoglycaemia with insulin 
regimes in stroke, it is important to question whether the harmful effects of 
acute hyperglycaemia pertain to all stroke patients, or whether they differ in 
those with and without pre-existing insulin resistance.  
4.1.2 Pre-clinical research of PSH 
Hyperglycaemia in focal cerebral ischaemia is widely accepted to increase 
infarct size in animal models (Berger and Hakim 1989; Bomont and MacKenzie 
1995; Duverger and MacKenzie 1988; Huang et al 1996; Liu et al 2007; 
Nedergaard 1987; Nedergaard and Diemer 1987; Quast et al 1997; Slivka 1991). 
However the majority of preclinical studies fail to model PSH appropriately, 
providing little relevance to the clinical situation (MacDougall and Muir). 
Streptozotocin, which destroys the insulin producing beta cells of the pancreas, 
has been often used to induce hyperglycaemia even though this more closely 
models type-1 diabetes, which doesn’t represent the general stroke population 
(Duverger and MacKenzie 1988; Huang et al 1996; Nedergaard 1987; Quast et al 
1997). Glucose infusions models emulate PSH much better, however extremely 
high levels of blood glucose have been used, which are rarely seen clinically 
(Berger and Hakim 1989; Bomont and MacKenzie 1995; Liu et al 2007; 
Nedergaard and Diemer 1987; Slivka 1991). Moreover preclinical research on 
hyperglycaemia following focal cerebral ischaemia has not been studied using a 
model of insulin resistance common to the stroke population. This highlights a 
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need for better modelling of PSH in animal models so that clinical trials can be 
better informed. 
The majority of the literature focuses on assessing infarct volume at 24 hours or 
48 hours post MCAO. There are few studies that have focussed on the fate of the 
potentially salvageable penumbral tissue that is present in the acute stage of 
cerebral ischaemia. Evidence of hyperglycaemia-exacerbated damage at early 
time points would suggest that early management of PSH could be beneficial, 
potentially preventing or slowing the recruitment of the penumbra into the 
infarct. This early management could also benefit patients who are potentially 
eligible to receive rt-PA since many pre-clinical studies have shown more 
profound exacerbation of ischaemic damage in reperfusion models of cerebral 
ischaemia compared to permanent occlusions under hyperglycaemic conditions 
(MacDougall and Muir 2010).  
A few studies have investigated the effects of hyperglycaemia at the acute time 
points of lesion evolution and penumbral loss, utilising MRI to assess ischaemic 
damage even at very early time points. Single slice or multi slice imaging has 
been used in the acute period at a single time point (Quast et al 1995; Quast et 
al 1997). Serial multi slice imaging is able to track the development of damage 
and this provides a more suitable method of tracking the ischaemic damage 
using a relevant PSH model (Huang et al 1996; Martin et al 2006; Quast et al 
1995; Wei et al 1997; Wei and Quast 1998; Wei et al 2003; Wei et al 2004).  
4.1.3 Oxidative stress associated with hyperglycaemia 
The mechanisms by which hyperglycaemia exacerbates ischaemic damage are 
still not widely understood. In the context of chronic hyperglycaemia, as occurs 
in diabetes, a central event implicated in the development of disease-related 
complications is oxidative stress. It is thought that hyperglycaemia leads to 
diabetic tissue damage via 5 mechanisms that are all activated by the 
overproduction of reactive oxygen species (ROS) by mitochondria. 
Hyperglycaemia can increase the production of ROS, such as superoxide(Muranyi 
and Li 2006). Moreover a simple glucose challenge in patients was shown  to 
increase the production of ROS from leukocytes as well as increase the 
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expression of p47phox, the key protein component in the formation of NADPH 
oxidase, the enzyme responsible for ROS production (Mohanty et al 2000).  
One of the aims of this study was to examine whether hyperglycaemia-induced 
changes in ischaemic damage were associate with increased oxidative stress 
4.1.4 Study Aims 
1) To determine the effect of hyperglycaemia on early ischaemic lesion 
development using the MRI derived DWI-PWI mismatch in rats with and 
without insulin resistance and other cardiovascular co-morbidities. 
2) To assess the effect of hyperglycaemia on final infarct volume determined 
24 hours post MCAO in rats with and without insulin resistance and other 
cardiovascular co-morbidities. 
3) To investigate the potential role of oxidative stress in hyperglycaemia 
induced damage, using the lipid peroxidation marker 4-hydroxynonenal (4-
HNE), in rats with and without insulin resistance and other cardiovascular 
co-morbidities.  
127 
4.2 Materials and Methods 
All experiments were carried out under licence from the Home Office and were 
subject to The Animals (Scientific Procedures) Act, 1986. 10 week old male rats 
were obtained from breeding colonies of SHRSP and WKY within the Institute of 
Cardiovascular and Medical Sciences, University of Glasgow. SHRSPs were fed on 
a 60% fructose diet for 2 weeks prior to any experimentation. WKYs were fed on 
standard rat chow and both food and water were available ad libitum. All 
experiments were conducted when rats were 12 weeks of age.  
SHRSP rats fed the fructose-rich diet were randomly assigned to either fructose 
fed (ffSHRSP, n=10) or fructose fed plus acute hyperglycaemia (ffSHRSP + G, 
n=10) groups upon arrival at Biological Services from the breeding colony and 
were singly housed. WKY rats were randomly assigned upon arrival to either WKY 
(n=10) or WKY + G (n=10) groups and were also singly housed. 
4.2.1 Blood pressure measurements 
Systolic blood pressure was measured 1-3 days prior to induction of cerebral 
ischaemia in all animals, whilst conscious, using tail-cuff plethysmography as 
previously described in Chapter 2.9. The mean systolic blood pressure for each 
rat was calculated and the data were compiled to compare the mean systolic 
blood pressure for each group. 
4.2.2 Surgical procedures 
Rats fasted overnight, were anaesthetised initially with 5% inhaled isoflurane in 
an induction chamber and then orally intubated. Animals were artificially 
ventilated with 2.5% isoflurane delivered in a nitrous oxide-oxygen mixture 
(70:30). All rats were given an intraperitoneal injection of the anti-muscarinic 
drug atropine sulphate (0.4ml, 600µg/ml, Martindale Pharmaceuticals, UK). This 
was used to prevent the production of bronchial secretions that could potentially 
block the airway during the experiment.  
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A polyethylene catheter (Portex, external diameter 0.96 mm; internal diameter 
0.58 mm; 70 cm long) was inserted into the right femoral artery, to continuously 
monitor blood pressure and conduct blood gas analysis 
Blood sampling was done immediately after the catheter was in place and then 
each hour to ensure blood gases were maintained within the normal 
physiological range apart from increased PaO2 due to the oxygen enriched 
mixture used to maintain physiological stability during surgery. A rectal 
thermocouple provided continual monitoring of core body temperature which 
was maintained at 37±0.5oC using a heat lamp. 
Permanent focal cerebral ischaemia was induced using the distal diathermy 
method, as previously described in Chapter 2.3.2, via a small craniectomy. Once 
the MCA was cauterized it was cut to confirm occlusion before placing 
haemostatic sponge (Spongostan) over the area and stitching with a 4-0 suture.  
4.2.3 Induction of hyperglycaemia 
A single dose of a 15% glucose solution (aqueous, 10ml/kg) was administered i.p. 
10 minutes prior to occlusion of the MCA in  WKY (WKY + G) and fructose fed 
SHRSP (ffSHRSP + G) rats. Their respective control groups (ffSHRSP & WKY) 
received the vehicle (distilled water, 10ml/kg).  
4.2.4 MRI scanning protocol 
Immediately following MCAO the ventral surfaces of the left and right hind limbs 
as well as the chest were shaved using an electric shaver. Electrode gel (Sigma) 
was applied to the shaved areas and ECG leads were placed on top and secured 
with tape. The rat was then disconnected from the ventilator and blood pressure 
transducer before being transferred to the MRI cradle where the intubation tube 
was reconnected to a ventilator to maintain anaesthesia. 
The rat was secured in the cradle using tooth and ear bars to prevent head 
movement during scanning. Body temperature was maintained for the duration 
of the scanning protocol using a closed circuit thermal jacket and was monitored 
by a rectal thermocouple. The ECG leads were connected and a pressure sensor 
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was attached to the back of the rat to measure respiration.  The blood pressure 
transducer was similarly reconnected to monitor blood pressure throughout the 
scanning protocol. A linear surface receiver coil (2cm diameter) was placed 
above the head of the animal before being transferred to the scanner described 
in Chapter 2.5.1.  
Diffusion-weighted imaging was performed to identify ischaemically damaged 
tissue in 8 coronal slices within the MCA territory using the sequence described 
in Chapter 2.5.3.1. Scans were acquired at 1 hour post MCAO and then each 
subsequent hour for 4 hours. ADC maps were subsequently produced from post-
processing of DWI images and in-house determined strain specific thresholds of 
tissue viability were applied to WKY (≤0.61x10-3mm2sec-1) and ffSHRSP (≤0.59x10-
3mm2sec-1) 
Non-invasive quantitative cerebral blood flow measurements were carried out on 
6 coronal slices, that were spatially identical to slices 2-7 acquired from DWI 
scans, using a form of pseudo-continuous arterial spin labelling (cASL) based on a 
train of adiabatic inversion pulses (Moffat et al 2005). The sequence is described 
in Chapter 2.5.4.1. Similarly to DWI scans the cASL scans were obtained at 1, 2, 
3 and 4 hours following MCAO. 
Unfortunately due to technical difficulties with the cASL scans, CBF maps were 
not able to be generated for the majority of animals. Due to this the diffusion 
perfusion mismatch could not be calculated and so the progression of the DWI 
defined lesion was used as an alternative measure of the evolution of damage. 
The technical problems with the cASL were resolved which allowed CBF maps to 
be generated for 16 animals. This perfusion data has been included in section 
4.3.7. 
4.2.5 Animal recovery 
At the end of the 4 hour scanning protocol, the rat and cradle were removed 
from the MRI scanner. Once the rectal thermocouple, ECG leads, respiration 
sensor and ear bars were removed, the ventilator and blood pressure transducer 
were disconnected and the animal was immediately transferred from the cradle 
to the operating theatre where the ventilator was reconnected. The isoflurane 
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concentration was reduced to 1% to start the recovery process. The femoral 
catheter was removed and the femoral artery was sealed by electrocoagulation. 
The site was then re-sutured and the anaesthesia was withdrawn. At this point 
the nitrous oxide-oxygen mixture was readjusted to a 50:50 ratio to aid 
recovery. Once the animal had started to breathe against the ventilator for a 
period of 5 minutes the ventilator was temporarily disconnected. If the animal 
continued to breathe unassisted for a period of 5 minutes the intubation tube 
was carefully removed and the rat was transferred to a facemask to continue the 
oxygen supplementation. Once motor function had began to return the animal 
was transferred to a recovery cage containing some bedding and sawdust from 
its previous cage and its own cardboard tube. Soft diet, containing softened 
normal rat chow, was placed in the cage and dry pellets and water were also 
available ad libitum. The general condition of the animals was assessed at least 
3 times during recovery and this was recorded. 
4.2.6 Infarct determination 
Rats were transcardially perfusion-fixed with heparinised saline followed by 4% 
paraformaldehyde in PBS at 24 hours after MCAO. Tissue was dehydrated and 
processed through to paraffin wax blocks as described in Chapter 2.4.2. Infarct 
was assessed using haematoxylin and eosin stained coronal sections (7µm). 
Ischaemic tissue was quantified at 8 pre-determined levels spanning the MCA 
territory. Areas of damage were transcribed on to representative line diagrams 
to correct for brain swelling or processing (Osborne et al 1987). For volumetric 
assessment the areas of ischaemic damage were calculated using Image J and 
integrated with the known distance between each coronal level, using 
stereotaxic atlas co-ordinates (Paxinos & Watson, 1998) as described in detail in 
Chapter 2.4.5. 
4.2.7 Immunohistochemistry 
Sections adjacent to those used for infarct measurements were processed for 
immunohistochemistry with an antibody against the lipid peroxidation by-
product 4-hydroxynonenal (4-HNE, Clone 198960, R&D systems) as described in 
Chapter 2.6.1. Light microscopy was used to transcribe the location of increased 
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4-HNE immunopositivity compared to contralateral tissue onto a separate set of 
line diagrams to those used for infarct measurements. Image J was used to 
determine the volume of 4-HNE staining for each animal. This analysis was 
performed blinded to group identity and the infarct volume data. 
4.2.8 Randomisation, blinding and statistical analysis 
Animals were allocated upon arrival from the breeding colony to 
normoglycaemic or hyperglycaemic groups and randomised by the toss of a coin. 
The investigator was blinded to animal identity during the analysis of ADC lesion, 
infarct and 4-HNE volumes. Blood glucose levels and ADC lesion volumes were 
assessed using a 2 way ANOVA repeated measures test with Bonferroni post test. 
Infarct and 4-HNE immunopositivity volumes were assessed using a 1 way ANOVA 
with Bonferroni post test. Data are expressed as mean ± standard deviation. 
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4.3 Results 
4.3.1 ffSHRSP rats exhibited hypertension compared to the WKY 
strain 
Non-invasive blood pressure measurements, obtained in the conscious state prior 
to induction of cerebral ischaemia, confirmed the known strain differences 
between SHRSP and WKY rats (Table 4.1). The ffSHRSP groups both exhibited 
substantially elevated systolic blood pressure compared to the WKY groups. 
There was also no difference between rats assigned to the vehicle treatment or 
glucose treatment groups for subsequent experiments in either WKY or ffSHRSP 
groups.  
4.3.2 Physiological variables 
The ffSHRSP groups weighed significantly less compared to the WKY groups 
(Table 4.1). This is consistent with previously reported differences between the 
SHRSP and WKY strain.  
During anaesthesia ffSHRSP rats had significantly higher MABP than WKY rats, as 
reflected in the elevated conscious blood pressure exhibited by the ffSHRSP 
groups compared to the WKY groups. There was no difference in core body 
temperature, blood gas or pH measurements between any of the four groups 
(Table 4.1). The PaCO2 and pH were maintained within normal physiological 
limits however the PaO2 was elevated out with this due to the oxygen enriched 
mixture used to deliver the anaesthesia compared to the percentage oxygen 
present in air. 
There was no mortality in any of the 4 groups following MCAO surgery. However 
there were 7 surgical deaths that occurred due to bleeding from the MCA whilst 
attempting to electocoagulate the vessel. This occurred in 3 WKY rats and 4 
ffSHRSP rats.
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Table 4.1: Physiological variables: Body weight measured on the day of MCAO; Systolic BP measure 3-5 days prior to MCAO; PaO2, PaCO2, pH 
measured at time of MCAO; MABP, Temperature (rectal) expressed as mean for anaesthesia period. **, P<0.001 vs. WKY; ##, P<0.001 vs. WKY + 
glucose. Data presented as mean ± standard deviation.
 
 
 Prior to anaesthesia During anesthesia 
Group 
 
Weight 
(g) 
 
Systolic BP 
(mmHg) 
PaO2 
(mmHg) 
PaCO2 
(mmHg) 
pH 
 
MABP 
(mmHg) 
 
Temperature (°C) 
WKY  
(n=10) 
271 ± 16 123.6 ± 6.9 139.1 ± 17.4 
 
38.2 ± 4.0
  
7.39 ± 0.05 93.4 ± 12.1 37.1 ± 0.5 
WKY + G 
(n=10) 
274 ± 15 
 
122.7 ± 6.5 
140.8 ± 17.3 
 
39.9 ± 5.3 
 
7.40 ± 0.06 
 
96.1 ± 8.9 
 
37.3 ± 0.5 
 
ffSHRSP 
(n=10) 
219 ± 13 ** 
 
177.9 ± 5.9** 
136.5 ± 14.2 
 
36.5 ± 2.4 
 
7.40 ± 0.07 
 
116.7 ± 13.5 ** 
 
37.2 ± 0.4 
 
ffSHRSP+G 
(n=10) 
225 ± 13 ## 
 
183.3 ± 8.4 ## 
134.2 ± 13.9 
 
37.0 ± 2.1 
 
7.41 ± 0.06 
 
114.6 ± 10.2 ## 
 
37.3 ± 0.6 
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4.3.3 Glucose administration led to clinically relevant 
hyperglycaemia in both WKY and ffSHRSP 
The baseline blood glucose measurements, taken just prior to i.p. glucose or i.p. 
vehicle administration, were not significantly different between vehicle and 
glucose treatment groups or between the WKY and ffSHRSP strains (Figure 4.1).  
Following i.p. glucose administration in the ffSHRSP + G and WKY + G groups, 
blood glucose increased significantly (Figure 4.1). The mean peak blood glucose 
levels in both WKY+G and ffSHRSP + G groups recorded at 1 hour post MCAO were 
similar. In the WKY+G group blood glucose reduced slightly between 1 hour and 2 
hours however still remained significantly elevated compared to the vehicle 
treated WKY group. The ffSHRSP + G group maintained the peak level of 
hyperglycaemia until a small decrease was observed at 3 hours and similarly 4 
hours following MCAO compared to the ffSHRSP group. At all time points 
examined during the MR scanning period, blood glucose levels in the WKY+G and 
the ffSHRSP + G groups were significantly greater than in vehicle-treated 
controls. There was no change in blood glucose levels in either WKY or ffSHRSP 
groups following vehicle treatment. This suggests that stress hyperglycaemia 
following MCAO was not observed during the MRI scanning period.  
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Figure 4.1: Blood glucose levels before and after MCAO in WKY (A) and ffSHRSP (B) rats. Glucose or vehicle was administered 10 mins before MCAO 
(-10). Peak levels measured in WKY and ffSHRSP rats after glucose administration were similar. In rats administered glucose, blood glucose levels 
remained elevated above the vehicle treated group for at least 4 hours after MCAO. Data analysed using a 2-way ANOVA, * P < 0.001 glucose versus 
vehicle. Data presented as mean ± standard deviation. 
A B 
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4.3.4 Hyperglycaemia accelerated the development of ischaemic 
injury in both WKY and ffSHRSP 
Strain-specific ADC thresholds were applied to each of the hourly ADC maps 
obtained following MCAO to assess the acute evolution of ischaemic injury in 
each of the 4 experimental groups (Figure 4.2). From 1 hour to 4 hours post-
MCAO the ADC-derived region of ischaemic damage expanded in WKY and 
ffSHRSP rats with and without glucose administration. At the earliest time point 
examined, 1 hour after MCAO, the mean ADC lesion was significantly larger in 
hyperglycaemic than in normoglycaemic WKY rats (Figure 4.3A) and the effect of 
hyperglycaemia was maintained over the subsequent 3 hours. The mean ADC 
lesion in hyperglycaemic ffSHRSP rats was larger than in normoglycaemic 
ffSHRSP at 1 hour after MCAO (Figure 4.3B) and the effect of hyperglycaemia on 
ADC lesion volume was maintained over subsequent time points in this strain. 
Thus, hyperglycaemia exacerbated early ischaemic brain damage in both normal 
rats and rats with features of metabolic syndrome.  
The rate of ADC-derived lesion growth was significantly increased in both WKY + 
G and ffSHRSP + G compared to their respective vehicle treated control groups 
between 0 and 1 hour post MCAO (Figure 4.4). No further significant differences 
were observed at subsequent time points. This suggests that glucose dependant 
damage primarily occurs during the first hour following occlusion. 
At 1 hour after MCAO the effect of hyperglycaemia on ADC lesion volume was 
similar in WKY and ffSHRSP rats causing a similar absolute increase in ischaemic 
damage (WKY, 50.8mm3; ffSHRSP, 51.1mm3; Table 4.2). Subsequently the 
difference between WKY and WKY + G groups increased further illustrating that 
hyperglycaemia was continuing to exacerbate ischaemic injury. However, the 
mean difference between the ffSHRSP groups did not change. Although a formal 
statistical analysis was not performed on these data they suggest that while 
hyperglycaemia exacerbated ischaemic damage in the first hour after MCAO in 
both ffSHRSP and WKY rats, its effect was less pronounced at later time points in 
ffSHRSP compared to WKY rats. 
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Figure 4.2: ADC-derived ischaemic injury in A) WKY and B) ffSHRSP rats following permanent MCAO both with and without glucose administration. 
Eight coronal slices from the median animal within each experimental group is displayed. The red areas represent the ischaemic injury at 1 hour post-
MCAO whereas the white area represents the lesion at 4 hours post-MCAO. This highlights the spatial profile of the lesion and how it develops over the 
acute time period.  
Vehicle 
Glucose 
Vehicle 
Glucose 
A 
B 
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Figure 4.3: Volumetric analysis of ADC maps from 8 coronal slices 1-4 h after MCAO in WKY rats (A) and ffSHRSP rats (B). Hyperglycaemia 
exacerbated damage at all time points in both WKY and ffSHRSP rats. Data analysed using a 2-way ANOVA, *, P<0.001 compared with 
normoglycaemic vehicle-treated controls. Data presented as mean ± standard deviation. 
A B 
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Figure 4.4: Rate of ADC lesion growth over each hour following MCAO in (A) WKY and WKY + G groups and (B) ffSHRSP and ffSHRSP + G groups. 
The rate was calculated from the volume of lesion growth occurring in each hour. Data analysed using a 2-way ANOVA, *, P<0.001 compared with 
normoglycaemic controls at that particular time point. Hyperglycaemic groups indicated by +G. Data presented as mean ± standard deviation
A B 
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Table 4.2: Difference in infarct size between normo- and hyperglycaemic groups. 
 Difference in mean volume of ischaemic damage between groups (mm
3) 
Time after MCAO (hours) WKY vs. WKY+G ffSHRSP vs. ffSHRSP+G 
1 51 51 
2 62 48 
3 69 56 
4 72 49 
141 
4.3.5 Hyperglycaemia increased infarct volume in WKY but not in 
ffSHRSP rats. 
Infarct volume was significantly larger in hyperglycaemic WKY than in 
normoglycaemic WKY rats (Figure. 4.5A). The most pronounced differences were 
observed in sections at the rostral and caudal poles of the lesion (Figure. 4.5C). 
Infarct volume in hyperglycaemic ffSHRSP rats was not increased compared to 
normoglycaemic controls (Figure. 4.5B); the rostro-caudal distribution of the 
lesion being similar in both groups (Figure. 4.5D). Thus, hyperglycaemia in the 
early period after MCAO exacerbated infarct size at 24 hours only in rats lacking 
features of metabolic syndrome. 
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Figure 4.5: Volumetric analysis of cerebral infarction 24h after MCAO in WKY rats (A) and ffSHRSP rats (B) with and without glucose loading. The 
mean is illustrated by the horizontal bar.  Data analysed using a 1-way ANOVA with Bonferoni post test.* P<0.001 glucose compared to vehicle 
administration. The rostro-caudal profile of the infarct is shown for WKY (C) and ffSHRSP (D). Hyperglycaemic groups indicated by +G. Data presented 
as mean ± standard deviation. 
A B 
C 
D 
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4.3.6 Hyperglycaemia exacerbated the extent of oxidative stress. 
Compared to the contralateral hemisphere 4-HNE immunoreactivity was higher 
in ischaemically damaged tissue and peri-infarct regions. Intense staining for 4-
HNE was observed in neurons and axons in both grey and white matter (Figure 
4.6). Hyperglycaemia in WKY rats was associated with a greater volume of tissue 
exhibiting immunopositivity for 4-HNE (Figure 4.7a). In contrast, there was no 
significant difference in the volume of 4-HNE-positive tissue between ffSHRSP+G 
and the normoglycaemic ffSHRSP rats (Figure 4.7b). As these results mirrored 
the group differences observed for infarct volume, the volume of 
immunopositivity was expressed as a % of infarct volume (Figure. 4.7c, 4.7d). In 
both normo- and hyperglycaemic WKY rats, 4-HNE immunostaining occupied a 
smaller volume of tissue compared to the infarct in all animals. However, 4-HNE 
staining occupied a significantly greater proportion of tissue in hyperglycaemic 
WKY rats compared to controls indicating that hyperglycaemia was associated 
with greater lipid peroxidation. In ffSHRSP rats there were some animals in 
which 4-HNE staining occupied a greater volume of tissue than the infarct. There 
was no difference between normo- and hyperglycaemic ffSHRSP rats in the 
proportion of tissue occupied by 4-HNE staining indicating that hyperglycaemia 
was not associated with greater lipid peroxidation. The ffSHRSP rats had larger 
proportions of tissue occupied by 4-HNE staining compared to the WKY rats. 
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Figure 4.6: Line diagrams illustrating the distribution of immunostaining and infarct in a 
representative animal from (A) WKY and (B) WKY+G. The blue outlined areas indicated 
infarcted tisse and the orange outlined areas represent -HNE immunopositive tissue 24 h 
post MCAO  
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Figure 4.7: Volumetric analysis of 4-HNE immunopositivity 24 h post MCAO in both WKY (A) and ffSHRSP (B) with and without glucose loading. To 
confirm that the amount of immunopositivity wasn’t just due to the size of the infarct 4-HNE staining was also expressed as a percentage of the infarct in 
both (C) WKY and (D) ffSHRSP with and without glucose loading.*, Data analysed using 1-way ANOVA with Bonferoni post test. P<0.001 compared to 
normoglycaemic controls 
A B 
C D 
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4.3.7 Hyperglycaemia exacerbated perfusion deficit in WKY but 
not ffSHRSP group 
Due to the technical issues experienced with the cASL scanning protocol, it was 
not possible to generate cerebral blood flow maps for the majority of animals. 
However once this technical problem had been resolved the remaining animals 
were assessed for perfusion differences between groups (Figure 4.8).  
The perfusion deficit at 1 hour post MCAO showed that there was a significantly 
larger volume of tissue with CBF below the threshold for tissue survival in the 
WKY + G group compared to the WKY group (Figure 4.9A). This suggests that 
hyperglycaemia in the WKY strain increased the perfusion deficit compared to 
the vehicle treated WKY group. This effect was not seen in the ffSHRSP groups 
where there was no increase in perfusion deficit as a result of glucose loading 
(Figure 4.9B).  
There was no significant difference in contralateral CBF between WKY and WKY 
+ G groups at any time point measured although a temporal decrease was 
observed in both groups (Figure 4.10). This suggests that although 
hyperglycaemia is potentially increasing the perfusion deficit, this isn’t due to a 
global reduction in CBF compared to the vehicle treated WKY group. 
The ffSHRSP and ffSHRSP + G groups had a significantly larger perfusion deficit 
than the WKY group at 1 hour post MCAO which is reflective of the volume of 
ischaemic injury derived from ADC maps. Interestingly the perfusion deficit 
increases in the ffSHRSP and the ffSHRSP +G over the 4 hours post MCAO whereas 
the perfusion deficit remains similar in the WKY and WKY + G groups over the 
duration of the MRI scanning protocol (Figure 4.11). 
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Figure 4.8: Quantitative CBF maps displaying hypoperfused tissue at 1 hour post-MCAO over 5 coronal slices in A) WKY and B) ffSHRSP with and 
without glucose administration. Darker regions represent areas of reduced blood flow which is predominantly found in the ipsilateral cortex as expected. 
The data shown are from the median animal in each group. 
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Figure 4.9: Volume of tissue 1 hour post MCAO exhibiting a perfusion deficit in (A) WKY and (B) ffSHRSP with and without glucose loading. Strain 
specific thresholds, which predict tissue that will become infarcted if not reperfused, were applied to CBF maps to quantify the perfusion deficit. Data 
presented as scatter plots with the means indicated. Data anaylsed with unpaired t-test. *, P>0.05 compared to vehicle treated control. 
 
 
A B 
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Figure 4.10: Mean contralateral CBF in WKY and WKY + G groups following permanent 
MCAO. No difference between the groups was seen at any measured time point. Data 
expressed as mean ± standard deviation. 
 
 
Figure 4.11: Temporal evolution of perfusion deficit, derived from CBF maps, WKY and 
ffSHRSP with and without glucose loading. Data presented as mean ± standard deviation. 
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4.4 Discussion 
Previous studies of hyperglycaemia in animal models of ischaemia, while useful 
in establishing the principle that elevated blood glucose exacerbates brain 
damage, did not use models that reproduce features of typical human PSH; the 
majority used models of type I diabetes and very high concentrations (16 – 30 
mmol/l) of blood glucose (MacDougall and Muir 2010). The current study 
modelled clinically relevant levels of blood glucose and also addressed the 
impact of moderate hyperglycaemia in the context of existing insulin resistance 
and hypertension.  
4.4.1 Hyperglycaemia accelerates early lesion expansion in both 
WKY and ffSHRSP rats 
The data demonstrate that moderate hyperglycaemia, present at the time of 
onset of focal cerebral ischaemia, markedly accelerates lesion growth over the 
first few hours. The effect of hyperglycaemia was pronounced as early as 1 hour 
after MCAO indicating the rapid nature of its detrimental actions in the 
ischaemic brain. This is consistent with data from a previous diffusion-weighted 
MRI study after permanent MCAO in rats(Huang et al 1996), although in the 
presence of substantially higher levels of blood glucose (~25 mmol/l) than those 
used in the present study (~12 mmol/l). Our data further demonstrate that 
clinically-relevant levels of hyperglycaemia accelerate lesion growth not only in 
normal rats but also in those with features of metabolic syndrome. The absolute 
increase in lesion size 1 hour post MCAO, attributable to the elevation in blood 
glucose, was very similar between the WKY and ffSHRSP rats. After the initial 
acceleration in growth the rate became consistent with that of the 
normoglycaemic groups for the remainder of the acute time frame. This suggests 
that to be able to improve the longevity of the penumbra the management of 
PSH needs to be very rapid.  
The effect of hyperglycaemia on ischaemic lesion size at acute time points was 
proportionally greater in normal rats compared to those with features of 
metabolic syndrome. Thus, rats without co-morbidities commonly associated 
with stroke appear to be more susceptible to the detrimental effects of 
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hyperglycaemia. Acute lesion sizes in ffSHRSP rats were larger than those in WKY 
groups regardless of glycaemic profile, likely attributable to the known 
differences between SHRSP and WKY strains (McCabe et al 2009). We postulate 
that the lesser effect of hyperglycaemia in the metabolic syndrome group may 
be the result of a prevailing role for hypertension and poor collateral flow (Coyle 
and Heistad 1987) in exacerbating the evolution of damage in these animals such 
that there is less tissue at risk available to be influenced by hyperglycaemia in 
the acute phase. The pre-existence of metabolic syndrome components might 
already have induced an adverse metabolic state (e.g. increased oxidative 
stress) such that moderate hyperglycaemia could not significantly exacerbate 
what was already primed to be a larger infarct than that in the rats without the 
features of metabolic syndrome. 
4.4.2 Hyperglycaemia exacerbates infarct size 24 hours post 
MCAO in WKY but not ffSHRSP 
Moderate hyperglycaemia significantly increased infarct volume 24 hours post 
MCAO, but only in animals lacking features of metabolic syndrome. This suggests 
that there is a more profound effect in the absence of components of the 
metabolic syndrome. A systematic review of patient data reported that for stress 
hyperglycaemia, relative risks of mortality and poor functional outcome were 
increased in non-diabetic stroke patients, but not those with a diagnosis of 
diabetes(Capes et al 2001). It is possible that hyperglycaemia does not 
significantly influence the evolution of ischaemia in diabetic subjects, and that 
this review finding reflects the pathophysiological effects that are demonstrated 
in the present study, although it is possible that diabetic subjects numbers were 
too small to reliably detect a detrimental effect of hyperglycaemia. 
Potentially any additional effect of hyperglycaemia on infarct size may have 
been masked by the extensive nature of the damage incurred in the ffSHRSP 
groups. The lesions were large encompassing the majority of the affected MCA 
territory downstream of the occlusion. It is possible that the level of damage in 
the ffSHRSP groups was close to maximal and therefore a ceiling effect may be 
present. This may explain why a significant difference was observed in the acute 
evolution of ischaemic damage between the glucose and vehicle treated ffSHRSP 
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groups but not at the 24 h time point used for infarct determination. The ceiling 
effect was the reason why the distal diathermy occlusion model was used 
instead of the more severe intraluminal filament model. 
The clinical implication of our current findings could be that glycaemic control 
may be more important in acute stroke patients who do not have insulin 
resistance or other co-morbidities such as hypertension. However, although the 
effect of hyperglycaemia in ffSHRSP rats was less marked than in WKY, the 
former group incurred the largest infarcts. While glycaemic control might 
influence the early evolution of the infarct in patients with pre-existing 
metabolic syndrome, glycaemic control may be less beneficial since 24 hour 
infarct volume was not significantly exacerbated by acute PSH.  
These comments can only be speculative since the clinical picture in stroke is 
more complex, and includes insulin treatment with its attendant risk of 
hypoglycaemia, the development of late rather than early hyperglycaemia, late 
complications of large infarction such as brain swelling and malignant oedema, 
and interaction with reperfusion therapies, none of which was modelled in the 
present study (McCormick et al 2010).    
4.4.3 Possible mechanisms associated with hyperglycaemia 
dependent damage 
Hyperglycaemia may be toxic to the ischaemic brain however the mechanism is 
not fully understood. In hypoperfused tissue at risk hyperglycaemia may 
contribute to the accumulation of lactate and intracellular acidosis as a result of 
increased anaerobic metabolism. In a rabbit model of stroke after 4 hours of 
permanent occlusion moderate hyperglycaemia (~11 mmol/l) caused a 
significant reduction in intracellular brain pH compared to controls (Anderson et 
al 1999). Acidosis may accelerate ischaemic injury and enhance production of 
free-radicals (Kagansky et al 2001; Siesjo et al 1996) leading to rises in 
intracellular calcium (OuYang et al 1994). Elevated intracellular calcium is a key 
component of glutamate-mediated excitotoxicity, which is a major pathological 
mechanism of ischaemic damage. This has been supported by a study that found 
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that elevated blood glucose led to a rise in extracellular glutamate in cerebral 
cortex after forebrain ischaemia (Li et al 2000).  
Hyperglycaemia is known to be associated with inflammation and oxidative 
stress and is implicated in a number of mechanisms. Oxidative stress, primarily 
originating from release of superoxide from the mitochondria, is thought to be 
the unifying mechanism underlying the deleterious effects of chronic 
hyperglycaemia in complications, including neuropathy, associated with diabetes 
(Brownlee 2005; Tomlinson and Gardiner 2008). Superoxide radicals can cause 
direct damage to cells through lipid peroxidation, protein carbonylation and DNA 
damage. In the present study, enhanced oxidative stress after MCAO in 
hyperglycaemic rats was suggested by more widespread immunostaining for 4-
HNE which may indicate the involvement of free radicals in acute 
hyperglycaemia. This supports previous findings that hyperglycaemia following 
cerebral ischaemia is able to increase production of superoxide. Using a global 
transient ischaemia model it was found that hyperglycaemia caused significant 
increase in superoxide production in the hippocampal CA1 neurons compared to 
normoglycaemic animals after 18 hours of recirculation, which preceded 
accelerated and enhanced neuronal death in the hippocampal CA1 area. 
(Muranyi and Li 2006). A 75g oral glucose challenge in humans has also been 
shown to cause an increase in superoxide generation in leukocytes by 140% 
above basal levels in addition to increasing production of the p47phox subunit of 
NADPH oxidase, which is responsible for superoxide generation (Mohanty et al 
2000).  
The proportion of tissue exhibiting 4-HNE immunopositivity was increased by 
hyperglycaemia in WKY but not in ffSHRSP rats in the present study. This 
preliminary evidence suggests that increased oxidative stress may contribute to 
the detrimental effect of hyperglycaemia in ischaemic brain in the absence but 
not presence of features of metabolic syndrome. However there are some 
limitations regarding the quantification of oxidative stress using 
immunohistochemistry. In this chapter areas of tissue, where staining for 4-HNE 
was present, were transcribed to line diagrams as a way of quantifying the level 
of oxidative stress in each animal. Obviously not every cell within these areas 
was stained and therefore this is a rather crude method of quantification. New 
advances in image analysis systems may provide the best way to analyse 
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immunostained sections rather than relying on a subjective method (Taylor & 
Levenson, 2006). These sytems are not economically viable for small laboratory 
needs and therefore subsequent studies in this thesis will move to a tissue assay 
for markers of lipid peroxidation and oxidative stress. 
In addition to oxidative stress, the small amount of CBF data collected during 
this study indicates that hyperglycaemia may accelerate lesion expansion by 
increasing the perfusion deficit following MCAO. Interestingly, this 
hyperglycaemic effect was once again only seen in the WKY rats and hence 
suggests that hyperglycaemia can influence the CBF only in the absence of 
insulin resistance, hypertension and other features of the metabolic syndrome 
associated with the ffSHRSP model. Obviously the results from the perfusion 
data are underpowered in comparison to the other analyses conducted in this 
chapter but it is supported by some previous studies that show that 
administration of glucose to conscious rats can reduce regional CBF by 24% 
compared to normoglycaemic controls in the absence of cerebral ischaemia 
(Duckrow et al 1985; Duckrow et al 1987). This reduction is blood flow could not 
be explained purely by the increase in plasma osmolality as administration of 
mannitol, that lead to a similar osmolality observed following glucose 
administration, only reduced blood flow by 10%. This is also supported by a study 
conducted in cats that found after a 3 hour MCAO the hyperglycaemic animals 
suffered a 70% reduction in CBF compared to 34% in the normoglycaemic controls 
(Wagner et al 1992). It is known that ROS and free radicals can directly and 
indirectly act on cerebral blood vessels to alter vascular tone, which could 
potentially affect CBF. Superoxide, in high concentrations primarily causes 
vasoconstriction in the cerebral vasculature and this has been demonstrated in 
cerebral arteries using NADPH (Didion and Faraci 2002). Superoxide reacts with 
endothelial nitric oxide (NO), a potent vasodilator, at a rate 3 times faster than 
with superoxide dismutase (SOD). The inactivation of NO, by reacting with 
superoxide, results in the loss of the vasodilatory influence of NO on basal 
vascular tone causing vasoconstriction. The reaction of superoxide with NO leads 
to the production of the free radical peroxynitrite which may have its own 
effects on vascular tone. Interestingly a study has also highlighted the potential 
vasoconstrictory effects of superoxide on vascular smooth muscle independent of 
endothelial mediated mechanisms. Increasing superoxide levels have been shown 
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in vivo to contract basilar arteries, without endothelium, implying that 
superoxide may be able to directly contract cerebral arteries (Tosaka et al 
2002). The ability of glucose to reduce cerebral perfusion could increase the 
volume of hypoperfused tissue and therefore lead to substantially larger infarcts 
and greater penumbral loss. Glucose-induced ROS can neutralise NO which can 
further reduce its availability for NO dependant vasodilation (Frank et al 2005). 
This loss of cerebrovascular reactivity pertains to chronic changes in glucose 
homeostasis and so the mechanism associated with this may not be conserved in 
acute hyperglycaemia. However from the results of this study it can be 
postulated that glucose may enhance ischaemic damage by oxidative stress and 
potentially increase the perfusion deficit associated with MCAO, and this may all 
be modulated by glucose-induced ROS. 
4.4.4 Conclusions 
Clinically relevant levels of hyperglycaemia have a rapid and profound 
detrimental effect on the early evolution of focal ischaemic brain damage in 
both the absence and presence of metabolic syndrome components. Despite this, 
infarct size at 24 hours post MCAO was increased only in the absence of these 
features. Therefore managing blood glucose levels as early as possible may 
benefit all hyperglycaemic stroke patients in the acute phase, but greater 
benefit is likely to be seen in those who do not have metabolic syndrome.  
Mechanistically this study suggests an involvement of ROS under hyperglycaemic 
conditions in the absence of insulin resistance and other metabolic syndrome 
components. The potential involvement of oxidative stress in the detrimental 
effect of glucose is addressed in the subsequent chapter. 
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 Chapter 5 - Increased superoxide generation in 
hyperglycaemia-induced ischaemic damage: 
Effects of SOD/catalase mimetic EUK-134 
157 
5.1 Introduction 
Based on the findings in the previous chapter and the known role of superoxide 
in chronic hyperglycaemia associated pathologies, the experiments presented in 
this chapter were designed to investigate the role of oxidative stress in 
hyperglycaemia mediated damage following experimental stroke using the 
SOD/catalase mimetic EUK-134.  
In the acute development of ischaemic damage following permanent MCAO, 
excitotoxicity and oxidative stress mechanisms are thought to be predominantly 
responsible for lesion expansion following bioenergetic failure (Chapter 1, Figure 
1.7). Preclinical studies have implicated a role of superoxide in focal cerebral 
ischaemia using superoxide dismutase (SOD) knockout mice. In SOD2 knockouts, 
elevation of oxidative stress markers such as DNA fragmentation and 
mitochondrial cytochrome C were associated with increased infarct volume 
following permanent MCAO (Fujimura et al 1999; Murakami et al 1998).  
The findings of Chapter 4 suggested that hyperglycaemia had increased free 
radical production, enhancing oxidative stress and lipid peroxidation in normal 
rats and therefore this was potentially the mechanism for hyperglycaemia-
mediated damage in experimental stroke.  
5.1.1 Hyperglycaemia mediated oxidative stress 
In diabetes there are a number of associated complications, including 
neuropathies, which are thought to be mediated through increased flux through 
the polyol pathway, intracellular production of advanced glycation end products 
(AGEs), protein kinase C activation and increased hexosamine pathway 
activation (Brownlee 2005). Hyperglycaemia activates these 4 pathways via 
increased production of mitochondrial superoxide. Increased glycolysis results in 
higher NADH production which in turn results in increased electron transfer 
through the electron transport chain in the mitochondrion. This results in the 
accumulation of a number of intermediates, including ubisemiquinone which can 
transfer an electron to molecular oxygen to form superoxide. It has been shown 
in endothelial cells that 30mM glucose causes a 3 fold increase in reactive 
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oxygen species (ROS) production compared to 5mM glucose, and this increase is 
attenuated by overexpression of superoxide dismutase (Nishikawa et al 2000). 
Brownlee et al. claim that mitochondrial production of superoxide is the unifying 
mechanism of the 4 pathways leading to diabetic complications associated with 
hyperglycaemia, whereby superoxide partially inhibits the glycolytic pathway 
enzyme glyceraldehyde-3 phosphate dehydrogenase causing upstream 
accumulation of the substrates for the 4 pathways. PKC-dependent activation of 
NAD(P)H oxidase is also a significant source of superoxide. This evidence 
suggests that superoxide is likely to be involved in hyperglycaemia associated 
ischaemic damage. The role of superoxide in hyperglycaemic cerebral ischaemic 
damage is supported by the observations made in Chapter 4 regarding increased 
lipid peroxidation, which reflected increased infarct volume, in hyperglycaemic 
rats compared to normoglycaemic controls. It is known that acute 
hyperglycaemia can cause oxidative stress. In healthy human subjects using a 
glucose clamp test to increase plasma glucose to around 15mmol/L it was 
observed that circulating levels of nitrotyrosine, a marker of oxidative stress, 
were increased compared to subjects whose blood glucose was maintained at 
normal physiological levels (Marfella et al 2001). Nitrotyrosine is formed by 
nitrosylation of tyrosine residues by peroxynitrite, a free radical produced by the 
reaction of superoxide with nitric oxide. Vascular nitric oxide production is an 
important physiological response to induce vasodilation, inhibit platelet 
aggregation and leukocyte adhesion. Overproduction of superoxide can cause an 
imbalance between superoxide and nitric oxide leading to endothelial 
dysfunction and the formation of peroxynitrite. Inhibition of nitric oxide 
synthase with -nitro-arginine methyl ester (L-NAME) has been shown to reduce 
infarct volume in the streptozotozin diabetic rat model following transient MCAO 
(Quast et al 1995), and this is thought to be due to reductions in peroxynitrite 
formation.  
Attenuating an increase in superoxide production to prevent possible 
downstream activation of damaging pathways, inactivation of critical enzymes 
and the further generation of free radicals could potentially reduce 
hyperglycaemia-associated ischaemic damage. It is thought that conventional 
antioxidants might not be appropriate because they neutralise ROS molecules on 
a one-to-one basis. The Superoxide dismutase (SOD)/catalase mimetic EUK-134 
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is a catalytic antioxidant that has been previously shown to reduce infarct 
volume by nearly 90% compared to controls in a rodent experimental stroke 
model (Baker et al 1998). EUK-134 mimics the actions of two enzymes, SOD and 
catalase which catalyses the neutralisation of superoxide to water and oxygen. 
EUK-134 is therefore able to target superoxide as its production is heightened 
both in response to ischaemia and furthermore to hyperglycaemia. This may be 
more appropriate than conventional antioxidants to neutralise this 
overproduction of ROS, which do so on a one-to-one basis. Affecting the 
overproduction of superoxide more successfully may uncover the mechanistic 
role in hyperglycaemic cerebral ischaemia. 
5.1.2 Measuring the effects of EUK-134 
In addition to exacerbation of infarct volume the studies in the previous chapter 
showed that lipid peroxidation, a marker of oxidative stress, was increased in 
the brains of hyperglycaemic rats compared to controls. It was therefore 
important to assess whether or not EUK-134 administration could reduce lipid 
peroxidation back to control levels and therefore determine the role of 
superoxide in hyperglycaemia mediated ischaemic damage. Lipid peroxides are 
unstable and decompose to form a complex series of compounds including 
reactive carbonyl compounds. Polyunsaturated fatty acid peroxides generate 
malondialdehyde (MDA) and 4-hydroxyalkenals, such as 4-Hydroxynonenal, upon 
decomposition. Measurement of MDA and 4-hydroxyalkenals has been used 
frequently as an indicator of lipid peroxidation. In this study tissue MDA levels 
were quantified in both cortical and subcortical structures for both the 
ipsilateral and contralateral hemispheres following experimental stroke.  
To confirm that any effect associated with the administration of EUK-134 is as a 
result of a reduction in superoxide, circulating levels of the ROS were measured. 
Electron paramagnetic resonance (EPR) or electron spin resonance (ESR) 
spectroscopy is a technique for studying chemical species that have one or more 
unpaired electrons, such as the reactive oxygen species, superoxide.  EPR works 
in a similar way to MRI although EPR is used to detect the transitions of unpaired 
electrons in an applied magnetic field, rather than H+ in proton MRI. The 
unpaired electron, like a proton, has spin. When an external magnetic field is 
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applied, the paramagnetic electrons either orient in a direction parallel or 
antiparallel to the direction of the magnetic field. This creates two distinct 
energy levels for the unpaired electrons and allows them to be measured as they 
are driven between the two levels by applying microwave radiation. As 
superoxide is highly reactive, a spin probe, which reacts with superoxide, can be 
used to detect the levels of the ROS in blood samples. The spin probe, 1-
hydroxy-3-carboxy-pyrrolidine (CPH) is oxidised to 3-carboxy-proxy by 
superoxide which yields an EPR spectra. Detection of circulating superoxide 
levels provided an indication of an effect of EUK-134 on the systemic level of 
superoxide. 
5.1.3 Animal model 
The previous Chapter adopted the ffSHRSP metabolic syndrome model and the 
control WKY strain for experimentation. Pragmatically, for the experiments 
described in this chapter, it was impossible to use the SHRSP or WKY rats due to 
supply issues from the University colony. Therefore the acute hyperglycaemia 
model was transferred to the Sprague-Dawley strain.  However, this does not 
necessarily represent a limitation since, in preclinical stroke research, it is 
important to not focus studies solely on one particular model or strain.  The 
predictability of pre-clinical research to clinical stroke is strengthened if results 
can be recreated in different models, strains and species. 
5.1.4 Hypothesis  
I hypothesised that pre-treatment with EUK-134 would attenuate the 
hyperglycaemia-associated ischaemic damage following MCAO and this would be 
reflected by a reduction in brain tissue lipid peroxidation, quantified by the 
marker malondialdehyde and circulating superoxide using EPR.  
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5.1.5 Study Aims 
1) Establish if hyperglycaemia exacerbated infarct volume compared to 
normoglycaemia in Sprague-Dawley rats. 
2) Investigate if EUK-134 was able to reduce the level of arterial superoxide 
compared to vehicle-treated animals. 
3) Determine if EUK-134 could reduce infarct volume, and if this was associated 
with reduced lipid peroxidation, in both normoglycaemia and hyperglycaemic 
rats.  
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5.2 Methods 
5.2.1 Animals 
All experiments were carried out under licence from the Home Office and were 
subject to The Animals (Scientific Procedures) Act, 1986. Male Sprague Dawley 
rats (253±13 g, Harlan, Bicester, UK) were randomly assigned (see section 5.2.7) 
to one of 4 groups; Normoglycaemia (n=8), Hyperglycaemia (n=8), 
Normoglycaemia+EUK (n=8) or Hyperglycaemia+EUK (n=8) 
5.2.2 Surgical procedures 
Rats fasted overnight, were anaesthetised initially with 5% inhaled isoflurane in 
an induction chamber and then orally intubated. Animals were artificially 
ventilated with 2.5% isoflurane delivered in a nitrous oxide-oxygen mixture 
(70:30). All rats were given an intraperitoneal (i.p.) injection of the anti-
muscarinic drug atropine sulphate (0.4ml, 600µg/ml, Martindale 
Pharmaceuticals, UK). This was used to prevent the production of bronchial 
secretions that could potentially block the airway during the experiment.  
Polyethylene catheters (Portex, external diameter 0.96 mm; internal diameter 
0.58 mm; 20 cm long) were inserted into the right femoral artery and the right 
femoral vein, for blood pressure/blood gas analysis and drug administration, 
respectively.  
Blood sampling was done immediately after the catheter was in place and then 
each hour to ensure blood gases were maintained within the normal 
physiological range apart from increased PaO2 due to the oxygen enriched 
mixture used to maintain physiological stability during surgery. A rectal 
thermocouple provided continual monitoring of core body temperature which 
was maintained at 37±0.5oC using a heat lamp. 
EUK-134 (2.5mg/kg in ~2ml saline, Cayman Chemicals) was infused intravenously 
at a rate of 0.6 ml per minute, 20 minutes prior to MCAO in 
Normoglycaemia+EUK and Hyperglycaemia+EUK groups. The dose was selected 
based on the solubility of the drug stated by the manufacturer 
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(http://www.caymanchem.com/pdfs/10006329.pdf) and a previous in vivo focal 
ischaemia study (Baker et al 1998). The Normoglycaemia and Hyperglycaemia 
groups were infused with vehicle (saline) of an equivalent volume. A single dose 
of a 15% glucose solution (aqueous, 10ml/kg) was administered i.p. 10 minutes 
prior to occlusion of the MCA to Hyperglycaemic and Hyperglycaemia+EUK 
groups. Their respective normoglycaemia control groups received vehicle 
(distilled water, 10ml/kg).  
Permanent focal cerebral ischaemia was induced using the distal diathermy 
method, as previously described in Chapter 2.3.2, via a small craniectomy. Once 
the MCA was cauterized it was cut to confirm occlusion before placing 
haemostatic sponge (Spongostan, Ferrosan UK) over the area and stitching the 
wound closed with a 4-0 suture.  
An arterial blood sample (475µl) was taken 2 hours post-MCAO and immediately 
deposited into a heparinised vacutainer and stored on ice. The blood was then 
processed for EPR analysis (see section 5.2.7) 
5.2.3 Animal Recovery 
After the 2 hour post-MCAO blood sample was taken the isoflurane concentration 
was reduced to 1% to start the recovery process. The femoral artery and vein 
catheters were removed and the entry hole in the artery and vein was sealed by 
electrocoagulation. The site was then re-sutured and the anaesthesia was 
withdrawn. At this point the nitrous oxide-oxygen mixture was readjusted to a 
50:50 ratio to aid with recovery. Once the animal had started to breathe against 
the ventilator for a period of 5 minutes the ventilator was temporarily 
disconnected. If the animal continued to breathe unassisted for a period of 5 
minutes the intubation tube was carefully removed and the rat was transferred 
to a facemask to continue the oxygen supplementation. Once motor function had 
began to return the animal was transferred to a recovery cage containing some 
bedding and sawdust from its previous cage and its own cardboard tube. Soft 
diet, containing softened normal rat chow, was placed in the cage and dry 
pellets and water were available ad libitum. The general condition of the 
animals was assessed at least 3 times a day during recovery and this was 
recorded. 
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5.2.4 Magnetic Resonance Imaging 
Magnetic resonance imaging data were acquired on the system as described in 
Chapter 2.5.1. The rat was anaesthetised in a Perspex anaesthetic chamber with 
5% isoflurane in a nitrous oxide-oxygen mixture (70-30) before being placed 
prone in the MRI cradle and attached to a face mask to continue delivery of 
anaesthetic at 2% isoflurane. The head was restrained using tooth and ear bars 
and body temperature was maintained for the duration of the scanning protocol 
using a closed circuit thermal jacket. Core body temperature was monitored by 
a rectal thermocouple. A linear surface receiver coil (2cm diameter) was placed 
above the head of the animal before being transferred to the scanner. A coronal 
RARE T2 sequence (effective TE: 46.8 ms, TR: 5000 s; in plane resolution of 97 
um; 16 slices of 0.75 mm thickness) was acquired at 24 hours after stroke onset 
for infarct volume determination. ImageJ was used to separate the 16 images 
and the hyperintense region that represented the infarct was manually 
delineated using the freehand function. Measurement of individual images gave 
the infarct areas in millimetres squared, and infarct volume was calculated by 
summing the 16 areas and multiplying by the slice thickness (0.75 mm). The 
infarct was corrected for brain swelling as described in Chapter 2.5.5. 
5.2.5 Neurological Scoring  
An 18 point neurological score, as described in Chapter 2.7, was carried out ~23 
hours post MCAO prior to the animal being scanned in the MRI for infarct 
determination. 
5.2.6 Lipid peroxidation  
At the end of the MRI scanning protocol the rat was removed from the cradle 
and transferred back to the operating theatre. Anaesthesia was increased to 5% 
isoflurane and 2 terminal blood samples (475 µl) were taken via cardiac puncture 
for EPR (see section 5.2.7). The brain was removed and the T2-defined region 
(encompassing all 16 slices) was dissected using the rostral-caudal positioning of 
the coronal T2 scan for guidance. The cortex was removed and separated into 
ipsilateral and contralateral sections. This was also done with the subcortical 
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structures. These 4 regions were then processed for MDA and LPO analysis as 
described in Chapter 2.6.2. The quantity of MDA was corrected for the amount 
of protein in the sample using a BSA assay and standard curve.  
5.2.7 Electron Paramagnetic Resonance (EPR)  
The arterial blood samples collected at 2 hours and 24 hours post MCAO were 
incubated with 15µl CPH spin probe, mixed well and incubated at 37°C for 15 
minutes. The sample was taken up into a 1ml syringe and the reaction between 
superoxide and CPH was stopped by immersing the sample in liquid nitrogen. 
The samples were then stored at -80°C until the EPR analysis was carried out. 
The EPR analysis was conducted by Jim McCulloch, chief technician in the 
Institute of Cardiovascular and Medical Sciences. Standards of known 
concentrations of CP were analysed alongside to obtain a standard curve. The 
concentration of CP in the blood samples was calculated from the standard 
curve as a measure of superoxide. 
5.2.8 Randomisation, blinding and statistical analysis 
To calculate the number of animals needed in each group a sample size 
calculation was conducted based on the changes in infarct volume, at 24 hours 
post MCAO, exhibited in WKY under hyperglycaemic conditions compared to 
normoglycaemic controls from Chapter 4 (Figure 5.1).   
 
 
 
 
Figure 5.1: Sample size calculation. A) Equation for sample size determination for 
continuous data where d = difference expected based on previous findings, s = standard 
deviation of group, C = constant derived from power and significance level. B) Table for 
determining C. α = significance level (95% or 99%), 1-β = Power (80% or 90%). 
 
 α 0.05 0.01 
1-β 0.8 7.85 11.68 
 0.9 10.51 14.88 
n = 1 + 2C 
   s 
  d 
2 
A B 
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The difference in infarct volume observed between the WKY and WKY+G at 24 
hours was 20 mm3. The standard deviation for the WKY and WKY+G groups was 
12.85 and 13.66 respectively. The sample size was based on an 80% power (1-β = 
0.8) and a 95% significance level (α = 0.05) and therefore the value for C was 
7.85 according to Figure 5.1B. The sample size needed was calculated to be 7.8 
animals in each group. In light of this 8 animals were assigned to each group. 
Rats were assigned to 1 of the 4 groups using a randomisation plan generated at 
the beginning of the study (Table 5.1). I was blind to both the glucose 
administration and the EUK-134 administration. A colleague, who was in 
possession of the randomisation plan, presented me with the correct syringes at 
the time of drug administration. I was also blind to animal identity during the 
analysis of infarct volume and tissue MDA levels. Blood glucose levels were 
assessed using a 2 way ANOVA repeated measures test with Bonferroni post test. 
Infarct volume and MDA quantification were assessed using a 1 way ANOVA with 
Bonferroni post test. Neurological scores were assessed using a Kruskal-Wallis 
test with Dunn’s multiple comparison post test. Data are expressed as mean ± 
standard deviation or as a scatter plot with the mean indicated. 
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A Randomization Plan 
from 
http://www.randomization.com
1 Normoglycaemia+EUK 17 Normoglycaemia+EUK 
2 Hyperglycaemia 18 Normoglycaemia 
3 Hyperglycaemia+EUK 19 Hyperglycaemia 
4 Hyperglycaemia 20 Hyperglycaemia+EUK 
5 Normoglycaemia 21 Hyperglycaemia 
6 Normoglycaemia 22 Normoglycaemia+EUK 
7 Normoglycaemia+EUK 23 Normoglycaemia 
8 Hyperglycaemia+EUK 24 Hyperglycaemia+EUK 
9 Hyperglycaemia+EUK 25 Hyperglycaemia+EUK 
10 Normoglycaemia+EUK 26 Normoglycaemia+EUK 
11 Normoglycaemia+EUK 27 Hyperglycaemia+EUK 
12 Normoglycaemia 28 Normoglycaemia+EUK 
13 Hyperglycaemia 29 Normoglycaemia 
14 Hyperglycaemia 30 Normoglycaemia 
15 Normoglycaemia 31 Hyperglycaemia 
16 Hyperglycaemia+EUK 32 Hyperglycaemia 
 
Table 5.1: Randomisation plan generated for the EUK-134 study with 8 animals in each of 
the 4 groups.  
 
168 
5.3 Results 
5.3.1 Physiological variables 
There was no difference in body weight between any of the 4 groups at the start 
of the study (Table 5.2). During anaesthesia there was no significant difference 
in the MABP, core body temperature, blood gases or pH measurements between 
any of the four groups (Table 5.2). The PaCO2 and pH were maintained within 
normal physiological limits.  However the PaO2 was elevated out with this due to 
the oxygen enriched mixture used to deliver the anaesthesia. 
There was no mortality in any of the 4 groups following MCAO surgery. 
5.3.2 Glucose administration led to hyperglycaemia in 
Hyperglycaemia and Hyperglycaemia+EUK groups 
The baseline blood glucose measurements, taken just prior to i.p. glucose or i.p. 
vehicle administration, were not significantly different between hyperglycaemia 
and normoglycaemia groups or between the vehicle and EUK-134 treatment 
groups (Figure 5.2).  
Following i.p glucose administration to hyperglycaemia and hyperglycaemia+EUK 
groups, blood glucose increased significantly. The mean peak blood glucose 
levels in both hyperglycaemic groups recorded at 1 hour post MCAO were similar. 
The peak observed was higher than that previously observed in the WKY rats in 
Chapter 4 even though the same dose was used. There was no change in blood 
glucose levels in either the normoglycaemia or normoglycaemia+EUK groups 
following vehicle treatment. 
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Table 5.2: Physiological parameters of vehicle or EUK-134 treated hyperglycaemia and normoglycaemia groups. Body weight was measured 
immediately prior to anaesthesia. PaO2, PaCO2, pH, MABP and temperature were measured every 30 minutes and an average taken for the duration 
of anaesthesia.  Data are presented as mean±SD, n=8 per group. MABP – mean arterial blood pressure
 Prior to anaesthesia During anaesthesia 
Group 
 
Weight  
   (g) 
 
  PaO2 
(mmHg) 
PaCO2 
(mmHg) 
pH 
 
MABP  
(mmHg) 
 
Temperature (°C)   
Normoglycaemia 
(n=8) 
243 ± 5 139.1 ± 39.4 38.2 ± 4.0 7.39 ± 0.05 93.4 ± 12.1 37.1 ± 0.5 
Normoglycaemia+EUK  
(n=8) 
251 ± 7 140.8 ± 27.3 39.9 ± 5.3 7.40 ± 0.06 93.3 ± 7.2 37.3 ± 0.5 
Hyperglycaemia 
(n=8) 
247 ± 7 136.5 ± 34.2 36.5 ± 2.4 7.40 ± 0.07 89.7 ± 13.5 37.2 ± 0.4 
Hyperglycaemia+EUK 
(n=8) 
248 ± 6 134.2 ± 44.9 37.0 ± 2.1 7.41 ± 0.06 93.2 ± 7.7 37.3 ± 0.6 
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Figure 5.2: Blood glucose levels before and after glucose or vehicle administration. 
Peak levels measured in hyperglycaemia and hyperglycaemia+EUK groups after glucose 
administration were similar. There was no change in blood glucose following vehicle 
administration to normoglycaemia and normoglycaemia+EUK groups. Data analysed 
using 1 way ANOVA with Bonferoni post test. * P<0.001 compared to respective 
normoglycaemia controls. 
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5.3.3 Hyperglycaemia increased infarct volume irrespective of 
EUK-134 administration. 
T2-derived infarct analysis showed that hyperglycaemic animals consistently 
exhibited ischaemic damage over a greater spatial profile than normoglycaemia 
animals (Figure 5.3). Infarct volumes were significantly larger in hyperglycaemic 
rats compared to normoglycaemic rats, which was consistent with the findings 
from Chapter 4(Figure 5.4). There was no significant difference between EUK-
134 or vehicle treated normoglycaemia groups and similarly this was mirrored in 
the hyperglycaemia groups suggesting that EUK-134 was unable to reduce 
hyperglycaemia mediated damage following MCAO. Interestingly comparing the 
normoglycaemia group to the hyperglycaemia+EUK group, there was no 
significant difference between these groups.  
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Figure 5.3: T2-derived infarcted tissue (circled red) in A) normoglycaemia and B) hyperglycaemia groups following permanent MCAO both with and 
without EUK-134 administration. The data presented are from the median animal within each experimental group. 
Vehicle 
EUK134 
A) 
Vehicle 
EUK134 
B) 
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Figure 5.4: Volumetric analysis of cerebral infarction 24h after MCAO in normoglycaemia 
and hyperglycaemia groups both with and without EUK-134 administration. Data analysed 
using 1 way ANOVA with Bonferoni post test. * P<0.01 glucose compared to vehicle 
administration. Data presented as a scatterplot with mean indicated. 
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5.3.4 Neurological scores 
The 18 point neurological score was conducted on all of the animals prior to 
experimentation (Figure 5.5). 31 animals were scored 18 out of 18 with one 
animal scoring 17. Following ischaemia all animals scored significantly worse 
than the baseline score. There was no difference between the EUK-134 and 
vehicle treated normoglycaemia groups (normoglycaemia, 11±2; 
normoglycaemia+EUK, 8±2) or hyperglycaemic groups (hyperglycaemia, 11±2; 
hyperglycaemia+EUK, 9±2). 
The correlation between infarct volume and the neurological score was assessed 
in each of the 4 groups (Figure 5.6). The normoglycaemic group shows no 
obvious trend across the group as infarct volumes increase (Figure 5.6A). The 
hyperglycaemic group shows clustering around the higher infarct volumes but 
the lowest infarct volumes share the best neurological scores in the group 
(Figure 5.6B). The normoglycaemia+EUK group hints at a downward trend in 
neurological score with increasing infarct volume (Figure 5.6C), however the 
most convincing correlation exists in the hyperglycaemia+EUK group (R2= 0.6, 
P=0.02, Figure 5.6D). Grouping all of the animals together there is a visible 
linear relationship between neurological score and infarct volume (R2=0.5, 
P<0.001, Figure 5.7).
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Figure 5.5: Neurological score ~23h after MCAO in normoglycaemia and hyperglycaemia 
groups following permanent MCAO both with and without EUK-134 administration. Prior to 
MCAO the baseline score for the rats was 18 in all groups. Data presented as scatterplot 
with mean indicated. 
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Figure 5.6: Correlation between level of infarct volume and 18 point neurological score in A) normoglycaemia and B) hyperglycaemia C) 
normoglycaemia+EUK and D) hyperglycaemia+EUK groups. A significant correlation was found in the hyperglycaemia+EUK group (R2= 0.6, P=0.02)
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Figure 5.7: Correlation between neurological score and T2-derived infarct volume from all 
animals in the study. A significant correlation was found between the 18 point neurological 
score and infarct volume (r2 =0.5, P<0.001). 
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5.3.5 MDA was reduced by EUK-134 administration in 
normoglycaemia but not hyperglycaemia groups 
Analysis of MDA levels in tissue homogenates from the infarct regions showed 
that following EUK-134 administration, the level of MDA in normoglycaemia 
animals was reduced in ipsilateral cortex compared to vehicle treated 
normoglycaemia animals (Figure 5.8A). This effect was however not observed in 
hyperglycaemic animals.  
The level of MDA was not increased in hyperglycaemic animals compared to 
controls in the absence of EUK-134 suggesting that the effects of hyperglycaemia 
on infarct volume were not due to changes in lipid peroxidation.  EUK-134 had 
no effect on MDA levels in the contralateral cortex, ipsilateral or contralateral 
subcortical ROIs (Figure 5.8 and 5.9).  
5.3.6 MDA and infarct volume show little evidence of a correlation 
 The data collected for infarct volume and MDA analysis were compared to see if 
a correlation existed between the two measures (Figure 5.10). Looking at the 
graphs it is obvious that in each of the four groups there is no significant 
correlation between the level of MDA and the resulting infarct volume following 
MCAO. However grouping all of the animals together a weak association was 
established (R2 = 0.191, P = 0.01, Figure 5.11). This suggests that independent of 
treatment ~20% of the infarct volume can be determined by the level of MDA. 
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Figure 5.8: Levels of the lipid peroxidation marker, MDA, in A) ipsilateral and B) contralateral cortex 24 h post MCAO in normoglycaemia and 
hyperglycaemia groups both with and without EUK-134 administration. Data analysed using 1 way ANOVA with Bonferoni post test. *, P<0.01 compared 
to normoglycaemia group. Data presented as scatterplots with means indicated. 
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Figure 5.9: Levels of the lipid peroxidation marker, MDA, in A) ipsilateral and B) contralateral subcortical structures 24 h post MCAO in normoglycaemia 
and hyperglycaemia rats both with and without EUK-134 administration. 
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Figure 5.10: Correlation between level of MDA and T2-derived infarct volume in A) normoglycaemia and B) normoglycaemia+EUK C) hyperglycaemia 
and D) hyperglycaemia+EUK groups. No significant correlation was found in any of the 4 groups. 
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Figure 5.11: Correlation between level of MDA in ipsilateral cortex and T2-derived infarct 
volume from all animals in the study. A small but significant correlation (r2 = 0.191, P = 
0.01) was found between the level of MDA and infarct volume. 
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5.3.7 Arterial superoxide levels were unchanged under 
hyperglycaemic conditions 
No significant difference in CP concentration was found between the EUK-134 
and vehicle treated hyperglycaemia or normoglycaemia groups in the 2 hour post 
MCAO blood samples. This suggests that hyperglycaemia is not exacerbating 
ischaemic injury at this time point via increased superoxide levels in the blood.   
EUK-134 administration resulted in a decreasing trend of CP concentration in the 
arterial blood samples collected 2 hours post MCAO in both normoglycaemic and 
hyperglycaemic animals, compared to respective vehicle treated groups (Figure 
5.12A). The administration of EUK-134 led to changes in the distribution of 
animals with regards to CP levels (Figure 5.12A). There is a significant, yet weak 
correlation between infarct volume and CP concentration 2 hours post MCAO in 
the EUK-134 treated groups (R2 = 0.3, P = 0.04). This suggests that superoxide is 
weakly associated with final infarct. 
At 24 hours post MCAO, arterial superoxide levels were  significantly lower in all 
groups compared to 2 hours post MCAO (P<0.01, Figure 5.12B). The level of 
superoxide was again similar between the normoglycaemia and hyperglycaemia 
groups suggesting that systemic superoxide levels do not correlate with 
hyperglycaemia dependent damage.  
To see if the levels of circulating superoxide 2 hours post MCAO predicted the 
extent of lipid peroxidation at 24 hours the data from both measures were 
compared (Figure 5.13). Visually there does not seem to be an obvious 
relationship between superoxide levels 2 hours post MCAO and the resulting level 
of malondialdehyde at 24 hours post MCAO. There was a statistically significant 
correlation, although the R2 value was very low (r2 = 0.2, P=0.02). 
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Figure 5.12: Level of CP produced by superoxide in arterial blood samples taken (A) 2 
hours and (B) 24 hours post MCAO. Data expressed as scatter plots with mean for each 
group indicated. 
A 
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Figure 5.13: Correlation between level of CP (measure of superoxide) in blood and MDA 
in ipsilateral cortex from all animals in the study. A small but significant correlation was 
found between the level of CP and tissue MDA (r2 = 0.2, P=0.02). 
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5.4 Discussion 
Many mechanisms by which hyperglycaemia can exacerbate ischaemic brain 
injury have been proposed using various animal models of stroke as well as 
clinical observations. However these mechanisms remain poorly understood. 
Oxidative stress, and the lipid peroxidation it can induce, has often been 
implicated in how glucose can injure the ischaemic brain which is supported by 
the data in Chapter 4 using a model of metabolic syndrome alongside a control 
strain. The current study has shown that hyperglycaemia also enhances 
ischaemic damage in the Sprague-Dawley strain of rat at 24 hours post-stroke 
confirming the findings of the previous study in WKY and SHRSP rat strains, and 
demonstrating that the detrimental effect of hyperglycaemia is not restricted to 
one particular model or one particular rat strain. 
 
5.4.1 EUK-134 failed to reduce infarct volume in hyperglycaemic 
and normoglycaemic rats compared to vehicle treated 
controls. 
The administration of the SOD/catalase mimetic, EUK-134 to both 
normoglycaemic and hyperglycaemic rats had no effect on the resulting infarct 
derived from T2-weighted MRI scans. Previously, using a permanent occlusion 
model in the rat, it was shown that using a 2.5mg/kg dose of EUK-134 
administered intravenously in a single bolus dose three hours post occlusion 
infarct volume was attenuated compared to vehicle treated animals (Baker et al 
1998). In that study EUK-134 reduced infarct by around 90% compared to 
controls and the remaining damage was comparable to the lesion size observed 
at 3 hours without treatment. This suggests that in the study conducted by Baker 
et al., EUK-134 was able to prevent any further damage from the time 
administered. The dose of EUK-134 used by Baker et al. was equivalent to the 
present study and EUK-134 was also administered in a single bolus intravenous 
injection. Experiments into renal nephrotoxicity using EUK-134 suggest that 
scavenging and dismutation of superoxide was effective at doses of 10-300µM 
whereas the present study only used a dose of 5µmoles/Kg (Samai et al 2007). 
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The dose used in the present study was selected based on the study by Baker et 
al (1998) and additionally from the solubility data provided on EUK-134. To 
successfully dissolve a greater dose would require a considerably larger volume 
of solvent which would far exceed recommended volumes for intravenous drug 
administration to rats.  
The obvious difference between the studies is the administration time relating 
to the arterial occlusion. The present study was a proof of principle study to 
investigate the mechanism of hyperglycaemia mediated damage, rather than a 
neuroprotection study and therefore pre-treatment was selected on this basis.  
Baker et al (1998) administered EUK-134 3 hours post occlusion whereas in the 
present study EUK-134 was administered 20 minutes prior to occlusion and 10 
minutes before glucose loading in the hyperglycaemia groups. The reason for a 
much earlier administration was to make sure that scavenging of superoxide 
could take place immediately following hyperglycaemia to hopefully maximise 
the effect. The study by Baker et al (1998) fails to state if measures were taken 
to prevent bias. For example, lack of blinding and randomisation can have 
substantial effects on outcome and may account for a proportion of the effect 
size observed (Macleod et al 2009).  
5.4.2 Increased variability in infarct size in Sprague Dawley rats 
compared to WKY rats 
Compared to the results gathered in Chapter 4 using ffSHRSP and WKY rats, 
there was a much greater variability in the infarct sizes using Sprague Dawley 
rats and in all groups. Some rats displayed very small lesions suggestive of an 
incomplete occlusion. However the MCA of each animal, irrespective of group, 
was electrocoagulated and then cut in a similar fashion which suggests that 
variation in the branching of the MCA or collateral supply from adjacent arterial 
territories may have resulted in a reduced volume of ischaemically damaged 
tissue. Various different types of MCA branching have been previously 
documented in Sprague-Dawley rats with varying frequencies of occurrence 
(Rubino and Young 1988). Collateral flow in the Sprague-Dawley strain is known 
to be better than the in- SHRSP strain which may account for a more variable 
occlusion size (Coyle 1986). Some groups have added varying durations of 
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bilateral- carotid artery clamping to reduce global CBF and therefore collateral 
flow in similar models of MCAO to reduce variability (Brint et al 1988; Chen et al 
1986; Rubino and Young 1988). Rubino and colleagues (1988) found that in 
Sprague-Dawley rats no lesion was apparent in 38% and 43% of animals having 
undergone parietal or frontal branch MCAO respectively in addition to 30 minute 
bi-lateral occlusion of the ipsilateral and contralateral common carotid arteries. 
Another study showed that permanent ipsilateral common carotid occlusion in 
addition to distal MCAO produced reproducible infarcts in SHRSP rats but not in 
Fisher-344 or Wistar rats (Brint et al 1988). More reproducible infarcts were 
produced in a MCAO study where additional  permanent ipsilateral common 
carotid occlusion was combined  with 60 minutes of contralateral common 
carotid artery occlusion  in Long Evans rats compared to single common carotid 
occlusion or MCAO alone (Chen et al 1986).  
The model used for inducing focal cerebral ischaemia in the present study is 
perhaps not suitable for use in a normotensive strain of rat such as the Sprague 
Dawley due to the variability observed. Moving to either the 3 vessel occlusion 
model (Rubino and Young 1988) or the more widely used intraluminal filament 
model could potentially reduce the variability and increase the power of the 
experiment.  
5.4.3 Hyperglycaemia dependant infarct exacerbation was not 
reflected by neurological score 
No significant differences in neurological scores were seen between the 
hyperglycaemia and normoglycaemia groups or between the EUK-134 or vehicle 
treated groups. This suggests that hyperglycaemia does not worsen neurological 
scores in this study. However a correlation does exist between the volume of 
infarct and the resulting neurological score showing a relationship between the 
two outcome measures. The fact that the result obtained from the final infarct 
volume is not mirrored by the neurological score is perhaps due to the lack of 
sensitivity of the neurological score employed. PSH has been widely associated 
with worsening neurological deficit in patients (Baird et al 2003; Parsons et al 
2002). Previously it has been shown that in a transient model of 60 minute 
MCAO, hyperglycaemia induced by streptozotocin worsened neurological scores 
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compared to controls using the Bederson (Bederson et al 1986b) scale (Kamada 
et al 2007). Motor function has been shown to be reduced in hyperglycaemic 
animals compared to normoglycaemic controls in a separate study (Warner et al 
1995). The 18 point composite neurological score used in the present study 
incorporates many of the functional tests included in the Bederson Scale with 
numerous additions. This score has far more outputs with 15 possible outcomes 
(3-18) compared to the 4 grades in the Bederson Scale which may have made it 
more difficult to detect changes in the neurological function between the 
groups. Potentially the time at which the neurological score was carried out may 
have affected the results. The effect of the anaesthetic and the severity of the 
surgery might have influenced the result of the test rather than as a result of 
the ischaemic lesion.  
The results from the neurological score are unable to add any significant 
information as no differences between the groups could be ascertained. The 
correlation between neurological score and infarct volume does give confidence 
that there is a degree of sensitivity in the neurological score however there are 
a number of limitations. Firstly the score could have been affected due to the 
leftover effect of anaesthesia and the surgery prior to conducting the 
neurological scoring. Similarly the sample size calculation conducted for this 
study was based on differences in infarct volume between normoglycaemic and 
hyperglycaemic WKY rats rather than on the neurological score which perhaps 
implies that the study was underpowered for this outcome measure.  
5.4.4 EUK-134 reduced lipid peroxidation markers in ipsilateral 
cortex of normoglycaemia but not hyperglycaemia groups 
In normoglycaemic animals the level of MDA was increased in the ipsilateral 
cortex compared to the other three regions of interest suggesting that as a 
result of MCAO the level of lipid peroxidation had increased in the region of 
tissue affected by the ischaemia. In normoglycaemia animals administered with 
EUK-134 the level of MDA in the ipsilateral cortex was reduced to the level of 
the other 3 regions of interest suggesting that EUK-134 had reduced the level of 
lipid peroxidation to the baseline level of the contralateral hemisphere. In the 
hyperglycaemia group the MDA level in ipsilateral cortex was again raised but 
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this was not attenuated by EUK-134 administration. This may suggest that EUK-
134 is able to dampen the rise in superoxide production associated with cerebral 
ischaemia under normoglycaemic conditions, yet be overwhelmed at the current 
dose by the additional increase superoxide production that is associated with 
hyperglycaemia. EUK-134 has been shown to reduce lipid peroxidation in 
response to streptozotocin-induced oxidative damage in the brain and also 
reduce blood glucose to normoglycaemic levels (Bahramikia and Yazdanparast 
2011). The pathophysiology between the streptozotocin model (model of type 1 
diabetes) and glucose loading models of hyperglycaemia are very different and 
the mechanisms of damage between the two models are not conserved. 
Bahramikia et al (2011) used a dose of 20 mg/kg administered daily for three 
weeks by oral gavage. This is a chronic administration at a considerably higher 
dose than used in the present study or that used by Baker et al (1998) in the 
ischaemia model. The dose of EUK-134 selected for the present study was based 
on the accompanying data sheet which specified the solubility in saline and in 
line with the previous work on cerebral ischaemia (Baker et al 1998). For a 
higher dose to be achieved, the volume of vehicle would have been excessive for 
administration intravenously according to the Home Office guidelines.  
The dose used in the present study was not sufficient to cause a reduction in 
lipid peroxidation in hyperglycaemic animals and perhaps a different multiple 
administration protocol may have increased the efficacy on oxidative stress. The 
weak correlation between infarct volume and the level of lipid peroxidation 
suggests that other mechanisms must be predominantly involved in driving 
infarct size. 
5.4.5 Arterial blood superoxide levels were unchanged under 
hyperglycaemic conditions 
A number of pathologies associated with diabetes, including neuropathy, are 
thought to occur in chronic hyperglycaemia through a variety of pathways 
(Tomlinson and Gardiner 2008). However the mechanisms responsible for these 
associate pathologies are thought to originate from the overproduction of 
superoxide from the mitochondria (Brownlee 2005). The results from the present 
study suggest that in acute hyperglycaemia this is not the case as superoxide 
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levels in hyperglycaemic animals remained consistent with normoglycaemic 
controls at 2 hours and 24 hours post MCAO. However, the level of superoxide in 
the blood may not reflect cerebral levels which may still have been affected. 
The measure of superoxide was primarily to confirm the potential action of EUK-
134 to lower superoxide levels. The EUK-134 treated groups had a greater 
variation in the level of superoxide measured with a trend towards a reduction 
at 2 hours post MCAO compared to the vehicle treated groups. A number of the 
animals in both the hyperglycaemia + EUK and normoglycaemia + EUK groups 
possessed a similar level of superoxide to their respective vehicle treated 
groups, which might suggest a problem with the action or delivery of EUK-134 in 
these animals.  
5.4.6 Conclusions 
Although hyperglycaemia led to an increase in infarct volume the mechanism 
involved remains elusive. The SOD/catalase mimetic EUK-134 showed some 
efficacy in reducing systemic levels of superoxide and also reduced the level of 
lipid peroxidation as measured by MDA in normoglycaemia treated animals. 
However this drug had no effect on infarct volume and the level of lipid 
peroxidation correlated poorly with infarct volume suggesting mechanisms other 
than ROS damage are responsible for mediating hyperglycaemia dependant 
damage in permanent focal cerebral ischaemia.  
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 Chapter 6 - Determining a T2 threshold of 
abnormality from quantitative T2 maps 
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6.1 Introduction 
T2 relaxation, which denotes contrast on T2-weighted imaging, is the loss of 
transverse magnetisation between protons within a particular tissue as a result 
of spin-spin interactions (described in Chapter 1.3.5). When protons are 
subjected to a magnetic field, such as in an MRI scanner the magnetic moment 
of protons, or spin, precess around the axis of the magnetic field. The position 
of this precessional path is referred to as the phase of the proton. The 
application of electromagnetic radiation causes excitation of protons to a high 
energy state and leads to the synchronisation of spin precession. This state is 
known as spin coherence (Figure 6.1A). Phase coherence is gradually lost as 
energy is dissipated between protons, with some spins advancing and others 
falling behind on their precessional paths (Figure 6.1B).  
 
 
Figure 6.1: Diagrammatic representation of T2 relaxation. (A) Precessional paths are 
synchronised around the magnetic field (z) in the transverse plane (xy). (B) The 
precessional paths of protons are dephasing in the transverse plane (xy) around the 
magnetic field (z). 
 
 
T2 weighted imaging has been used to assess infarct volume non-invasively in a 
multitude of preclinical studies, including a number from our lab (Reid et al 
2012; Robertson et al 2011) and in various clinical stroke studies (Parsons et al 
2002; Simonsen et al 2002). The current imaging sequence that is used in our lab 
is a RARE T2 weighted imaging sequence and can be reliably used to identify 
ischaemically damaged tissue 12 to 24 hours following stroke, although prior to 
this time point the T2 signal changes are too subtle to assess the extent or 
severity of ischaemic damage(Baird and Warach 1998). Areas of injured tissue 
A B 
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produce higher signal intensity, reflecting a longer T2 relaxation time, than in 
normal tissue, allowing the infarct to be delineated visually. 
There are a number of limitations with the current RARE T2 weighted scan used 
in our lab. The current sequence does not provide a quantitative measure of the 
T2 relaxation times which prevents the comparative analysis of T2 relaxation 
values for specific structures between subjects. In addition to this the RARE T2 
sequence is susceptible to signal drop off, most notably from the tissue situated 
at the greatest distance from the surface coil (Figure 6.2).  
 
Figure 6.2: Coronal image acquired using RARE-T2 weighted MRI sequence. The red 
arrow indicates the direction of signal intensity loss which is visible on the image. 
 
 
This lower signal intensity can make it more difficult to distinguish between 
potentially ischaemic tissue and normal tissue. Multi Spin-Multi Echo (MSME) T2 
weighted images enable the production of T2 maps by using multiple echo times. 
This allows T2 values to be calculated for each pixel regardless of the signal 
intensity, correcting for signal drop off. The lack of quantification in the current 
RARE T2-weighted imaging means that the delineation of ischaemically damaged 
tissue must be done manually on the basis of visual differences in signal 
intensity, as the arbitrary values associated with contrast of the image can not 
be used to generate a biological threshold for normal and ischaemically damaged 
tissue. Inter- and intra-rater variability from manual delineation is a potential 
source of error in MRI imaging which has been previously examined (Ay et al 
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2008). Generating a T2 threshold for abnormality should remove the inter- and 
intra-rater variability and hence make infarct determination more reliable. 
Although quantitative T2 mapping has been used clinically (Siemonsen et al 
2012), manual delineation has still been used to calculate infarct volume 
(Loubinoux et al 1997).  
Thresholds of abnormality have been previously derived for both DWI (to detect 
ischaemic injury) and PWI (to define the perfusion deficit) for assessment of 
penumbra from PWI/DWI mismatch in a variety of preclinical studies (Kazemi et 
al 2004; Meng et al 2004; Reid et al 2012; Shen et al 2003). A number of 
experimental stroke studies have also used thresholds for quantitative T2 
mapping. A study in rats used TTC staining at 24 hours as a bench mark for 
infarct volume and a T2 threshold of abnormality was calculated for the fast 
spin-echo pulse sequence employed. Using a statistical analysis programme the 
T2 threshold was lowered until the number of pixels corresponded to the lesion 
size calculated from the TTC sections (Bardutzky et al 2007). The T2 threshold of 
abnormality that Bardutzky et al derived was 77.9±3.6 ms and this was 
subsequently used for infarct determination. Another group found that T2 
relaxation times in the contralateral hemisphere varied depending on the tissue 
compartmentalisation from 55.8±2.2 ms in the thalamus to 66.0±0.9 ms in the 
striatum and therefore concluded that a threshold of abnormality for the entire 
brain could not be set (Loubinoux et al 1997). The specific sequence employed 
for T2 quantification varies between scanners which means that inter-laboratory 
use of thresholds for T2 may result in an error in quantification. It is therefore 
necessary to determine a threshold in each lab, for each sequence. 
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This chapter describes the iterative process of selecting a suitable threshold of 
abnormality which defines tissue with a longer T2 relaxation than the threshold 
as infarct. The process for defining the T2 threshold of abnormality is as follows: 
 
6.1.1 Study Aims 
Using both quantitative mapping and RARE T2 images acquired from Chapter 5, 
the aims of this chapter are: 
1. Assess various T2 relaxation thresholds to identify the most suitable for 
infarct determination by comparison with the current RARE T2 sequence. 
2. Apply the derived T2 threshold to a separate group of animals to compare 
infarct volumes calculated from quantitative T2 maps with RARE T2. 
3. Apply the derived threshold to a separate group of rats subjected to a 
different model of MCAO to elucidate the suitability of the threshold to 
another model. 
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6.2 Methods 
6.2.1 MRI acquisition 
Magnetic resonance imaging data were acquired on the system described in 
Chapter 2.5.1. A phased array 4 channel surface receiver coil was placed above 
the head of the animal before being transferred to the MRI scanner. A coronal 
RARE T2 sequence (effective TE: 46.8 ms, TR: 5000 ms; in plane resolution of 97 
um; 16 slices of 0.75 mm thickness) was acquired for manual infarct volume 
determination.  
For automated infarct volume determination, using quantitative T2 mapping, a 
coronal MSME T2 sequence (effective TE 15ms, TR 9000 ms, number of echoes 
16, matrix 96 x 96, FOV 25 x 25 mm2, 8 slices of 1.5 mm thickness) was acquired. 
The MSME T2 images were processed in Paravision 5 to generate quantitative T2 
maps. 
The RARE T2 scan acquires 16 slices compared to the MSME T2 sequence which 
acquires 8. The thickness of the MSME T2 imaging slices are twice the thickness 
of the RARE T2 sequence slices. The geometry for the scans was identical to 
ensure the spatial profile used to calculate infarct volume were the same (Figure 
6.3).  
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Figure 6.3: Saggital Tripilot scan to set the geometry for A) RARE T2 weighted images 
and B) MSME T2 weighted images. Purple box indicates the region to be imaged with 
each slice represented. The geometry of the two scans is identical. 
 
6.2.2 Group analysis 
The T2-weighted MRI data generated from the study in Chapter 5 were used to 
define a threshold of abnormality for the quantitative T2 maps. The animals, all 
of which had undergone distal MCAO using diathermy, were split in two groups; 
the derivation group (n=17) and the comparison group (n=13). The derivation 
group was used to establish the mean T2 relaxation threshold for determining 
infarct. The comparison group was used to assess how well the defined 
quantitative T2 threshold correlates with the manually delineated volume from 
the RARE T2 images.  
The defined quantitative T2 threshold was then applied to data acquired from 
animals that had undergone MCAO using the intraluminal filament method of 
focal cerebral ischaemia to assess its suitability in a different model of MCAO. 
These data were collected by Dr Chris McCabe and analysed by David Tarr.  
 
A B 
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6.2.3 Calculating Infarct volume in derivation group animals from 
RARE T2 by manual delineation 
ImageJ was used to separate the 16 images from the RARE T2 weighted images 
and the hyperintense region that represented the infarct was manually 
delineated using the freehand function. Measurement of individual images gave 
the infarct areas in millimetres squared, and infarct volume was calculated by 
adding up the 16 areas and multiplying by the slice thickness (0.75 mm).  This 
provided a reference for selecting the threshold on quantitative T2 maps. 
6.2.4 Identifying the T2 threshold from Quantitative T2 maps that 
generates the same infarct volume as RARE T2 in derivation 
group animals 
The absolute T2 relaxation threshold for each animal in the derivation group was 
determined by applying a range of increasing threshold values (≥65 ms to ≥90 ms 
in increments of 1 ms) to the quantitative T2 maps acquired 24 hours post-MCAO 
to generate T2-derived lesion volume, for each threshold, across the 8 coronal 
slices. Each coronal slice was separated into ipsilateral and contralateral 
hemispheres and a histogram was drawn for each hemisphere based on the 
number of pixels within a range of T2 relaxation times using ImageJ (1-201 ms, 
Figure 6.4). 
The histogram data from each coronal slice were added together to produce a 
histogram for the entire imaged brain volume (Figure 6.5) and exported to 
Microsoft Excel where a macro was used to measure the lesion size at a range of 
thresholds based on the number of pixels at each T2 relaxation time. The area of 
a pixel in the quantitative T2 maps is 0.0678mm
2 allowing the number of pixels 
to be converted to an area and subsequently a volume by multiplying the total 
area by the slice thickness (1.5mm). 
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Figure 6.4: Coronal quantitative T2 maps generated from MSME T2 scans obtained 24 hours post MCAO, and corresponding histograms. Images and 
data are from 4 of the 8 coronal planes in one representative animal in the derivation group. Infarcted tissue in the ipsilateral hemisphere exhibits a 
higher T2 signal than normal tissue (images in top row). The corresponding histograms below each image illustrate the number of pixels from the 
quantitative T2 maps that correspond to a particular T2 relaxation time. The black line illustrates the contralateral hemisphere and the red line 
represents the ipsilateral hemisphere. Infarcted tissue has a longer relaxation time than normal tissue causing a shift to the right in the pixel distribution 
in the affected ipsilateral hemisphere.
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Figure 6.5: Example histogram for the imaged region of the brain generated from 8 
coronal quantitative T2 maps from a representative animal of the derivation group. Very 
few pixels have a T2 relaxation time of <50 ms or >110 ms. The 1-201ms range is suitable 
to include the majority of pixels. The shift in the ipsilateral peak to the right (highlighted in 
green) shows the range of T2 relaxation times that potentially relate to infarct. 
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6.2.5 Collating all the calculated T2 thresholds to generate a mean 
T2 threshold for the derivation group 
Once the T2 threshold for each animal within the derivation group had been 
selected the data was graphed together. The mean T2 threshold for the group 
was then calculated. This mean T2 threshold was then tested in the comparison 
group. 
6.2.6 Applying the mean T2 threshold to comparison group 
animals 
The quantitative T2 maps for each animal in the comparison group were 
independently analysed. Using ImageJ the mean T2 threshold value from the 
derivation group was applied to each of the 8 coronal slices acquired for each 
animal. The resulting area on each coronal slice corresponding to the threshold 
defined infarct was measured using the polygon tool. The areas from the 8 
acquired coronal levels were then added together and multiplied by the slice 
thickness (1.5 mm).  
6.2.7 Compare the infarct volumes generated with the threshold 
on T2 maps with manual delineation on RARE T2 images in 
the comparison group. 
The infarct volume calculated using the threshold on quantitative T2 maps was 
then formally compared to the manual delineation method using a Bland-Altman 
plot, which describes the bias (difference) between the two methods of infarct 
determination, in animals in the comparison group. 
6.2.8 Reproducibility 
Mean contralateral T2 values were measured from quantitative T2 maps to 
ascertain how consistent the T2 values were between subjects and between 
coronal slices. If the contralateral values varied significantly then an absolute T2 
threshold would not be appropriate and a percentage increase in T2 relaxation 
time would have to be derived.  
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Since the T2 threshold for infarction is based on the manual delineation of 
ischaemically damaged tissue (defined as hyperintense regions) visible in RARE 
T2 images, assessment of intra-rater reproducibility is important. A large error in 
the reproducibility of the manual delineation method of infarct quantification 
could lead to an error in the derivation of the T2 threshold. Manual delineation 
of the infarct in both the derivation and the comparison group was conducted 
twice two weeks apart and blinded to the subject identification. The mean, 
standard deviation and coefficient of variance were calculated for each animal. 
The coefficient of variance is useful in determining the variation as it represents 
a measure relative to the mean rather than an absolute value. This is important 
as the infarct sizes are varied within the groups. 
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6.3 Threshold Derivation 
6.3.1 T2 relaxation in the hemisphere contralateral to MCAO is 
consistent throughout the derivation group 
The mean T2 relaxation value for each of the 8 coronal slices from quantitative 
T2 maps was determined in each of the brains within the derivation group Table 
6.1). The contralateral value of T2 relaxation was consistent between each of 
the coronal levels analysed and also between brains. The mean value of T2 
relaxation for the contralateral hemisphere was 62.3±1.3 ms. The range of T2 
relaxation time thresholds, which will be assessed to identify the T2 threshold of 
abnormality, will increase in increments of 1 ms. The standard deviation from 
contralateral T2 is close to 1 ms which is an acceptable level of variation based 
on the thresholds to be tested. The reproducibility of T2 relaxation between 
subjects gives confidence that an absolute T2 threshold of abnormality can be 
derived, rather than calculating a percentage increase in T2 compared to 
contralateral T2 values. 
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Table 6.1: Contralateral hemisphere T2 relaxation times calculated form quantitative T2 
maps in all animals from the derivation group. SD = standard deviation, ms = millisecond. 
 
 
 
 
 
Subject 
Contralateral T2 relaxation time for each coronal image (ms) 
Mean  SD Slice 1 Slice 2 Slice 3 Slice 4 Slice 5 Slice 6 Slice 7 Slice 8 
DV1 
62.8 65.1 60.6 64.8 61.6 60.9 61.2 61.1 62.2 1.7 
DV2 
64.4 65.9 61.2 61.8 62.8 62.7 63.9 65.3 63.5 1.6 
DV3 
63.8 64.4 60.7 63.4 63.2 63.2 62.4 63.2 63.0 1.0 
DV4 
64.0 64.2 62.4 61.5 62.5 62.4 62.5 64.4 63.0 1.0 
DV5 
62.0 63.3 61.9 61.3 61.8 62.5 61.9 62.3 62.1 0.6 
DV6 
62.2 62.1 60.0 61.6 61.9 61.7 62.0 64.6 62.0 1.2 
DV7 
61.0 61.0 60.8 60.4 61.1 60.8 60.5 61.7 60.9 0.4 
DV8 
62.6 62.4 61.1 61.2 62.1 61.5 61.3 61.1 61.7 0.6 
DV9 
63.5 63.1 62.0 62.2 62.0 62.6 62.7 65.0 62.9 0.9 
DV10 
60.7 60.1 60.8 60.9 60.0 60.5 60.2 60.1 60.4 0.3 
DV11 
65.7 65.1 64.0 62.7 62.2 63.9 62.5 63.7 63.7 1.1 
DV12 
63.2 62.0 61.3 61.3 61.9 62.4 60.9 62.2 61.9 0.7 
DV13 
62.3 60.8 62.4 61.5 62.0 61.5 60.9 62.5 61.7 0.6 
DV14 
64.0 63.0 61.0 61.2 62.2 62.1 62.6 64.1 62.5 1.1 
DV15 
64.0 64.7 62.6 63.2 63.1 62.2 62.1 61.4 62.9 1.0 
DV16 
61.5 61.5 62.9 61.8 62.1 62.1 61.8 64.1 62.2 0.8 
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6.3.2 Intra-rater variation in the manual delineation of infarcts 
from RARE T2-weighted images  
Manual delineation of the infarct in both the derivation group (Table 6.2) and 
the comparison group (Table 6.3) was conducted twice and the variability was 
assessed (Figure 6.6). In the derivation group the variability was low with a 
coefficient of variation across the group of 6.9%. This was similar to that found 
in the comparison group which generated a coefficient of variation of 4.6%. The 
intra-observer variation found in both the derivation group and the comparison 
group is similar to the coefficient of variation found using a similar method for 
infarct determination on CT imaging (van der Worp et al 2001).  The Bland-
Altman scatterplots (Figure 6.5) show that in both groups there was only a very 
small bias (difference) between the repeat measurements of infarct volume. 
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Table 6.2: Intra-rater infarct volume assessment using manual delineation of RARE T2 
imaging in the derivation group.  
Animal Infarct volume measurement (mm3) Standard 
Deviation (mm3) 
Coefficient of 
variation (%) 1 2 Mean 
DV1 
63.1 62.2 62.7 0.6 1.0 
DV2 
18.5 22.8 20.7 3.0 14.7 
DV3 
51.3 50.1 50.7 0.8 1.7 
DV4 
47.5 65 56.3 12.4 22.0 
DV5 
39.5 34.2 36.9 3.7 10.2 
DV6 
120.8 118.4 119.6 1.7 1.4 
DV7 
88.5 77.9 83.2 7.5 9.0 
DV8 
131.2 149.9 140.6 13.2 9.4 
DV9 
19.7 18.4 19.1 0.9 4.8 
DV10 
75.7 68.6 72.2 5.0 7.0 
DV11 
301.4 285.3 293.4 11.4 3.9 
DV12 
120.5 115.7 118.1 3.4 2.9 
DV13 
197.3 180.1 188.7 12.2 6.4 
DV14 
125.4 142.1 133.8 11.8 8.8 
DV15 
167.9 159.1 163.5 6.2 3.8 
DV16 
182.7 175.7 179.2 4.9 2.8 
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Table 6.3: Intra-rater infarct volume assessment using manual delineation of RARE T2 
imaging in the comparison group.  
 
 
 
 
 
 
Animal Infarct volume measurement (mm3) Standard 
Deviation (mm3) 
Coefficient of 
variation (%) 1 2 Mean 
COM1 18.4 17.9 18.2 0.4 1.9 
COM2 117.1 120.3 118.7 2.3 1.9 
COM3 60.1 58.2 59.2 1.3 2.3 
COM4 210.3 195.9 203.1 10.2 5.0 
COM5 236.1 224.7 230.4 8.1 3.5 
COM6 194.3 174.2 184.3 14.2 7.7 
COM7 215.1 230.4 222.8 10.8 4.9 
COM8 195.1 179.9 187.5 10.7 5.7 
COM9 175.1 168.4 171.8 4.7 2.8 
COM10 45.3 50.1 47.7 3.4 7.1 
COM11 43.1 38.8 41.0 3.0 7.4 
COM12 175.3 190.1 182.7 10.5 5.7 
COM13 177.4 188.3 182.9 7.7 4.2 
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Figure 6.6: Scatterplots according to Bland and Altman presenting the intraobserver 
variability of the manual delineation method of infarct volume calculation from RARE T2 
images within A) the derivation group (n=16) and B) the comparison group (n=13). Each 
point represents one animal in the group. Mean difference (bias) indicated by the solid line 
with 95% confidence limits (mean±1.96SD) indicated by the dotted lines. 
 
A 
B 
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6.3.3  Identifying the T2 threshold from Quantitative T2 maps that 
generates the same infarct volume as RARE T2 in derivation 
group animals 
Infarct volume was manually delineated from RARE T2 weighted images for each 
animal in the derivation group. The quantitative T2 maps for each animal in the 
derivation group were then analysed individually. T2 thresholds of 65ms – 90 ms 
increasing in increments of 1 ms were applied and the infarct volume for each 
threshold was generated. This volume was based on the number of pixels lying 
above each threshold multiplied by the known volume of a pixel on the 
quantitative T2 maps. The threshold that generated the same volume of infarct 
as that manually delineated from RARE T2 images was selected (Table 6.4).  
Threshold (ms) Infarct Volume (mm3 
65 505.7 
66 478.5 
67 455.1 
68 434.0 
69 417.3 
70 401.4 
71 388.2 
72 377.5 
73 369.0 
74 361.1 
75 351.6 
76 344.1 
77 337.2 
78 330.2 
79 324.4 
80 319.1 
81 313.1 
82 306.5 
83 299.9 
84 293.6 
85 288.7 
86 282.8 
87 276.2 
88 269.9 
89 262.4 
90 255.3 
Infarct Volume (RARE T2): 301.4 mm
3
 
Table 6.4: Range of thresholds applied to quantitative T2 maps with resulting infarct 
volume described. The threshold that produced the infarct volume most similar to the 
manually delineated infarct from RARE T2 images was selected (highlighted in red) 
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The T2 threshold for the majority of the derivation animals could not be defined 
within the range of thresholds calculated (65-90 ms) (Table 6.5).  
 
Threshold (ms) Infarct Volume (mm3 
65 268.49 
66 242.86 
67 218.76 
68 195.67 
69 176.96 
70 162.62 
71 150.72 
72 141.2 
73 132.21 
74 125.90 
75 121.23 
76 116.96 
77 112.28 
78 107.1 
79 103.1 
80 99.0 
81 94.7 
82 91.3 
83 88.6 
84 84.4 
85 82.1 
86 78.9 
87 76.4 
88 73.5 
89 71.3 
90 68.7 
Infarct Volume (RARE T2): 19.7 mm
3 
Table 6.5: Range of thresholds applied to quantitative T2 maps with resulting infarct 
volume described. The upper limit of the threshold range was not sufficient to calculate 
the threshold that produced an infarct volume most similar to the manually delineated 
infarct from RARE T2 images. 
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Out of the 16 animals in the derivation group, only 8 had a T2 threshold that fell 
within the range of thresholds applied to the quantitative T2 maps (Figure 6.7). 
The threshold range was based on the mean T2 values from ROIs representing 
infarct calculated from the quantitative T2 maps and from visual observations of 
the whole hemisphere histograms (Figure 6.8). The minimum T2 relaxation time 
for infarct was calculated as 75.1±4.2 ms with the maximum T2 relaxation time 
being 126.6±12.8 ms. These values suggest that a threshold of 90 ms, the upper 
limit of the threshold range applied, would underestimate the infarct volume as 
it would not include the values from 75-90 ms which potentially represent 
ischaemically damaged tissue.  
Visual inspection of the quantitative raw T2 maps highlights that the ventricles 
have a high signal intensity which lies above the upper limit of the T2 relaxation 
threshold range (Figure 6.8). This means that the ventricles will be incorporated 
into the final infarct volume so that the infarct volume at each threshold within 
the applied range (65ms – 90ms) is overestimated.  
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Figure 6.7: Graphical representation of the T2 threshold which produced a similar infarct 
volume to the manual delineation method of RARE T2 images. Only 8 of the 16 animals 
had a T2 threshold that fell within the range applied. Mean indicated by a solid line. 
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Figure 6.8: Representative quantitative T2 maps from an animal in the derivation group with an applied threshold (red). It can be seen that the 
ventricles are incorporated into the derived infarct (circled green). 
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6.3.4 Image processing steps to improve the T2 threshold 
The quantitative T2 maps from each of the brains in the derivation group were 
modified to remove the ventricles from the images (Figure 6.9). This was done in 
both the ipsilateral and contralateral hemispheres by manually delineating the 
ventricles on the T2 maps and deleting them from the image. 
 
 
Figure 6.9: Coronal quantitative T2 maps before and after the removal of the ventricles 
(circled green). 
 
New histogram data were calculated for the modified T2 maps and the T2 
thresholds (65ms – 90ms) were reapplied to ascertain which threshold produced 
the most similar infarct volume to that calculated by manual delineation of RARE 
T2 images. This was carried out on each animal of the derivation group to get an 
animal specific threshold before a group threshold was calculated. 
Out of the 16 animals in the derivation group, 12 animals had a T2 threshold that 
fell within the range of thresholds applied to the quantitative T2 maps which is 
an improvement from the initial calculation (Figure 6.10). This highlights the 
involvement of the ventricles in the infarct defined by the threshold.  
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Figure 6.10: Graphical representation of the T2 threshold which produced a similar infarct 
volume to the manual delineation method of RARE T2 images. Only 12 of the 16 animals 
had a T2 threshold that fell within the range applied. Mean indicated by a solid line. 
 
 
 
As there were still a number of animals whose T2 threshold could not be 
determined using the T2 threshold range applied, this suggested that another 
potential source of error, causing the infarct volume to be overestimated at a 
particular threshold, was present in the images. The modified quantitative T2 
maps were visually inspected to ascertain whether or not an inherent 
overestimation existed of infarct volume. It was obvious that there was a 
noticeable amount of noise around the brain incorporated in to the infarct 
(Figure 6.11). This noise, like the ventricles, will cause an overestimation of 
infarct volume at a given T2 relaxation threshold. 
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Figure 6.11: Representative quantitative T2 maps from an animal in the derivation group with an applied threshold (red). It can be seen that there is 
areas of noise around the outside of the coronal brain sections (circled in green) that is incorporated into the derived infarct.
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ImageJ allows you to apply a median filter to an image. This filter helps smooth 
out any noise pixels by taking the median value of each surrounding pixel and 
applying the median to that pixel. The quantitative T2 maps previously modified 
by manually removing the ventricles were subjected to a 1.0 pixel median filter 
(Figure 6.12). This was done to each of the 8 coronal slices for each brain within 
the derivation group.  
 
 
 
Figure 6.12: Coronal quantitative T2 maps before and after the application of a 1.0 pixel 
median filter. The noise previously observed (top row of images, circled green) has been 
removed by the filter (bottom row of images, circled green). 
 
 
New histogram data was calculated for the modified T2 maps once the median 
filter had been applied. The T2 thresholds (65ms – 90ms) were reapplied to each 
T2 map to ascertain which threshold produced the most similar infarct volume to 
that calculated by manual delineation of RARE T2 images. This was carried out 
on each animal of the derivation group to get an animal specific threshold 
before a group threshold was calculated. 
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6.3.5 Collating all the calculated T2 thresholds to generate a mean 
T2 threshold for the derivation group 
The data from the derivation group was collated to calculate a mean T2 
threshold for the group (Figure 6.13). Out of the 16 animals in the derivation 
group, all 16 animals had a T2 threshold that fell within the range of thresholds 
applied to the quantitative T2 maps.  
The mean T2 threshold calculated for the derivation group was 76.0±2.9 ms. The 
thresholds from each animal are quite comparable, although the standard 
deviation is around 3 times larger than that seen when calculating contralateral 
T2 relaxation. Compared to the previous attempts at selecting a T2 threshold the 
variability is much smaller between animals which suggests the amount of error 
present is lower. The 76 ms threshold also gave good spatial conformity with the 
manually delineated RARE T2 images which is obviously as important as 
generating the correct volume for infarct quantification (Figure 6.14).  
The images also highlight the infarct is spatial distinct from the ventricles. This 
means that it is possible to apply the threshold to images that have not been 
modified (had ventricles manually removed) and calculate infarct, visually 
discriminating between what is obviously ventricle/CSF signal and what 
represents infarct. 
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Figure 6.13: Graphical representation of the T2 threshold which produced a similar infarct 
volume to the manual delineation method of RARE T2 images. All 16 of the 16 animals 
had a T2 threshold that fell within the range applied. The mean T2 threshold is indicated 
by a solid line. 
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Figure 6.14: Representative quantitative T2 maps from an animal in the derivation group with the 76ms threshold applied (top row, filled red) and 
corresponding RARE T2 weighted coronal images with the manual delineation of the infarct superimposed (bottom row, circled red). The images show 
the infarct defined by the 76ms threshold shares good spatial conformity with the manual delineation method.
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6.3.6 Applying the mean T2 threshold to comparison group 
animals 
The mean T2 threshold from the derivation group needed to be tested in a 
separate group of animals to confirm its suitability. The comparison group (n=13) 
all had infarcts calculated from the RARE T2 images by manual delineation. The 
quantitative T2 maps for each animal of the comparison group were opened in 
ImageJ and subjected to the 1.0 pixel median filter to remove any unwanted 
noise from the images. Each coronal slice had the 76 ms threshold applied and 
the resulting area of infarct defined by the threshold was measured. 
The two methods for infarct determination were compared (Figure 6.15). The 
76ms threshold produces similar infarct volumes, generally overestimating 
slightly compared to the manual delineation method. The Bland-Altman plot 
confirmed the 76 ms threshold overestimated infarct volume by 7.5±12.5 mm3 
compared with the manual delineation of RARE T2 images (Figure 6.16).  
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Figure 6.15: Comparison of infarct volume derived from manual delineation (black) and 
the quantitative T2 maps (green), using the calculated 76 ms threshold, in the comparison 
group.  
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Figure 6.16: Bland-Altman plot comparing the 2 methods of infarct quantification. Each 
point represents and animal in the comparison group. Solid line indicates the bias, dotted 
lines indicate 95% limit of agreement. 
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6.3.7 Application of threshold of abnormality from quantitative T2-
maps for the intraluminal filament model of MCAO 
It was important to ascertain whether or not the derived threshold would 
generate similar infarct volumes from quantitative T2 maps compared to T2 
images in animals that had under gone MCAO using the intraluminal filament 
model. Confirming the suitability of this threshold will allow it to be used for ILF 
studies. However if it fails to reproduce the result then a new threshold would 
have to be derived for this model. 
The 76ms threshold was applied to 14 male Sprague-Dawley rats and the 
threshold defined infarct was determined. The 76ms threshold-defined infarct 
encompasses the ventricles which interfere more with the infarct volume 
determination in this model of MCAO due to the increase in infarct volume and 
proximity of the lesion to the ventricles (Figure 6.17). This made it impossible to 
use this threshold to generate an accurate calculation of infarct based on this T2 
threshold.   
The CSF that is present in the ventricles in known to have a very long T2 
relaxation time in the region of 2000ms. In theory an upper threshold limit could 
potentially delineate the infarct tissue from the CSF in the ventricles.  
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Figure 6.17: Quantitative T2 maps from a representative animal (A) and with the 76 ms threshold applied indicating infarction (red) (B). Green circles 
indicated examples of ventricles in the contralateral hemisphere that have a T2 value above the 76 ms threshold of abnormality and are consequently 
included in the threshold-defined infarct.
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T2 values were obtained for ROIs within the ipsilateral and contralateral 
ventricles to assess the mean, minimum and maximum T2 values associated with 
the CSF. Similarly ROIs associated with infarct were measured to ascertain 
whether or not these regions could be separated based on their respective T2 
relaxation times (Figure 6.18).  
 
 
 
Figure 6.18: Quantitative T2 maps illustrating the ROIs used for ipsilateral and 
contralateral ventricle measurement (red square) and infarct T2 measurement (green 
square). 
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The mean T2 for infarct was 107.5±5.9ms with a mean minimum T2 value of 
85.8±7.8ms and a mean maximum value of 136.1±11.9ms from all of the regions 
measured. The mean T2 relaxation obtained from ROIs associated with the 
ventricles was 219.9±48.4ms with a mean minimum T2 value of 148.0±43.6ms 
and a mean maximum value of 304.5±82.2ms from all of the regions measured.  
The 76ms threshold was then applied to the quantitative T2 maps with an upper 
T2 relaxation time of 147ms which equates to the mean maximum T2 value for 
infarct plus one standard deviation as calculated from the ROI measurements 
(Figure 6.19). This threshold range for infarct volume improved the delineation 
between ventricles and infarct, especially in areas where the ventricles are of a 
substantial size, rostral to the hippocampus. However in more caudal slices the 
lateral ventricles still become incorporated in to the threshold defined infarct. 
The border zone of the ventricles tends to be incorporated into the 76-147ms 
threshold which equates to a measurable area and inherent error with the 
threshold for quantitative T2 maps. 
The threshold range was compared to the manually delineated volume from T2 
images (Figure 6.20). Generally, from the comparison it seemed that this 
threshold overestimated the infarct volume compared to the manual delineation 
method. A Bland-Altman plot highlighted that the difference between the 
methods became larger as the average infarct volume became larger (Figure 
6.21A). This difference between the methods was therefore expressed as a 
percentage which showed that the bias between the two methods was 
18.5±10.5% (Figure 6.21B).  
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Figure 6.19: Quantitative T2 maps (A) with 76 ms threshold (B) and 76-147 ms threshold range applied (C). The 76-146 ms range provides a more 
accurate estimation of infarct volume as the ventricles are now not completely included in the threshold-determined infarct. However it can be seen that 
there is still considerable areas of threshold-determined infarct surrounding the ventricles which is not infarct. 
A 
B 
C 
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Figure 6.20: Comparison of infarct volume derived from manual delineation (black) and 
the quantitative T2 maps using the calculated 76-147 ms threshold (purple) in the 
intraluminal filament (ILF) group. 
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Figure 6.21: Bland-Altman plots comparing the 2 methods of infarct quantification. A) 
Comparison based on absolute difference in infarct volume between methods. Solid line 
indicates the bias, dotted lines indicate 95% limit of agreement. B) Comparison based on 
% difference in infarct volume between methods. Solid line indicates the bias, dotted lines 
indicate 95% limit of agreement. 
B 
A 
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6.4 Discussion 
This study is the first to derive a T2 relaxation threshold of abnormality for the 
quantitative T2 map derived from an MSME T2 weighted sequence in animals 
subjected to MCAO using the distal diathermy occlusion model. An in-house T2 
relaxation threshold was established for the Sprague Dawley strain based on the 
final infarct volume at 24 hours post MCAO using the RARE T2 weighted imaging 
that has been previously used to for final infarct quantification (Reid et al 2012; 
Robertson et al 2011). The mean calculated threshold was then applied to a 
separate group of animals and compared once again to the RARE T2 weighted 
imaging to confirm its utility.  
6.4.1 A threshold for abnormality was successfully derived for the 
distal diathermy model of MCAO 24 hours post MCAO 
The use of histograms to plot the number of pixels relating to specific T2 
relaxation times for the entire hemisphere led to substantial overestimation of 
the T2 threshold for the quantitative T2 maps due to the inclusion of the 
ventricles within the hemisphere. This was highlighted in the Bland-Altman plot 
which showed that the bias between the manual delineation and the threshold 
derived infarct was around 40 mm3. Manually removing the ventricles reduced 
the threshold of abnormality to 85 ms which in turn reduced the bias to around 
30 mm3, although this is still a considerable bias between the two methods. 
Applying a filter helped smooth the images by removing pixels from around the 
periphery of the image which obviously did not form part of the ischaemic 
damage. This reduced the threshold to 76 ms and this resulted in a similar 
infarct volume between the manual delineation and the threshold defined 
infarct confirmed by a bias of -4 mm3 calculated from the Bland-Altman plot. 
Good spatial correlation was observed using this threshold. 
The spatial separation between the ventricles and the ischaemically damaged 
tissue in the distal diathermy MCAO model means that no prior alteration, i.e. 
manually removing the ventricles from the image, is needed when applying the 
threshold. A median filter is however still required to remove erroneous pixels. 
This is common practice within our lab for acute ischaemic damage 
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quantification on ADC maps and perfusion deficit measurement on quantitative 
CBF maps.  
6.4.2 T2 threshold only valid for experimental setup from which it 
was derived 
The 76 ms threshold relates only to the specific sequence and equipment set up 
that is used in our lab. This is because magnetic field strength can affect T2 
relaxation time. It has been shown that in rats, an increase in magnetic field 
strength from 4T to 11.6T led to a shortening of T2 relaxation of water in all 
brain structures measured (de Graaf et al 2006). Interestingly a study using a 
4.7T MRI scanner derived a T2 threshold against TTC staining at 24 hours and 
calculated the threshold to be 77.9±3.6 ms which is quite similar to that 
calculated in this study. This perhaps highlights that field strength is not the 
only factor that can significantly affect T2 relaxation and hence the threshold of 
abnormality.  
The time at which the MSME imaging was conducted in relation to occlusion time 
is important and this T2 relaxation threshold of 76 ms can only be used for 
images acquired 24 hours post MCAO. From 0-12 hours post MCAO it is known 
that the changes in T2 values are insignificant and can not be used to reliably 
detect ischaemic damage unlike ADC maps generated from DWI (Baird and 
Warach 1998). Similarly lengthening the time post-stroke also invalidates this 
threshold due to pseudonormalisation of T2 relaxation with time (Verheul et al 
1992). T2 defined lesion volume can be visualised from as early as 5 hours, 
although it is severely underestimated compared to DWI defined ischaemic 
damage, with peak lesion volume occurring around 24 to 48 hours following 
permanent MCAO (Verheul et al 1992). This lesion volume then diminishes to 
almost half the peak volume after a week post MCAO due to the reduction in 
cellular water content as brain oedema resolves. This highlights the potential 
error that may be incurred if using this threshold even 48 hours post MCAO, as 
small but significant changes in the threshold of abnormality might be present.  
Strain differences could also potentially influence the T2 threshold of 
abnormality as similar differences have been found in thresholds of abnormality 
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for both ADC and for CBF. The ADC threshold for Sprague Dawley rats has been 
reported as a 30% reduction in ADC compared to the contralateral hemisphere to 
predict final infarct volume (Foley et al; Shen et al 2003), whereas in the WKY 
and SHRSP strains this has been calculated as 21% and 23% respectively (Reid et 
al 2012). CBF thresholds also differ with strain and a lower threshold of 
23ml/100g/min has been calculated for WKY rats (Reid et al 2012) compared to 
30ml/100g/min in Sprague Dawley rats (Shen et al 2003). Differences between 
SHRSP and the WKY control strain were also found between the CBF thresholds 
(Reid et al 2012). 
These factors all highlight the importance of deriving a threshold for the specific 
MRI scanner, stroke model, strain and time post onset of ischaemia to achieve 
the most accurate and reliable threshold for determining final infarct volume 
using quantitative T2 mapping. 
6.4.3 Application of threshold to ILF MCAO model was 
unsuccessful 
The T2 threshold derived from animals that underwent MCAO using the distal 
diathermy model did not successfully calculate the infarct volume in animals 
subjected to the ILF model of MCAO. The close proximity of the much larger 
infarcts to the ventricles in the ILF model of MCAO made it impossible to 
demarcate ischaemically damaged tissue from the CSF-containing ventricles. CSF 
is known to have a T2 relaxation of approximately 2000 ms which prompted the 
calculation of an upper threshold limit of 147 ms which equates to the mean 
maximum T2 value for infarct over a number of voxels plus one standard 
deviation. The current MSME T2 weighted sequence produces mean T2 values of 
around 220 ms for CSF which is far lower than expected. The mean minimum 
value for CSF was calculated to be 148±48 ms which highlights potential 
crossover of T2 values between the CSF and the infarct tissue. This was clear on 
the quantitative T2 maps which exhibited considerable areas of tissue around the 
proximity of the ventricles and particularly the lateral ventricles that were 
included in the lesion determined by the 76-147 ms threshold. The Bland-Altman 
plots confirmed this error showing a 20% bias between the manual delineation 
and the threshold derived ischaemic damage.  
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The current sequence for the MSME T2 weighted imaging does not give a true 
reading of CSF T2 relaxation. The current upper threshold cannot successfully 
differentiate between infarct and CSF which inevitably leads to error in infarct 
volume quantification. Potentially the resolution of the MSME T2-weighted 
images is not sufficient to visualise the border. The relatively large voxel size 
compared to the RARE T2-weighted images mean that the pixels at the border 
between parenchymal tissue and CSF are influenced by signal from both with 
regards to T2 relaxation. This would mean that normal parenchymal tissue, with 
a relatively short T2 relaxation time, could display a longer T2 due to the 
inclusion of CSF signal and vice versa. The MSME T2 sequence acquires images 
based on the geometry and matrix size of the DWI and PWI sequences so that 
direct comparisons can be made on a pixel by pixel basis. The resolution of these 
scans is limited due to the time it takes to acquire a higher resolution image. 
This means that currently there is no option to increase the resolution of the 
MSME T2 sequence. Similarly the sequence may need fine tuning to improve the 
differentiation between tissue and CSF. This would create a significant 
distinction, based on T2, between the infarct and CSF which is not currently 
achieved with the available sequence.  
The main problem with T2-weighted imaging sequences is that aqueous solutions, 
including CSF have a long T2 relaxation time. As ischaemically damaged tissue 
has an increased T2 relaxation time the measurement of purely damaged tissue 
is difficult. Removing the CSF signal from the images would reduce the inherent 
error caused by this. Manually removing the ventricles from each image is not a 
solution as this requires manually distinguishing the ventricles from infarct, 
which leads to investigator error that the T2 threshold of abnormality set out to 
eliminate. 
A potential method for defining infarct volume using a quantitative T2 map is by 
using cluster image analyses of ADC and T2 maps where the ADC versus T2 values 
from the contralateral hemisphere are plotted to generate a two-dimensional 
cluster scatterplot (Jiang et al 1997). The cluster associated with cerebrospinal 
fluid, with its characteristic high ADC values, are distinct from parenchymal 
tissue and ischaemically damaged tissue which enable these pixels to be 
excluded from the T2 analysis. This prevents any operator error and image 
modification based on visual differences in signal intensity. Jiang et al (1997) 
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also defined the threshold of abnormality based on the mean T2 values of the 
parenchymal tissue cluster excluding the pixels associated with CSF. Normal 
pixels were defined as mean T2 ± 2 SD. A 2-dimensional cluster plot was then 
generated for the ipsilateral hemisphere and pixels lying outwith the defined 
normal cluster were classed as abnormal, representing the ischaemic lesion, and 
the normal pixels were defined using mean ADC ± 1.5 SD and mean T2 ± 2 SD. 
Once the normal tissue cluster was defined, the two-dimensional cluster 
scatterplot from the coronal section of brain was then generated, and the 
abnormal pixels were defined as pixels outside the normal cluster. The numbers 
of normal and abnormal pixels were calculated within the ipsilateral hemisphere 
which can be used to calculate lesion area on a coronal slice and lesion volume 
based on slice thickness. This method must be conducted on DWI images and T2 
maps that share identical geometry, matrix size and field of view so that pixels 
in both images refer to the same anatomical location to allow pixels 
representing CSF to be discarded. 
Another potential solution is to employ a different form of T2-weighted MRI that 
is able to distinguish between CSF and parenchymal tissue. Fluid Attenuated 
Inversion Recovery (FLAIR) imaging is a T2 weighted imaging technique that can 
potentially improve the detection of ischaemically damaged tissue. The 
technique suppresses the signal generated by CSF yet retains the increased 
intensity consistent with infarct (Hajnal et al 1992a; Hajnal et al 1992b). FLAIR 
imaging techniques are used clinically (Brant-Zawadzki et al 1996; Hjort et al 
2008; Israeli et al 2011), and although less accurate than DWI, FLAIR imaging has 
be shown to detect early ischemic lesions better than T2-weigted imaging 
(FLAIR, 91%; T2-weighted, 71% detected)(van Everdingen et al 1998).  
Adaptations of the FLAIR technique have been achieved to help reduce the 
acquisition time and increase the number of slices that can be imaged as initial 
sequences were taking too long a time to acquire, to be clinically useful [ give 
an idea of how long](Simonson et al 1996). In preclinical stroke research very 
few studies have adopted this technique (Taoka et al 2004) although a number 
of studies looking at tumour development in rats have done so (Jahnke et al 
2009; Soussain et al 2007). FLAIR imaging sequence development for infarct 
quantification in rats would significantly benefit preclinical studies by reducing 
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both the error in infarct determination caused by the inclusion of ventricles and 
CSF and the post-image processing to remove the CSF signal.  
6.5 Conclusions 
Quantitative T2 mapping allows comparison of T2 relaxation times on a pixel by 
pixel basis. Utilising a threshold for abnormality can remove the intra- and inter 
investigator error inherent with the manual delineation of ischaemic damage 
from RARE T2-weighted images. A threshold of 76 ms can accurately determine 
infarct volume in the distal diathermy method of MCAO but not in the 
intraluminal filament model. Interference from CSF signal is a problem with the 
current MSME T2-weighted sequence and some fine tuning is required. 
Acquisition of both DWI and MSME T2 scans is recommended to attempt to 
exclude pixels corresponding to CSF which will reduce the error associated with 
the CSF signal.  
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The studies presented in this thesis have demonstrated that acute 
hyperglycaemia, at clinically relevant levels, is detrimental to both early 
ischaemic lesion evolution and final infarct volume in animals lacking stroke co-
morbidities such as hypertension and insulin resistance. Oxidative stress has 
been implicated in hyperglycaemia-associated ischaemic damage and in diabetic 
complications. However the studies in this thesis suggest that oxidative stress is 
not the primary mechanism to exacerbate damage attributable to acute 
hyperglycaemia following permanent MCAO.  
In this chapter the findings of this thesis will be put into clinical context to 
discuss how these results can inform the clinical situation and what the current 
treatment options and guidelines are for hyperglycaemic stroke patients.  The 
studies conducted in this thesis represented one of the first attempts to model 
clinically relevant hyperglycaemia in animals with and without features of the 
metabolic syndrome. Based on the findings of thesis, the direction of future 
work utilising clinically relevant models will be discussed. Before that I will start 
by discussing some of the issues surrounding the conduct of preclinical stroke 
studies that have been raised within the stroke research community in recent 
years.  
7.1  Animal models in preclinical stroke research 
In experimental stroke research it is important to bear in mind that animals are 
used to model pathophysiological processes but they cannot model stroke as a 
disease. The reliance on one particular model of focal cerebral ischaemia or one 
particular model of hyperglycaemia may lead to a biased preclinical opinion that 
does not translate to the clinical situation. The knowledge that over 7,000 
studies examining the neuroprotective effects of more than 1,000 therapeutic 
interventions have been published (O'Collins et al 2006), yet only one successful 
pharmacological treatment has been successfully translated from bench to 
bedside highlights the importance of generating a broad preclinical picture with 
the use of many animal models and species.  
Selection of the most suitable models to investigate PSH was deemed important 
for the work reported in this thesis as the majority of the previous literature 
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investigating hyperglycaemia in focal ischaemia models used the streptozotocin, 
type-1 diabetes model or glucose infusion/injection models which lead to 
extremely high blood glucose. The levels of hyperglycaemia previously 
investigated do not represent those observed in the majority of the 
hyperglycaemic stroke population. The acute hyperglycaemia model used 
throughout this thesis consistently produced clinically relevant levels of 
hyperglycaemia based on the range of glucose values included in the GIST-UK 
(Gray et al 2007) and the SELESTIAL trial (McCormick et al 2010). Interestingly 
however, different rat strains may require the glucose dosing to be altered. The 
Sprague-Dawley rats used in Chapter 5 had a higher baseline blood glucose 
compared to the WKY and SHRSP rats after an overnight fast. This also meant 
that dosing with glucose led to higher blood glucose levels in the Sprague-Dawley 
strain than in the WKY and SHRSP strains. This observation was surprising as in 
conscious Sprague-Dawley rats the baseline blood glucose level after an 
overnight fast are very similar to both the WKY and SHRSP strains. Currently in 
our lab, different strains of rat are being tested for baseline blood glucose 
values after overnight fasting and peak glucose after 50% glucose solution 
injection to select the most clinically relevant and reproducible strain for future 
investigations (Roy, unpublished 2012). 
The studies presented in Chapter 4 are one of the first to investigate the role of 
acute hyperglycaemia in a model of metabolic syndrome following permanent 
MCAO. There were a number of models available for studies of this type at the 
outset, however the fructose fed SHRSP and WKY control strain were preferred. 
A lot of information on the studies previously conducted in the SHRSP model was 
available having been used frequently over the past few years (Strahorn et al 
2005). The results demonstrate that hyperglycaemia did not increase infarct 
volume in the ffSHRSP compared to the WKY strain and this could be a result of 
a number of factors. Potentially the role of other co-morbidities could outweigh 
the additional effect of high blood glucose on ischaemic damage. The SHRSP is a 
well established model of hypertension which is the main phenotype of this 
strain. The SHRSP also lack sufficient collateral blood supply which is thought to 
increase their susceptibility to larger infarcts. Other models exist that do not 
have such a strong association with one particular risk factor associated with the 
metabolic syndrome. The Zucker rat is a well established model of insulin 
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resistance and obesity that develops its phenotype due to a mutation in the 
leptin receptor, which results in the rats overeating. This strain of rat was 
considered at the outset of the thesis, however Zucker rats were deemed 
unsuitable for acute imaging studies due to the physical limitations of the MRI 
scanner equipment. The cradle and physiological monitoring equipment is unable 
to accommodate a rat the size of an adult obese Zucker (>500g compared to 
~270g for WKY and Sprague Dawley). Numerous high fructose feeding protocols 
(D'Angelo et al 2005; de Moura et al 2009; Hwang et al 1987; Oron-Herman et al 
2008), and high fat feeding protocols(Buettner et al 2006; Deutsch et al 2009) in 
a variety of rat strains have been proposed and have shown similar phenotypes, 
encompassing insulin resistance, hyperinsulinaemia and hypertriglyceridaemia 
after fructose feeding, and additionally obesity in high fat feeding. These models 
are limited by the period of time it takes to induce an insulin resistant or 
metabolic syndrome phenotype, with many protocols lasting 10 weeks. However 
such chronic diet modification in these models may induce more clinically 
relevant changes in pathophysiology compared to the ffSHRSP which has such a 
relatively short (2 weeks) period of diet modification. Although one model of 
metabolic syndrome was selected for the studies presented in this thesis, the 
pathophysiology between the available models no doubt varies between the 
Zucker rat and the ffSHRSP rat and this should be borne in mind when 
considering the conclusions made from studies of only one model.  
The studies presented in Chapters 4 and 5 highlight the challenges posed when 
studying models of focal cerebral ischaemia. Using WKY and SHRSP rats and the 
distal diathermy method of MCAO, the infarct volume at 24 hours was highly 
reproducible within each strain. However there was significant variability in final 
infarct volume when the distal diathermy model was used in Sprague-Dawley 
rats. Increasing the variability in turn means that larger group sizes are needed 
to achieve the same experimental power and this is associated with ethical, 
economic and pragmatic considerations. In addition to variability in infarct size, 
the extent of the ischaemic damage is also potentially an issue, especially when 
investigating factors which may increase infarct volume. In Chapter 4 using the 
SHRSP the lack of hyperglycaemia-mediated ischaemic damage could potentially 
be due to a ceiling effect such that the maximum extent of damage was 
reached. Effectively this could mean that any additional effect of 
242 
hyperglycaemia on infarct size is being masked as the infarct cannot grow any 
larger due solely to the physical size of the brain tissue available. The ILF model 
of MCAO was initially considered for the work in this thesis and in Chapter 3 was 
shown to cause extensive damage in the SHRSP strain. This model was therefore 
dropped in favour of the distal diathermy model to try and avoid such a ceiling 
effect on ischaemic damage. The distal diathermy model of MCAO has its 
limitations with regards to the mechanism of occlusion. The need for a 
craniectomy means it is far more surgically invasive and an open skull does not 
mimic the clinical situation. However the use of the ILF model of MCAO or 
embolic models suffer themselves from variability caused by incomplete 
occlusion. Embolic models are useful for investigating synergistic effects of 
agents with rt-PA. However generally they produce far less reproducible lesions 
than the ILF or electrocoagulation models of MCAO due to clot instability and 
location of the occluding embolus (Dinapoli et al 2006). Understanding the 
limitations of each MCAO model available is crucial in the selection of the most 
appropriate model for a particular experiment.  
Rats are the most commonly used species used in experimental stroke due to the 
similarity of the cerebrovasculature to humans as both possess a circle of Willis. 
The use of specific inbred strains also improves reproducibility in infarct volume 
and other outcome measures. Furthermore the cost of purchasing and 
maintaining rats is relatively low compared to larger mammals and their use in 
preclinical research is thought to be more socially acceptable (Sicard and Fisher 
2009). However, there are a number of limitations associated with using rats to 
model human stroke. Rodents possess small lissencephalic brains which are not 
directly comparable with the large gyrencephalic brains of humans. Additionally, 
rats only have a small proportion of subcortical white matter which makes it 
difficult to study ischaemic damage of white matter or to model lacunar 
infarction (Carmichael 2005). Rodents are capable of rapidly recovering from 
behavioural deficits induced by cerebral ischaemia, unlike in humans, which 
makes it difficult to investigate a number of neurological deficits (Sicard and 
Fisher 2009). More suitable species with regards to cerebral macrostructure 
include dogs, pigs and non-human primates as these possess large gyrencephalic 
brains with similar proportions of grey and white matter to humans (Howells et 
al 2010). These species difference should be taken into account in model 
243 
selection depending on the outcome measures that are to be investigated rather 
than focusing solely on rodents, especially for more longitudinal behavioural 
studies. 
 
 
Figure 7.1: Brain size and gyral complexity in mammal species. Reproduced from 
Howells et al. (2010). 
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7.2 Study design in preclinical stroke research 
Suboptimal study design in preclinical studies may also contribute to the poor 
translation from bench to bedside in stroke research. Only a minority of 
preclinical studies reporting neuroprotective effects of pharmacological agents 
have reported randomised treatment allocation and blinding of investigators 
(van der Worp et al 2005).  A previous meta-epidemiological study examined a 
number of meta-analyses of experimental stroke studies and showed that those 
studies that failed to blind the investigator to the induction of ischaemia 
reported greater treatment effects than those that were blinded (Crossley et al 
2008). Analysis of the publications that supported the efficacy of NXY-059 
showed that at least half of the reported 44% improvement in outcome could be 
attributed to experimental bias (Macleod et al 2008). This was primarily as a 
result of the failure to randomise experimental group allocation and lack of 
blinding of investigators to the treatment and assessment of outcome.  
The methodology employed in this thesis aimed to minimise the experimental 
bias often present in preclinical stroke studies. The recommendations set out by 
the Stroke Therapy Academic Industry Roundtable (STAIR 1999) were taken into 
account for studies presented in Chapter 4 and Chapter 5. In Chapter 5, sample 
size calculations were employed, based on the differences in infarct volume 
between normoglycaemic and hyperglycaemic WKY rats to inform the number of 
animals required to investigate the effects of hyperglycaemia in Sprague-Dawley 
rats. Animal group allocation in Chapter 4 was done with the flip of a coin for 
the WKY and SHRSP strains. In Chapter 5 a randomisation plan was used. I was 
blinded to the animal identity during the analysis in all experimental chapters. 
However, in Chapter 4 there were limitations that may have led to a degree of 
bias. Firstly, although the WKY and SHRSP rats look identical in their 
appearance, the WKY rats are larger than their age-matched SHRSP 
counterparts. This means it was obvious which strain of rat was being used at 
any given time. The induction of hyperglycaemia was also not blinded in Chapter 
4. This should have been blinded, even though frequent blood sampling for blood 
glucose analysis during the conduct of individual experiments confirms either 
glucose or vehicle administration almost immediately. In Chapter 5 I was blinded 
to the administration of both glucose and EUK-134. Neurological scoring was 
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blinded to EUK-134 but again the glucose administration was known due to 
previous blood sampling which may have led to a degree of bias in what is 
already a subjective assessment. Finally in Chapter 5, the infarct measurements 
from RARE T2-weighted images were thought to include error due to the manual 
delineation of the infarct based on increased signal intensity. The development 
of a threshold of abnormality for infarct volume calculations from T2 maps will 
reduce inherent inter- and intra-investigator error when using this MRI 
technique. However, as discussed in that Chapter this approach is not without 
limitations. 
The measures taken in this thesis to remove experimental bias are extremely 
important, especially for informing potential clinical trial design. All preclinical 
studies should be designed based on the guidelines set out for clinical trials and 
explicitly state the measures put in place to reduce experimental bias in the 
results. The use of a multitude of models is also important to gain a broader 
sense of the mechanisms involved which may advise management of PSH 
patients in the future. 
7.3 Hyperglycaemia mediated ischaemic damage: Role of 
oxidative stress 
The brain is particularly vulnerable to oxidative stress due to its high 
polyunsaturated fatty acid content, low antioxidant capacity, and insufficient 
neuronal cell repair activity (Traystman et al 1991). From the data presented in 
this thesis the role of oxidative stress in hyperglycaemia-mediated ischaemic 
damage remains unclear. The data presented in Chapter 4 suggested that under 
hyperglycaemic conditions WKY at 24 hours post MCAO had significantly larger 
infarcts than normoglycaemic WKY rats. Similarly hyperglycaemic WKY rats 
experienced a greater extent of lipid peroxidation compared to their 
normoglycaemic counterparts following permanent MCAO. This data suggested 
that hyperglycaemia associated ischaemic damage was mediated via oxidative 
stress. However this was not replicated in Sprague-Dawley rats (data in Chapter 
5) where no difference in the level of the lipid peroxidation marker, MDA, was 
found in any of the brain regions analysed. This did not reflect the difference in 
infarct volume where in Sprague-Dawley hyperglycaemia exacerbated infarct 
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volume at 24 hours post MCAO, similar to the differences seen in WKY rats. 
There are a number of limitations with the oxidative stress data. One of which is 
that in Chapter 4 only one marker of lipid peroxidation was used. This was due 
to a shortage of tissue available for immunohistological staining. In Chapter 5, 
although only MDA was quantified the level of circulating superoxide ions was 
measured. The EPR protocol had its limitations. Most notably was the incubation 
time with the spin probe CPH. Preliminary experiments were undertaken to 
select the optimum incubation time which was found to be 15 minutes. However 
the majority of the samples taken at 2 hours were off the scale when measured. 
This meant that the samples had to be diluted and refrozen before analysis. It is 
unclear what the effect of diluting the samples and the different dilutions that 
had to be used had on the results.  
The results from this thesis suggest that oxidative stress following permanent 
MCAO is not a major facilitator of hyperglycaemia-induced ischaemic damage. 
Furthermore, the proof of concept study described in Chapter 5 did not provide 
evidence that a drug which reduces oxidative stress could attenuate the 
detrimental effect of hyperglycaemia on the extent of ischaemic damage. 
However, the role of oxidative stress in reperfusion injury has been indicated in 
a number of studies (del Zoppo 2006; Schaller 2005; Traystman et al 1991). The 
ability of ROS to enter reperfused brain regions after recanalisation may provide 
a larger volume of tissue to cause injury to compared to the moderately 
hypoperfused, relatively small penumbra present following permanent MCAO.   
7.4 Management of post stroke hyperglycaemia 
One of the overall aims of this thesis was to inform future clinical trials design to 
assess whether patients may benefit from blood glucose lowering treatments. 
Co-ordinated stroke unit care is of proven benefit with studies demonstrating 
that stroke unit care reduces mortality and dependency (Candelise et al 2007; 
Collaboration 2007; Terent et al 2009). Rigorous physiological monitoring could 
therefore benefit patients in the acute phase of stroke and could potentially 
extend the time window in which reperfusion therapies could be used.  
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American and European guidelines regarding the management of PSH advise for 
active treatment of hyperglycaemia, although the criteria for the use of insulin 
as a treatment vary. European Stroke Initiative guidelines advise intervention if 
blood glucose exceeds 10 mmol/L, and the American Stroke Association advise a 
threshold of 11 mmol/L (Adams et al 2007). In a survey across 22 countries, the 
mean threshold of blood glucose concentration for intervention was found to be 
10.6 mmol/L but ranged from 7.4 to 14.0 mmol/L in different countries 
(Thomassen et al 2003). In this thesis the blood glucose level induced for 
hyperglycaemia in rats was ~12 mmol/L which meets the criteria for both the 
American and European guidelines. The findings presented in the thesis 
demonstrate that hyperglycaemia at the time of onset of focal cerebral 
ischaemia exacerbates both the acute development of the ischaemic lesion and 
the final volume of infarct determined at 24 hours, at least in animals lacking 
co-morbidities such as hypertension or insulin resistance. The detrimental effect 
of hyperglycaemia was found not to be confined to one strain of rat, having been 
demonstrated in both WKY and Sprague-Dawley rats. Therefore, since infarct 
volume was not increased in hyperglycaemic ffSHRSP rats compared to 
normoglycaemic ffSHRSP rats (modelling aspects of the metabolic syndrome) the 
results are consistent with the suggestion that patients who lack co-morbidities, 
such as insulin resistance and hyperlipidaemia, may respond more favourably to 
management of blood glucose. This is in line with clinical data which has shown 
that PSH led to worse clinical outcomes compared to normoglycaemia in non-
diabetic populations (Scott et al 1999; Williams et al 2002).  
The lack of clinical evidence for the benefit of the vigorous management of 
glucose in acute stroke patients questions the usefulness of interventions using 
insulin. The GIST-UK trial was the first large clinical trial of blood glucose 
modulation in acute stroke. Insulin administration, as a GKI infusion, had no 
significant effect on mortality within 90 days or prevalence of severe disability 
at 90 days compared to patients who received saline only (Gray et al 2007). The 
heterogeneous population presented by acute stroke patients may mask the 
beneficial effects of interventions to lower blood glucose. The GIST-UK trial did 
not discriminate patients based on diabetic or impaired glucose tolerance status 
unless insulin was already prescribed (Gray et al 2007). From the results 
presented in this thesis, it would suggest that patients who may not have 
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benefitted from reducing blood glucose (i.e. those with the features modelled 
by the ffSHRSP rat) were included in the trial.  
7.5 Future investigation of post stroke hyperglycaemia 
The clinical picture in acute ischaemic stroke is more complex than the 
processes modelled in this thesis and therefore conclusions about the role of 
hyperglycaemia and in turn its management in patients must be qualified. The 
studies conducted had a number of limitations and additional experimental 
studies will be required to inform more effective management of patients. 
Insulin treatment was not investigated and so the effectiveness of glucose 
lowering treatments in models of acute hyperglycaemia, in the presence and 
absence or insulin resistance and other co-morbidities, remain to be elucidated 
as does the associated risk of hypoglycaemia with insulin treatment. It will be 
interesting to see whether hypoglycaemia develops similarly in different rat 
models.  Hyperglycaemia can develop later, often in the first 24-48 hours 
following stroke, while I only investigated the effects of high blood glucose at 
the time of stroke. The complications of large infarcts, brain swelling and 
malignant oedema were similarly not modelled in this thesis and these could be 
important factors when selecting patients for treatment of hyperglycaemia. 
Another important consideration is the interaction of hyperglycaemia with 
reperfusion therapies. Future preclinical evaluation of PSH needs to focus on the 
use of glucose lowering agents in models of acute hyperglycaemia and also in 
models of insulin resistance and metabolic syndrome to confirm whether or not 
insulin can improve outcome measures. The synergistic effects of 
hyperglycaemia and rt-PA need to be investigated, again in the presence and 
absence of co-morbidities. Utilising embolic models of MCAO and the transient 
ILF model of MCAO provide a good basis for investigating these processes. This 
thesis focussed on clinically relevant levels of hyperglycaemia, informed by the 
GIST-UK trial rather than the extremely high blood glucose levels achieved in the 
majority of preclinical work. Including mild, moderate and severe 
hyperglycaemia may elucidate different mechanisms that could be upregulated 
at different thresholds of hyperglycaemia. 
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7.6 Conclusions  
The studies presented in this thesis have highlighted that acute hyperglycaemia 
increases the rate of ischaemic lesion growth and final infarct volume in rats 
lacking insulin resistance and associated cardiovascular co-morbidities. The 
mechanism by which hyperglycaemia exacerbates ischaemic damage remains 
elusive. Oxidative stress may be involved, although from the investigations 
conducted in this thesis this is not a primary mechanism of hyperglycaemia 
associated ischaemic damage following permanent MCAO. This thesis has 
highlighted the need to use clinically relevant models of PSH, with regards to 
the level of hyperglycaemia and the pathophysiology associated with it, and 
future investigations in to PSH should continue to utilise such models.   
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